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Abstract 
Current approaches for the discovery of bioactive molecules tend to treat all 
molecules in large collections with the same significance regardless of their 
ultimate biological activity. Furthermore, these approaches exploit a limited 
palette of reliable well-working reactions, that have been optimised for the 
preparation of individual compounds.  
This thesis describes the development of a new discovery approach –
Activity-Directed Synthesis. The approach  aims to merge the discovery of 
small bioactive molecules with the emergence of a synthetic route. In this 
regard Activity-Directed Synthesis may be analogous with the evolution of  
biosynthetic pathways as is observed in Nature.  
 
 
 
For the implementation of Activity-Directed Synthesis, a well-studied 
chemical toolbox – metal carbenoid chemistry – that has been underutilised 
in bioactive molecule discovery was used. The approach was demonstrated 
in the discovery of novel chemotypes of small bioactive molecules that 
agonise the Androgen Receptor. Both intra- and intermolecular reactions 
were exploited in sequential rounds of carbenoid reactions which had many 
alternative outcomes. Three iterative rounds of screening crude reaction 
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mixtures and design of subsequent reaction arrays enabled the rapid 
discovery of reactions that yielded bioactive products. Hence small-molecule 
modulators of the Androgen Receptor, based on scaffolds with no previously 
annotated activity were discovered.  
 
 
 
A total of 272 microreactions was performed in the case of intramolecular 
reactions and a total of 326 microreactions was performed in the case of 
intermolecular reactions. In the case of the intramolecular chemistry, it was 
demonstrated retrospectively that the approach enabled the parallel 
optimisation of both the structure of bioactive molecules and the routes for 
their synthesis. In the case of the intermolecular chemistry, it was 
demonstrated that non-exhaustive reaction arrays could still lead to the 
discovery of sub-micromolar modulators of the Androgen Receptor, greatly 
improving the efficiency of Activity-Directed Synthesis. 
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1. Chapter 1 
Evolutionary approaches for the discovery of bioactive 
molecules 
Synthetic and naturally occurring small bioactive molecules are of 
immense value both as tools for chemical biology and starting points for drug 
discovery.1 This chapter outlines current approaches for the discovery of 
bioactive molecules, and emerging evolutionary approaches. This 
description is followed by an overview of the proposed project in which an 
evolutionary approach to bioactive molecule discovery – activity-directed 
synthesis – was developed.  
1.1. Introduction 
Advances in molecular and biological sciences have provided a 
dramatically improved understanding of many biological mechanisms and 
diseases at the molecular level.2 However, the discovery of biologically 
active molecules suited to study these mechanisms is lagging.3 It can be 
argued that this gap between these two aspects of drug discovery is not due 
to a lack of the necessary synthetic methods but, rather, a lack of tools to 
select which molecules should be synthesised.2-3  
Historically,  chemists have often initiated  bioactive molecule discovery 
using high-throughput screening (HTS) of a large collection of compounds 
as a starting point. This process can identify active compounds or classes of 
compounds with similar scaffolds or three-dimensional structures. 
Subsequent determination of Structure-Activity Relationships (SARs) 
indicates the structural features which contribute most to the displayed 
activity. To establish SARs, a focused set of molecules is usually prepared; 
each molecule purified usually in series and tested usually in parallel to 
identify the most active molecules. These molecules are submitted to further 
evaluation in vitro and in vivo. Test results are used to confirm the desired 
bioactivity, the mechanism of action, and provide feedback for further 
structural optimisation. An illustrative example is shown in Figure 1.1. 
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Figure 1.1: Illustrative example of a bioactive molecule discovery in drug 
discovery. HTS highlights hit molecules which are then optimised and tested. 
 
SAR studies and combinatorial chemistry have been proven 
successful in generating promising drug candidates.4 Nevertheless, this 
approach is highly empirical and time consuming. Equal resource in invested 
in all molecules regardless of their ultimate biological activity because each 
stage – molecular design, synthesis purification and testing – is undertaken 
in isolation. Furthermore, chemists tend to exploit a limited palette of reliable 
well-working reactions, optimised for the preparation of a single, pure 
compound.5 This bias has led to a historically uneven exploration of the 
chemical space and may inadvertently limit the diversity of the structures 
being investigated.6  
In sharp contrast, Nature applies a highly efficient evolutionary 
approach from which bioactive natural products ultimately emerge. Nucleic 
acids are transcribed and translated to give biosynthetic enzymes which use 
simple bioavailable small molecules to synthesise constellations of more 
elaborate structures: natural products. If the natural products have a 
beneficial effect for the host organism, the latter lives on to inherit these 
characteristics. Through iterative rounds of cell survival and selection, 
ultimately biosynthetic pathways emerge to yield natural products with 
beneficial functions. This approach led to the emergence of bioactive 
products and associated synthetic pathways in parallel (Figure 1.2).  
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Figure 1.2: Evolution of biosynthetic pathways. Nature generates bioactive 
molecules through iterating rounds of selection based on cell-survival. 
   
1.2. Current approaches in bioactive molecule 
discovery 
The biological activity and structural diversity which are displayed by 
natural products have stimulated researchers to corporate selection 
strategies inspired by Nature into in vitro approaches for the discovery of 
bioactive molecules. These approaches outlined below attempt to drive 
efficient selection of biologically active compounds from large or putative 
libraries based on biological activity. Some also introduce elements of 
feedback into molecule optimisation. 
Dynamic Combinatorial Chemistry (DCC) has emerged as an approach 
that enables the synthesis of molecules from building blocks to be directed 
on the basis of their affinity for a target protein. In DCC, a library of building 
blocks armed with functionalities which allow reversible bond formation, is 
incubated with a target protein. The target then templates the assembly of 
productive combinations of building blocks to yield a molecule that forms a 
stable protein-ligand complex. Despite the fact that DCC has been proven 
successful in several cases,7 it has significant limitations, such as the 
requirement for stoichiometric amounts of the target protein and the need to 
conduct reversible chemical reactions in conditions under which the target 
protein is stable. These limitations can also restrict the 
the bioactive products. 
An alternative approach which directly linked cell survival with the 
presence of a bioactive molecule was developed by Benkovic and co
workers. A systematic approach for discovering genetically selected cycli
peptide modulators of protein
The approach exploits split
genetically-encoded intracellular libraries of cyclic peptides (
These libraries of cyclic peptides are then screened using a reverse two
hybrid system. Here, cell growth is coupled to the desired bioactivity, 
disruption of a specific PPI (
disrupted, the transcription of genes necessary for cell survival in a specific 
growth medium is prevented
PPI inhibitor is thereby directly linked to the survival of the host cell. 
Figure 1.3: A. Simplified illustration of the split
create a library of cyclic amides.
system. Disruption of the PPI 
transcription of a gene cluster 
for cell survival (Adapted from 
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potential diversity of 
 
-protein interactions (PPIs) was developed.
-intein ligations,9 and leads to the formation of 
Figure 1.3.B). If the targeted PPI is 
. The ability of the cyclic peptide to function as a 
-intein ligation system to
 B. Illustration of the reverse two
(pink and purple protein) results in
(green, brown and yellow codons) necessary 
Nat. Protocols 2007, 2, 1126
-
c 
8
 
Figure 1.3.A). 
-
e.g. the 
not 
 
 
 
-hybrid 
 the 
).  
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Genetic expression and selection occur simultaneously mimicking the 
naturally-imposed selection pressure. Benkovic’s group has demonstrated 
the applicability of their method on a range of targets such as the disruption 
of the  homodimerisation of a HIV-1 protease8 and AICAR transformylase,10 
as well as inhibition of a DAM methyltransferase in E. Coli.9 This system is 
able to utilise the natural synthetic pathways of the host organism to produce 
vast numbers of different cyclic peptides and mimic Nature’s effective 
selection and amplification features via cell survival. However, this system is 
only able to produce peptidic molecules and can only be exploited in the 
discovery of cyclic peptides. 
1.2.1. DNA-encoded libraries 
A recent approach which can integrate some evolutionary aspects into 
bioactive molecule discovery approaches  involves DNA-encoded libraries. 
These libraries are classed into two categories: DNA-recorded and DNA-
templated libraries. 
1.2.1.1. DNA-recorded libraries 
In DNA-recorded libraries, DNA duplex tags or strands are used to 
record the history of the synthesis and enable deconvolution of the structure 
of the synthesised molecule using DNA sequencing.  The generation of the 
library starts from a chemically functionalised DNA template. An initial pool is 
split into several batches and different chemical reactions with various 
building blocks are performed; at each step of the synthesis, a DNA tag 
which indicated the transformation used is enzymatically attached in order to 
track the synthesis, before the sub-pools are re-combined. Clark and co-
workers11 have reported the discovery of a novel, p38 MAP kinase inhibitor 
using the approach. The initial free amine group was conjugated with a DNA 
duplex template. In only four cycles of splitting, reacting, tagging and pooling 
a library of over 800 million members was generated (Figure 1.4). 
Figure 1.4: Generation of a DNA
pool” combinatorial approach. 
step to record the history of the synthesis (Adapted from 
2009, 5, 647). 
An aliquot of the library was 
and non-binding molecules were then 
denatured and the binding molecules were retrieved. PCR was used to 
amplify the DNA sequences of the binding molecules which were then and 
incubated with a fresh sample of protein. After only three iterative rounds of 
incubation and selection of the DNA sequences by PCR, potent inhibitors of 
the same scaffold family were identified (
revealed by sequencing of the corresponding DNA sequences.
Figure 1.5: Three
bind to p38 MAPK 
position of the triazine ring
647). 
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-recorded library using a “split
A DNA-tag is enzymatically attached at each 
incubated with the immobilis
washed away. The protein was then 
Figure 1.5), whose structures were 
-dimensional SAR diagram illustrating compounds which 
(left). All hits share a common scaffold, varying only at the 
 (right) (Adapted from Nat. Chem
 
-tag-and-
Nat. Chem. Biol. 
ed protein 
 
 
. Biol. 2009, 5, 
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Re-synthesis of the hit compounds as individual molecules confirmed 
both their inhibitory actions against the p38 MAPK and their nanomolar 
binding potency. Furthermore, a crystal structure of one of the hit 
compounds bound to p38 MAPK revealed that the DNA template was 
unlikely to affect the compound binding in any way, since the DNA-linking 
carboxamide was found to be exposed to solvent.  
Undertaking a related approach, Neri and co-workers exploitted DNA-
encoded libraries of fragments in combination with the concept of DCC.12  
These encoded self-assembling chemical libraries comprise various small 
molecular fragments attached to different single-stranded DNA, containing a 
common hybridisation region and a unique label. The DNA-tag enables both 
the assembly of fragments and their identification (Figure 1.6). Neri’s group 
has reported the application of this approach in the discovery of pairs of 
fragments that bind to trypsin,12a,13 MMP-313 and streptavidin.14 Although 
efficient this approach is not evolutionary as there is no possibility for 
mutations to vary the structure of the fragments or ligands. Also, this 
approach identifies combinations of fragments which still need to be linked 
together in order to synthesise a potentially bioactive molecule. Additional 
effort is thus required to  identify an appropriate linkage between the two 
fragments.  
 
Figure 1.6: Application of the ESAC library on trypsin. A: A known ligand 
was used as a warhead. B: Chemical structure of the known ligand and 
linker to the DNA oligos when assembled. A library of 620 small molecules 
was screened (blue triangle). C: Examples of small molecules selected. 
D: New molecule synthesised with nanomolar inhibitory activity against 
trypsin. A suitable linker needs to be identified to link the two fragments. 
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1.2.1.2. DNA-templated libraries 
In contrast to DNA-recorded libraries, DNA-templated libraries rely on 
the recognition and hybridisation properties of nucleic acids to encode the 
synthesis: reactants are brought into close proximity, thus increasing their 
effective concentration and the rate of the reaction, enabling the DNA to 
encode the structure of the synthesised molecule. Work carried out mainly 
by Liu and co-workers has demonstrated that this templated concept can be 
implemented to perform a wide range of chemical transformations including 
reactions in organic solvents,15 stereoselective reactions16 and multi-step 
reactions.17  
The sequence specific hybridisation properties of DNA-templates 
assure that at low concentrations, reactions between mismatched DNA 
templates will not occur. In this sense, each DNA-template can be 
considered as a virtual “nano-vessel”. This aspect of DNA-templated 
synthesis sets the basis for the generation of DNA-templated libraries, as 
parallel reactions can be performed in a single reaction vessel and libraries 
of compounds can be prepared as a whole. DNA-templates and reagents 
can be pooled together and the individual building blocks will only react as 
directed by DNA sequence specificity. The intermediates can be purified as 
a whole library and be submitted to the next round of reactions in order to 
introduce different levels of structural diversity and generate the full library 
(Figure 1.7).  
Figure 1.7: Generation of a DNA
in the same vessel, programmed by the sequence specificity of the DNA
templates. 
To eliminate complications stemming from low concentration
PCR amplification and DNA
structures of highly
Liu and co-workers have demonstrated the applications of their approach by 
preparing two DNA
library of 65 members
members (Figure 
concept study.19 
PCR before and after selection. After only three selection rounds, a 10
enrichment was observed for some molecules, which allowed the 
amplification of high affinity binding molecules present in low concentration. 
This enrichment of the overall library population with more active binders 
demonstrated the viability of the 
templated libraries. 
principle, by introducing mutations to the DNA template, such an example 
has not yet been demonstrated experimentaly.
Liu’s methodology has been com
Ensemble Discovery
drug discovery.20 
potent molecules are identified by PCR amplification and DNA
- 9 - 
-templated library. Parallel reactions occur 
-sequencing can be used to identify the 
-active molecules that are present in low concentration. 
-templated macrocyclic fumaramide libraries; a small 
17b
 and a larger one containing 13 824 different 
1.8A).18 Liu’s group used the small library for a 
The DNA-conjugated library members were amplified by 
selection-based screening and DNA
Although evolution of structure would be possible in 
 
mercialised by the company 
 applying the principles of DNA-templated libraries in 
After screening and selection against a biological target, 
 
-
 factors, 
proof-of-
3
-fold 
-
 sequencing. 
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The selection data are used for the design of the next generation optimised 
library providing an aspect of evolution to this promising drug discovery 
approach. 
 
Figure 1.8: Macrocycles prepared using DNA-templated synthesis. 
A: macrocyclic furamide structures with DNA oligo attached. B: Example of 
an Ensemblin macrocycle able to inhibit a certain protein-protein interaction. 
 
Nature has developed a wide range of biologically active small 
molecules by imposing selection pressure on constellations of natural 
products derived from a set of available starting materials. This process 
generates molecules whose high affinity and specificity for their designated 
biological targets increases over iterating rounds of cell-survival. Achieving  
the combination of both the selection and evolution aspects, i.e. a 
methodology mimicking Nature’s approach is extremely challenging to 
implement. Current approaches implement methods which enable the 
selection of active molecules from a large set of possible combinations.9-14,21 
However, few of these approaches exploit the evolutionary aspects that 
characterise Nature’s approach, i.e. utilising the activity of a group of 
products as feedback element in an iterative manner. 
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1.3. Activity-Directed Synthesis 
The aim of the project was the development of a new chemical 
evolutionary approach for the discovery of novel bioactive molecules. It was 
envisaged that the new approach would be able to focus on active 
molecules rather than treating all molecules with the same significance. 
Furthermore, in contrast to current approached where synthesis and 
selection occur in isolation of each other, the new approach aims to bring the 
synthesis of molecules and their screening together, much like its observed 
in biosynthetic pathways. It was hypothesised that it should be possible to 
mimic the evolutionary process of Nature by replacing metabolites with 
starting materials susceptible to different chemical transformations, and 
biosynthetic proteins with chemical catalysts and reagents.  
As shown in Figure 1.9, the methodology would exploit arrays of 
reactions with inherently unpredictable outcome to produce mixtures of 
products. After removing the catalyst by scavenging and the solvent by 
evaporation, the crude produt mixtures would be dissolved in buffer and 
screened, thus identifying reactions that yield bioactive products. The results 
would be analysed to inform the design of a subsequent reaction array. The 
process would be repeated with the subsequent array being screened at a 
lower concentration in order to impose selection pressure onto the system. 
Finally, promising reactions would be performed to scale in order to isolate 
the products, characterise and evaluate their biological activity. 
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Figure 1.9: Illustrative diagram describing Activity-Directed Synthesis. Such 
an approach would bring together all the stages in the discovery of bioactive 
molecules, and facilitate the parallel emergence of an associated synthetic 
route. 
 
By exploiting reactions with multiple possible outcomes rather than 
predictable and optimised chemical reactions, generating mixtures of diverse 
products rather than just a single compound, this process will allow the rapid 
and facile identification of molecules active against a desired biological 
target. Evolutionary feedback would be utilised through the analysis of the 
information from the screening of a first reaction array to design a second 
reaction array. Such an approach would, in principle, allow the optimisation 
of both the structure of the active component as well as a route for its 
synthesis simultaneously. 
Methods exploiting the possibilities of multiple reaction pathways   
have been applied for the discovery of novel chemical reactions or metal 
catalysts.22 For example, Hartwig and co-workers,22d utilised GC-MS as a 
screening method to identify three novel metal-catalysed reactions using a 
- 13 - 
HTS 384-well plate setup. Small molecule substrates were added to the 
rows of the well plate and mixed with different metal catalysts and ligands 
added to the columns of the plate. After the reactions were conducted, GC-
MS was used to identify the formation of products, the mass of which was 
significantly greater than that of the small molecule substrates. Products 
identified with positive biological activity using the suggested approach 
would be re-synthesised and tested individually to confirm their potency. 
A related approach to bioactive ligand discovery, dubbed synthetic 
fermentation was recently published by Huang et al.23 Multiple simple 
building blocks (isoxazolidine-based monomers) reacted in a well plate 
setup, with α-ketoacids to form β-amides. Initiating and terminating building 
blocks could only be functionalised on one end whilst elongating building 
blocks could be functionalised on either end (Figure 1.10A). Thus the range 
of oligomers produced was critically dependent on the combination of 
building blocks used. The elongated amide was capped with a terminating 
building block to cease the elongation process. As the synthetic process 
occurs in aqueous solution, the synthetic culture containing mixtures of 
products of different lengths, can be directly assayed against a desired 
biological target. By preparing mixtures with overlapping building blocks, the 
structure of the active compound can be deconvoluted by simple 
combinatorial strategies. The same principles of evolutionary feedback, 
miniaturisation and crude testing were applied in order to ferment up to 6000 
non-natural oligopeptides from which a micromolar inhibitor of a HCV 
protease was identified (Figure 1.10). This approach enables direct testing of 
a reaction mixture containing more than one possibly active products. 
However the inherent limitation is that it requires aqueous chemistry, greatly 
diminishing the range of transformations that may be exploited. 
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Figure 1.10: Example of Huang et al. synthetic fermentation of β-olipeptides. 
A: Simple building blocks are used in a combinatorial way to generate 
mixtures of multiple products. B: Example of the in situ preparation of an 
active molecule. 
 
1.4. Selection of a chemical toolbox for activity-
directed synthesis 
Current approaches for the discovery of bioactive molecules tend to 
exploit a limited palette of reliable well-working reactions, optimised for the 
preparation of a single, pure compound.5 Thus the existing chemical toolbox 
is not suited for this project. A new chemical toolbox is needed in order to 
overcome the limitations of conventional approaches in chemical 
connectivity5,24 and to produce mixtures of products instead of single 
products. 
The starting materials used were diazo-carbonyl compounds which 
were suitable for the purposes of this project for several reasons. First, 
diazo-compounds decompose in the presence of metal catalysts to generate 
highly reactive carbenoids species. (Figure 1.11) Commonly used metals 
include Cu, Co, Pd and Fe however the most abundantly studied class of 
metal catalysts are Rh catalysts. The carbenoid intermediates and can 
undergo a plethora of different transformations.25 C-H, O-H, N-H insertions, 
cyclopropanations and cascade cycloaddition processes, have all been 
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reported in both intra- and intermolecular reactions, affording the formation 
of diverse molecular scaffolds (Figure 1.12).25-26  
 
Figure 1.11: Formation of metal-carbenoid species after treatment with 
metal catalyst. These intermediates are highly reactive and can undergo a 
plethora of transformations. 
 
 
Figure 1.12: Examples of Rh(II) carbenoid chemistry. A: carbonyl ylide and 
intermolecular cycloaddition. B: isomünchnone intramolecular cycloaddition 
and π-cyclisation. C: merged alkyne metathesis and tandem cyclisation. 
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Moreover, the reactivity of the carbenoid species can be finely tuned to 
favour the formation of one possible product over one or two other possible 
co-products. The tunability stems from the interactions of the molecular 
orbitals of the metal, the ligands and the carbene. In the case of rhodium 
catalysts which have been more extensively studied, the HOMO of the sp2-
hybridised carbene interacts with the LUMO of the rhodium-ligand complex 
resulting in the formation of a σ-bond. The stability of the carbenoid though 
depends on the ligands of the catalyst which can donate or withdraw 
electrons from the metal and affect the degree in which it can participate in 
π-back donating bonding (Figure 1.13).  
 
Figure 1.13: Molecular orbital interactions between the metal catalyst and 
the carbene to form the reactive carbenoid. The stability of the carbenoid is 
mostly affected by the electron density donated by the catalyst ligands 
through π-back donating bonding. 
 
The more electron-density the ligand adds to the catalyst, the more 
stable the carbenoid and vice versa, affecting the relative rate of the various 
transformations.27 Apart from the catalyst’s ligands, the substituents of the 
carbenoid carbon atom can also influence the stability of the carbenoid 
formed through either steric and conformational or electronic effects.28 In a 
representative example, the diazoacetamide 1 can undergo an 
intramolecular cyclopropanation/rearrangement cascade to give product 2, 
or a C-H bond insertion to give product 3 (Figure 1.14).26 Similarly, the 
diazo-compound 4 can give both the C-H insertion and the cyclopropanation 
products 5 and 6 respectively. In both cases, changing the ligands resulted 
in favouring the formation of one product over the other. 
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Figure 1.14: Effects of Rh(II) catalysts on reaction selectivity; 
cyclisation/rearrangement (product 2) against C-H insertion (product 3) (top) 
and cyclopropanation (product 5) against C-H insertion (product 6) (bottom). 
 
Furthermore, a variety of chiral catalysts has been developed allowing 
for stereoselective control over the formation of chiral products28-29 as well 
as increasing the range of ligands used. These catalysts were developed 
based on chiral ligands and may be classed in three major groups: acetates, 
carboxamides and phosphates (Figure 1.15). Depending on the substitution 
pattern around the carbene carbon, different groups of catalysts have 
different effects of the reaction outcome, as described above.   
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Figure 1.15: Structures of representative examples of chiral Rh(II) catalysts. 
The three distinct groups, acetates, carboxamides and phosphates can be 
subdivided further based on the core of the ligand used.  
 
Being able to generate different scaffolds from the same starting 
materials by changing the Rh(II) catalyst is an ideal aspect for the purpose of 
this project, as a crude reaction mixture may contain more than one 
potentially bioactive molecules. Furthermore the tunability of the carbenoid 
chemistry may enable the optimisation of the synthetic route in parallel with 
the selection of the most active component. 
  
1.5. Selected Biological Target: The Androgen 
Receptor
1.5.1. The Structural and Chemical Biology
Receptor
The androgen receptor (AR) is a member of the steroid and nuclear 
receptor superfamily, which acts as an intracellular trans
function is modulated
or dihydrotestosterone)
receptor-protein and receptor
expression and development of male sexual characteristics. Numerous 
mutations of the AR have been identified and ass
as prostate cancer and Androgen Insensitivity Syndrome.
The AR gene is approximately 90 kb long and encodes a protein of 919 
amino acids, divided into three functional domains (
terminal domain (NTD) which has a modulatory function, the DNA
domain (DBD) and the 
hinge region is located between the DBD and the LBD. A nuclear localisation 
signal spans over 
translocation of the protein from the cytoplasm to the nucleus.
Figure 1.16:  Graphical representation of the AR protein domains. NT: 
terminus; NTD: N
region; LBD: Ligand
terminus. 
The unbound AR is mainly located in the cytoplasm. Upon ligand 
binding, the conformational changes induced result in the 
phosphorylation and translocation of the AR into the nucleus.
nucleus, the AR binds onto the DNA through its hormone response element 
(HRE), located in the promoter of AR gene targets, resulting in the 
recruitment of the transcriptional machinery and activating AR
gene expression (
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 which induce conformational changes 
-DNA interactions. The AR is crucial for the 
ociated with disease such 
30
Figure 
C-terminal ligand-binding domain (LBD). A small 
the DBD and the hinge region, responsible for the 
-terminal domain; DBD: DNA-binding domain; HR: hinge 
-binding domain; NLS: nuclear localisation signal; CT: 
Figure 1.17).  
 factor. Its 
affecting both 
 
1.16): the N-
-binding 
 
 
N-
C-
dimerisation, 
30
 Once in the 
-regulated 
Figure 1.17: Cartoon schematic of the transcriptional pathway induced by 
the activated androgen receptor. Upon bin
dimerises and is phosphorylated. It then enters the nucleus where it recruits 
the transcriptional machinery. If an antagonist binds, the conformational 
changes result in the recruitment of a co
transcriptional process. AR: Androgen receptor, HSP: heat shock protein, 
AG: agonist, ANG: antagonist, P: phosphorylation, HRE: hormone response 
element. 
 
The AR LBD consists of 11 
1.18). Ligand-propagated conformational changes in the LBD result in the 
formation of a functional activation region on the surface of the LBD, 
necessary for the interaction of the A
transcriptional activation.
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ding of an agonist, the receptor 
-repressor which 
α-helices, arranged in three layers (
R and co-activator recruitment during 
 
 
prevents the 
Figure 
Figure 1.18: The androgen receptor ligand
(Resolution: 2.0 Å) with DHT bound; front (left) and side (right) view (PDB: 
1I37). The LBD consists of 11 
conformation, forming an antiparallel “
(green), C-terminus (yellow) and DHT (grey) shown.
 
Known ste
AR ligand-binding cavity through hydrophobic interactions. Furthermore the 
3-keto-group of steroidal 
residues Gln711 and Arg752 whilst the 17
residues Asn705 and Thr877 (
residues are considered crucial for the induction of the conformational 
changes of the protein.
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-binding domain crystal structure 
α-helices and 2 short β-turns, in a three layer 
α-helical sandwich”. 
 
roidal agonists and antagonists generally interact with the 
agonists interacts through hydrogen bonding with 
β-OH group hydrogen
Figure 1.19).  The interactions with these 
4d,e,31
 
 
N-terminus 
-bonds with 
Figure 1.19: Crystal structure of AR
bound (PDB: 1I37), depicting key hydrogen bonding interactions with R752, 
Q711, T877 and N705.
Apart from its genomic pathway as a transcription regulation factor, the 
AR takes part in a non
kinase-signaling cascades or the modulation of intracellular calcium levels. 
This non-genomic pathway has been reported in oocytes, skeletal muscle 
cells, osteoblasts, and prostate cancer cells.
1.5.2. Androgen receptor ligands: agonists, antagonists and 
Selective AR modulators (
Androgen receptor ligands are classed as agonists or antagonists 
based on their ability to activate or inhibit the transcription of androgen 
receptor target genes. Agonists upregulate gene expression by inducing a 
conformation which favours co
5α-dihydrotestosterone (DHT
the AR. Antagonists are ligands that compete with TE and DHT for binding 
onto the AR and induce a conformation which promotes co
binding. Due to their wi
began with modifications of the steroidal scaffold of TE and DHT
stanozolol (III).32 
better pharmacological properties, 
analogues of flufenamic acid
- 22 - 
-LBD (Resolution: 2.0 
 
-genomic pathway involving either a rapid activation of 
30
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, II) (Figure 1.20) are endogenous agonists of 
de clinical use, development of novel AR ligands 
However, subsequently, non-steroidal ligands 
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,
31
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20). 
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Figure 1.20: Chemical structures of known steroidal and non-steroidal AR 
ligands. A: Agonists (left to right): Testosterone I, 5α-dihydrotestosterone II 
and stanozolol III.  B: Antagonists: R-bicalutamide IV and flutamide V. 
 
It has been shown through SAR studies30,33 that in flutamide 
analogues and derivatives, the electron-withdrawing substituents of the 
phenyl ring (Figure 1.21) favour AR binding. Binding of flutamide and 
bicalutamide analogues mainly occurs through hydrophobic interactions and 
less through hydrogen bonding. However, certain hydrogen bonding 
interactions have been identified occurring through residues Q711 and N705 
(Figure 1.22).33 
 
 
Figure 1.21: Phenyl-amide moiety of flutamide and bicalutamide analogues 
shown to favor AR binding (X = Cl, CN, NO2). 
Figure 1.22: Crystal structure (Resolution: 1.65 
bound to the AR
hydrophobic interactions. Key hydrogen bonding residues N705 and Q711
are depicted.  Certain non
omitted for clarity.
As demonstrated in a
(depicted in Figure 
development of novel AR antagonists. The authors had att
(trifluoro)methyl benzonitrile ring on carborane structures and observed 
antagonistic activity of the synthesised compounds at the micromolar region. 
Thus, this fragment would serve as a good starting point in order to 
showcase Activity
modulators of the Androgen Receptor.
Apart from agonists and antagonists, certain compounds display 
agonistic action in muscle tissue whilst they display an antagonistic action in 
the prostate. Such compounds
modulators (SARMs) and act by inducing a conformation which lies between 
agonism and antagonism. Zhi and co
a novel class of orally available SARMs.
Given the fact that the st
including the numerous SAR reports on non
the AR is an ideal
of the methodology to be developed by this project. 
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- 25 - 
screening methodology is well established. Invitrogen has developed a 
commercially available time-resolved fluorescence resonance energy 
transfer (TR-FRET) biochemical assay, allowing the identification of both 
agonists and antagonists for the AR, which provides a reliable screening 
methodology (see Chapter 3 for details). 
1.6. Project Outline 
Having chosen an appropriate chemical toolbox and biological target an 
experimental outline was developed, to develop and exemplify the Activity-
Directed Synthesis approach. First, the structure of the intra- or inter-
molecular diazo-substrates was decided (Figure 1.23). These substrates 
would bear the phenyl-amide motif as a minimal pharmacophore unit which 
would provide a starting point for active AR modulators. The N-appended R 
groups would be chosen such that they would either enable multiple possible 
carbenoid transformations (in the case of intramolecular substrates), or 
minimise intramolecular reactivity (in the case of intermolecular substrates). 
 
Figure 1.23: Common central structure for the diazo-substrates. The N-
appended group would be chosen accordingly for intra- or intermolecular 
substrates. 
These diazo-substrates would need to be tested for their activity 
against the AR, using the TR-FRET assay, in order to establish that any 
background signal or interference does not stem from these compounds 
before being used in the reaction arrays. Scavenging studies also needed to 
be undertaken to establish the degree to which the metal could be removed 
from the crude product mixture prior to the latter being biologically tested. 
Removal of the metal would minimise any effects the metal might have on 
either the functionality of the protein or the read-out of the screening method. 
The TR-FRET assay itself would need to be established and all its 
parameters optimised to assure its functionality and reliability. Successfully 
assaying known AR modulators, ideally an agonist such as testosterone and 
an antagonist such as cy
testing. 
Reactions would need to be performed in custom made PTFE 96
plates as regular plastic well pl
organic solvents. The well would have a minimum volume of 200 
to accommodate a reaction solution of 100 
sealing. The reactants could be easily pipetted into the reaction 
finite volumes of concentrated stock solutions of the diazo
co-substrates and 
reaction. The reactions could be monitored by LC
reaction end-point. 
need to be pipet
scavenging resin. After scavenging,
to evaporate at room temperature and then under re
remove the solvent, before being assayed (
Figure 1.24: Graphical illustration of the 
performing arrays of reactions to testing them using the TR
 
The concentrated crude product mixtures, could then be rediluted in 
DMSO to prepare a stock solution which could be further diluted accordingly 
in DMSO and assay buffer to screen the product mixtures in more than one 
concentrations. Screening at a lower concentration 
would be an efficient manner of imposing selection pressure onto the system 
and could facilitate the selection 
of a subsequent reaction array. These iterative rounds of screening, 
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proterone acetate, was deemed as sufficient 
ates would disintegrate with the use of most 
μL and residual space for 
finally the metal catalyst which would also 
-MS and TLC to establish a 
In order to scavenge the metal, the crud
ted into wells preloaded with the appropriate amount of 
 the crude product mixtures would
duced pressure to 
Figure 1.24). 
experimental process, from 
e.g.
of conditions which would dictate the design 
-well 
μL in order 
well using 
-substrates any 
initiate the 
e mixtures would 
 be left 
 
-FRET assay. 
 2-fold or 10-fold, 
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selection and redesign would continue until a total concentration of products 
which is low enough is met, e.g. 500-100 nM. Ideally, there should be no 
more than three or four reaction arrays in order to demonstrate the efficiency 
of the approach. 
1.7. Summary 
In order to overcome the limitations of conventional approaches for 
the discovery of small bio-active molecules, a new approach, Activity-
Directed synthesis was envisaged. This approach aimed to focus on active 
molecules rather than treating every molecule with the same significance. 
Exploiting promiscuous reactivity to generate mixtures of products and crude 
testing would enable the use of evolutionary feedback and through iterative 
rounds of screening and redesign it would be possible to optimise both the 
structure of the active molecule and the route to its synthesis 
simultaneously.  
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2. Chapter 2 
Synthesis of diazo substrates for intramolecular metal-
catalysed carbenoid reactions 
This chapter will describe the development of the synthetic routes 
employed for the preparation of the diazo substrates for intramolecular 
metal-catalysed carbenoid reactions. After establishing a reliable synthetic 
route on a model system (Section 2.1), sixteen N-aryl α-diazo amides were 
prepared (Section 2.2).  
2.1. Development of methods for the preparation of 
diazo-compounds 
As outlined in Chapter 1 (see Section 1.2.2 and Section 1.3) the 
substrates for intramolecular carbenoid reactions would be diazo-
butanamides and acetamides bearing the trifluoromethyl benzonitrile 
fragment. These diazo substrates would have the general structure I 
(Scheme 2.1, see Chapter 1). Scheme 2.1 provides an overview of two 
potential approaches to the synthesis of these compounds. 
 
Scheme 2.1: Retrosynthetic analysis of aryl diazo amides. 
 
The parent acetoacetamide II might be synthesised by acylation of the 
corresponding aniline III (route A), prepared by metal-catalysed cross-
coupling between the appropriate aryl halide IV and an amine V.35 
Alternatively, II might be prepared by a metal-catalysed cross-coupling 
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reaction between the appropriate aryl halide IV and an amide VI,36 derived 
by the acylation of a suitable primary amine (route B). Literature precedent 
for both approaches is fairly abundant.35-36  
2.1.1. Development of a synthetic approach using a model 
system 
 
In order to develop a robust synthetic route for the synthesis of the 
desired aryl diazo-acetamides, a model compound, the butanamide 5, was 
prepared (Scheme 2.2). Reductive amination of benzaldehyde by treatment 
with allylamine and NaBH4 in MeOH and 4 Å molecular sieves, produced the 
secondary amine 3. 3  was then acylated37 by reaction with 4 in refluxing 
toluene to afford the amide 5. 
 
Scheme 2.2: Synthesis of the model compound, the butanamide 5. 
The amide 5 was treated with triethylamine and para-
acetamidobenzenesulfonylazide (p-ABSA);37-38  however, the reaction 
yielded the unexpected product 7. This product was hypothesised to be 
formed by a [3+2] cycloaddition reaction between the alkene and the diazo 
moiety, followed by subsequent tautomerisation of the intermediate 6b 
(Scheme 2.3).  
 
 Scheme 2.3: Rationale for the formation of product 7. 
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The structure of the dihydropyrazole 7 was elucidated by spectroscopic 
analysis. Key to the determination of its structure were the peaks 
corresponding to the imine-like proton (6.64 ppm) and the proton at the ring 
junction (3.24 ppm). Additional confirmation was provided by the IR 
spectrum: there were clear absorbance peaks for the N-H bond (3285 cm-1) 
as well as the amide and ketone carbonyl groups (1665 cm-1 and 1702 cm-1). 
In order to prevent the subsequent cycloaddition reaction, the saturated 
analogue, amide 10 was prepared. The amine 9 was synthesised via a 
reductive amination, using propylamine and benzaldehyde with NaBH4 in 
MeOH. The amine 9 was then acylated by treatment with 4 in refluxing 
toluene, to afford the amide 10 (Scheme 2.4). 
 
 
Scheme 2.4: Preparation of the amide 10. 
 
With butanamide 10 in hand, the synthesis of diazo-butanamides and 
diazo-acetamides was investigated. Treatment of 10 with p-ABSA and 
triethylamine in acetonitrile gave the diazo-butanamide 11, which was 
subsequently deacetylated under basic conditions to give diazo-acetamide 
12 (Scheme 2.5).38 These results verified the applicability of the approach for 
the preparation of the N-aryl diazo-butanamide and acetamide substrates. 
 
 
Scheme 2.5: Synthesis of the diazo-butanamide 11 and diazo-acetamide 
12. 
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2.1.2. Development of a synthetic methodology for the 
preparation of aryl diazo-acetamides 
 
Following the proposed retrosynthetic route A, (Scheme 2.1) the 
commercially available benzonitrile 13 was employed as a starting material. 
Cu(I) catalysed cross-coupling36a of 13 with benzylamine and propylamine, 
produced respectively the N-benzyl and the N-allyl anilines 15a and 15a’ 
(Scheme 2.6). 
NC
CF3
I
CuI (10 mol%),
L-proline (20 mol%)
K2CO3, DMSO,
90 °C, 20 h
H2N
NC
CF3
N
H
15a'
NC
CF3
N
H
15a
87%
NC
CF3
I
H2N
13
13
14a
2
CuI (10 mol%),
L-proline (20 mol%)
K2CO3, DMSO,
80 °C, 20 h
93%
 
Scheme 2.6: Cu(I) catalysed cross-couplings to yield the anilines 15a and 
15a’. 
Acylation of anilines 15a and 15a’ was attempted using the dioxinone 4 
by refluxing in toluene (110 °C) or xylene (140 °C). Unfortunately, these 
procedures were initially unsuccessful, as summarised in Table 2.1, 
presumably due to the very poor nucleophilicity of the aniline.  The acylation 
of anilines with dioxinone derivatives has been reported to proceed 
successfully with microwave irradiation.39 The aniline 15a was successfully 
acylated by treatment with dioxinone 4 under microwave irradiation to afford 
butanamide 16 in 74% yield. 
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Table 2.1: Optimisation of the acylation of  the anilines 15 and 16. 
 
Entry 
Aniline 
substrate 
Solvent 
(Temperature) Time Outcome 
1 15a (R = Bn) Toluene (110 °C) 3 d No reaction 
2 15a (R = Bn) Xylene (140 °C) 2 d No reaction a 
3 15a’ (R = allyl) Toluene (110 °C) 2 d No reaction 
4 15a’ (R = allyl) Xylene (140 °C) 2 d No reaction 
5 15a (R = Bn) Toluene (110 °C, μw 
irradiation)  1 h 16, 74% 
a: 88% of the starting material (aniline 15) was recovered after flash chromatography. 
The β-keto-butanamide 16 was treated with p-ABSA and 
triethylamine, in acetonitrile, and afforded the diazo-butanamide 17a.  This 
product  was subsequently deacylated using NaOMe in MeOH, to yield the 
diazo-acetamide 18a (Scheme 2.7). 
 
Scheme 2.7: Preparation of the diazo-butanamide 17a and the diazo-
acetamide 18a. 
The microwave-assisted acylation and subsequent diazo-transfer step 
were successfully merged into a telescoped process, which did not require 
the isolation of the intermediate butanamide (Scheme 2.8). This telescoped 
synthesis afforded the diazo-butanamide 17a in 71% yield from the aniline 
15a over two steps. 
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Scheme 2.8: Telescoped approach for the synthesis of 17a.  
 
2.2. Preparation of the diazo-butanamide and 
acetamide precursors 
 
Having established a robust synthetic methodology for the preparation 
of aryl diazo-butanamides and their corresponding acetamides, twelve 
diazo-compounds were selected as initial substrates for intramolecular 
metal-catalysed carbenoid reactions.  Different N-appended groups, (Figure 
2.1) were selected to enable a wide range of possible reaction outcomes 
from the same substrate. Substrates with alkyl chains (17b, 18b, 17d and 
18d) were selected to allow the possibility of alkyl C-H insertions. Aryl 
groups (17a, 18a, 17c and 18c) were chosen to enable  aryl C-H insertions 
on different aryl rings (cyano-trifluoromethyl or phenyl) as well as the 
formation of different ring sizes. Unsaturated groups (17e and 18e) were 
selected to allow the possibility of cyclopropanation. Finally, the compounds 
17f and 18f were chosen to enable the possibility of carbonyl-ylide formation 
and subsequent cascade reactions (See Chapter 1). Following the results of 
the second reaction round (see Chapter 4) a set of four additional diazo 
butanamides was also prepared (Figure 2.1).  
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Figure 2.1: Structures of the designed diazo substrates for intramolecular 
carbenoid reactions. 
 
  
- 35 - 
2.2.1. Preparation of the diazo-compounds 
Diazo-compounds 17a – 18e and 17g – 17i were prepared from 
commercially available amines, using the established synthetic methodology 
(Table 2.2). In each case the appropriate amine precursor was heated with 
CuI, L-proline and K2CO3 in DMSO, to produce the corresponding aniline. 
The anilines were subsequently acylated using the dioxinone 4 under 
microwave conditions, and treated with p-ABSA and triethylamine in 
acetonitrile to afford the diazo-butanamides. The required diazo 
butanamides were deacetylated using NaOMe in MeOH to afford the 
corresponding diazo-acetamides. 
For the preparation of the aniline 17e, the amount of K2CO3 used in the 
Cu(I)-catalysed coupling was increased by two equivalents because the 
necessary amine was only available as the hydrochloride salt. The diazo-
butanamide 17e and the diazo-acetamide 18e, fortunately did not undergo 
the same [3+2] cyclisation as did the model compound intermediate 6a. This 
can be attributed to two distinct differences between the two systems. The 
extra length of the homologated butenyl chain might inhibit optimal orbital 
overlap disfavouring the cyclisation. Also, the N-benzylamide is more free to 
rotate around the amide bond compaired to the N-arylamide. This ability to 
rotate more freely could allow the allyl chain to be placed at the optimal 
position for the cyclisation to occur. 
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Table 2.2: Preparation of diazo-butanamides and acetamides from 
commercially available  amines. 
 
Entry Amine Aniline (Yield) Diazo-butanamide
 
(Yield) b 
Diazo-acetamide 
(Yield) c 
1  
14a 
 
15a (87%) 
 
17a (77%) 18a (93%) 
2 
 
14b 
 
15b (93%) 
 
17b (70%) 18b (91%) 
3 
 
14c 
 
15c (87%) 
 
17c (71%) 18c (82%) 
4  
14d 
15d (90%) 17d (70%) 18d (75%) 
5 
 
14e 
15ed (86%) 17e (77%) 18e (93%) 
6 
14f 
15f (72%) 17f (63%) 18f (76%) 
7  
14g 
 
15g (67%) 
 
17g (54%) N.A. 
8 
 
14h 
15h (89%) 17h (97%) N.A. 
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9  
14i 
 
15i (63%) 
 
17i (69%) N.A. 
10  
14j 
15j (15%)e 17j (91%) N.A. 
a: CuI (10 mol%), L-proline (20 mol%.), K2CO3 (3 eqiuv.), DMSO, 90 °C, 20 h; b: i) 
Dioxinone 4, microwave irradiation, 100 W, 50 psi, PhMe, 110 °C , 45 min, ii) p-ABSA, Et3N, 
MeCN, rt, 1 h; c: NaOMe, MeOH, 0 °C, 3 h; d: amount of K2CO3 increased to five 
equivalents; e: prepared via alternative route.  
 
Preparation of diazo-butanamide 17f and diazo-acetamide 18f 
required the preparation of the N-methylamine 20. The amine was prepared, 
as the hydrochloride salt, from the available 3-butenylamine hydrochloride 
14e by reduction of the carbamate 19 using LiAlH4 (Scheme 2.9).  
 
Scheme 2.9: Preparation of the N-methyl 3-butenylamine hydrochloride salt, 
20. 
Two synthetic approaches were investigated for the preparation of the 
aniline 15f (Scheme 8.13). Amide coupling reactions with esters, catalysed 
by triazabicyclo[4.4.0]dec-5-ene (TBD), have been reported.40 The ester 15k 
was prepared from aryl iodide 13 and glycine ethyl ester hydrochloride 14k, 
treating with CuI, L-proline and K2CO3 in DMSO. However, the TBD-
catalysed reaction between the glycine ester 15k and the amine 20 was 
unsuccessful (Scheme 2.10).  
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Scheme 2.10: Α ΤΒD-catalysed amide coupling between the ester 15k and 
the amine 20 was not successful. 
As an alternative, the amide 14f was prepared by a EDCI/HOBt 
coupling between N-Boc glycine 21 and the amine 20 with subsequent Boc-
deprotection. Treatment of the aryl iodide 13 and the amide 14f with CuI, L-
proline and K2CO3 in DMSO, afforded the aniline 15f in 72% yield (Scheme 
2.11). 15f was acylated with dioxinone 4 under microwave irradiation and the 
crude product was treated with p-ABSA and Et3N, in acetonitrile to afford the 
diazo-butanamide 17f. This product was subsequently deacylated using 
NaOMe in MeOH, to yield the diazo-acetamide 18f (Scheme 2.12). 
 
Scheme 2.11: The preparation of aniline 15f was successful using a Cu(I)-
catalysed coupling between the aryl iodide 13 and the amide 14f. 
 
Scheme 2.12: Preparation of the diazo-butanamide 17f and the diazo-
acetamide 18f, from the aniline 15f.  
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The synthesis of diazo-butanamide 17j proved to be more challenging 
as the Cu(I)-catalysed amine coupling was ineffective in yielding the 
precursor aniline 15j in a viable amount (Scheme 2.13). An alternative route 
for the preparation of 15j was hence developed: the propargyl 
methanesulfonate 24 was prepared by sulfonylation of the propargyl alcohol 
23. The methanesulfonate 24 was subsequently displaced by the 
commercially available aniline 15k to obtain the desired aniline 15j.  The 
aniline 15j was then successfully acylated with dioxinone 4 under microwave 
irradiation and the crude product was treated with p-ABSA and Et3N, in 
acetonitrile to afford the diazo-butanamide 17j in 55% yield over 3 steps 
(Scheme 2.14). 
 
Scheme 2.13: The established route failed to afford compound 15j in a 
viable yield. 
 
Scheme 2.14: Alternative synthetic route for the preparation of precursor 
17j. 
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2.3. Summary 
In total, 16 diazo-butanamide and acetamide precursors for 
intramolecular metal-catalysed carbenoid reactions were prepared. The 
synthetic route developed for their preparation involved a Cu(I)-catalysed 
arylation of a free amine or a corresponding amine hydrochloride salt. This 
step was followed by a microwave-assisted N-acylation, a telescoped diazo-
transfer reaction and finally, an optional deacetylation reaction (Scheme 
2.15). The initial Cu(I)-catalysed coupling was substituted by a nucleophilic 
displacement of a suitable methanesulfonate in the case of aniline 15j, as it 
was proved inadequate for the preparation of this compound (Scheme 2.16). 
 
Scheme 2.15: The overall synthetic process; Cu(I)-catalysed arylation 
followed by a microwave assisted acylation and diazotransfer reaction. The 
final deacetylation was only used for the preparation of the diazo-
acetamides.  
 
Scheme 2.16: A nucleophilic displacement of the appropriate 
methanesulfonate proved to be a suitable alternative to the Cu(I)-catalysed 
coupling for the preparation of the secondary anilines. 
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The microwave-assisted acylation and subsequent diazo-transfer 
reaction were successfully telescoped into one step. The telescoped process 
proved to be higher yielding and less time-consuming compared to isolating 
the intermediate butanamide. The diazo precursors prepared were 
successfully used in the reaction array rounds (Chapter 4). 
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3. Chapter 3 
Establishment of a high-throughput assay 
3.1. Invitrogen TR-FRET Androgen Receptor 
Biochemical Assay 
Invitrogen has commercialised a biochemical assay for the screening of 
AR agonists and antagonists based on TR-FRET.41 FRET assays are 
commonly used in HTS systems and are fast, sensitive and reliable for 
screening libraries of compounds.41 As in standard FRET, when two 
fluorophores are in close proximity (0-10 nm) and their excitation and 
emission spectra overlap, excitation of the donor can result in emission by 
the acceptor. In TR-FRET, long-lifetime lanthanide metals are used as 
donors to overcome issues associated with scattered light and 
autofluorescent compounds with much shorter lifetimes.41   
This particular assay uses a Tb+3-labeled anti-GST antibody as the 
FRET donor (excitation 340 nm, emission 495 nm), a fluorescein-labeled 
coactivator peptide (excitation 490 nm, emission 520 nm) and a rat 
recombinant GST-tagged AR LBD. When the Tb+3-anti-GST antibody is 
excited at 340 nm, it fluoresces, emitting sharp bands centred at 490 nm, 
540 nm, 580 nm and 620 nm (Figure 3.1, dashed line). The emission at 490 
nm is enough to excite the fluorescein which in turn emits sharply at 520 nm. 
The ratio of emission at 520 nm over emission at 495 nm is then used to 
calculate the FRET ratio. 
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Figure 3.1: Excitation and emission spectra of the Tb+3-anti-GST antibody 
(TR-FRET donor) and fluorescein (TR-FRET acceptor).  
 
Binding of an agonist to the AR LBD induces a series of 
conformational changes allowing the coactivator peptide to associate to the 
AR LBD. Association of the peptide to the AR LBD brings the Tb3+- donor in 
close proximity to the fluorescein acceptor allowing FRET to occur (Figure 
3.2A). The same system can also be used for antagonist identification. 
Binding of an antagonist promotes the dissociation of the fluorescein-labeled 
peptide resulting in a decrease of FRET (Figure 3.2B). 
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Figure 3.2: Simplified illustration of the basic principles of the Invitrogen TR-
FRET assay. A: Agonistic mode; upon binding of an agonist conformational 
changes result in the association of the fluorescein-labeled coactivator 
peptide. The two fluorophores are brought in close proximity allowing for 
FRET to occur. The FRET ratio is concentration-dependent. B: Antagonistic 
mode; Displacing an agonist and binding of an antagonist inhibits the 
association of the fluorescein-labeled peptide resulting in a decrease of the 
FRET ratio in a concentration-dependent manner. 
Although this was a commercially available assay, setting up the 
system and optimising all the parameters proved to be a challenging and 
laborious task. It was found that  the use of the specific combination of 
certain 384-well plates (Corning #3676) and filters on the plate reader 
(Perkin-Elmer excitation filter 340 nm with 30 nm bandwidth; emission filters 
520 nm with 25 nm bandwith and 495 nm with 10 nm bandwidth) were 
needed to obtain reproducible results. 
3.2. Establishing the plate reader set-up 
The plate reader was tested in order to verify that the combination of 
excitation and emission filters available to use was optimal for measuring the 
TR-FRET signal from the Tb3+-chelate donor and the fluorescein-labeled 
peptide acceptor. Five solutions of the acceptor in different concentrations 
ranging from 5 μM to 200 nM were prepared. Aliquots from these samples 
were added to the wells of a 96-well plate containing a Tb3+-chelate donor 
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solution. The diffusion FRET ratio stemming from simple interactions 
between the two fluorophores due to Brownian motion bringing them to close 
proximity, estimated by dividing the emission intensity at 520 nm by the 
emission intensity at 495 nm, was plotted against the acceptor concentration 
(Plot 3.1) displaying a concentration dependent increase of FRET as 
expected. 
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Plot 3.1: Diffusion FRET ratio (520nm:495nm) against acceptor 
concentration. 
 
The ratiometric signal was normalized by dividing the FRET ratio for 
each acceptor concentration with the FRET ratio for the lowest acceptor 
concentration (Plot 3.2). The results verified that the combination of 
excitation and emission filters used was optimal for measuring the FRET 
signal of the fluorescein acceptor and Tb3+-chelate donor supplied with the 
assay kit as they were consistent with the manufacturers values for these 
parameters. 
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Plot 3.2: Normalised diffusion FRET ratio against acceptor concentration. 
3.2.1. Determination of the activity of known agonists  and 
antagonists 
 
Having established the plate reader setup, a natural AR agonist, 
testosterone (TE) was tested. Α DMSO solution οf TE (500 μΜ) was 
prepared and then diluted in a  3-fold 12-step serial dilution manner in 
DMSO. These solutions were diluted further using the assay buffer and the 
solutions added to duplicate wells of a 384-well plate. The protein (ARLBD 
1.25 μΜ) and the two fluorphores (Tb+3-anti-GST-Ab 5 nM and Fluorescein-
labeled peptide 500 nM) were added and the plate was left to equilibrate for 
2 h before being read at the plate reader. A  synthetic antagonist – 
cyproterone acetate (CPA) – was also tested. In a similar fashion, a DMSO 
solution of CPA (2 mM) was prepared and then diluted in a  3-fold 12-step 
serial dilution manner in DMSO. As with TE, these solutions were diluted 
further using the assay buffer and the solutions added to the wells of a 384-
well plate in duplicate. The protein (ARLBD 1.25 μΜ) the two fluorophores 
(Tb+3-anti-GST-Ab 5 nM and fluorescein-labeled peptide 500 nM) as well as 
TE (360 nM) were added and the plate was left to equilibrate for 2 - 4 h 
before being read at the plate reader. 
Both compounds gave concentration-dependent curves consistent with 
literature values (Figure 3.3).33b Obtaining dose response curves with EC50 
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and IC50 values consistent with reported literature33b provided additional 
confirmation for the applicability of the Invitrogen assay for the purposes of 
the project. 
 
Figure 3.3: Dose-response curves for Testosterone, TE (left) and 
cyproterone acetate, CPA (right). EC50 and IC50 values, respectively, are 
consistent with literature values,1 TE EC50 17.3 nM; CPA IC50 6.4 nM. 
 
3.3. Metal scavenging studies 
In order to be able to screen reactions mixtures using the Invitrogen 
assay, removal of the residual Rh(II) catalysts was required. This is readily 
achievable using metal-scavenging macroporous polymeric resins.42 
Thiourea resins, such as the commercially available QuadraPure TUTM 
resin,42 (Figure 3.4) have been demonstrated to be excellent for the removal 
of Pd, Rh, Ru and other metals.  
 
Figure 3.4: Structure of thiourea polymeric resin used to scavenge Pd, Rh, 
Ru, Pt and other heavy metals from reaction mixtures. 
Briefly, 100 μL of 1 mM solutions of Rh2(OAc)4 in CH2Cl2 and THF and 
Rh2(pfb)4 in toluene and EtOAc were prepared in the wells of a custom made 
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96-well PTFE plate. Increasing amounts of QuadraPure TU resin were 
added to the wells.  No resin was added to the first row of each column and 
these wells served as negative controls. The wells were sealed using 
disposable sealing caps and left to scavenge. After 24 h the wells were 
unsealed and aliquots of the resulting solutions were analysed for heavy 
metal traces using an atomic absorbance microanalyser and compared 
against a calibration curve produced from three standard solutions (for 
rhodium: 5 ppm, 10 ppm and 15 ppm). As it can be observed in Plot 3.3, it 
was possible to remove >99% of the Rh(II) metal added using ca 30 mg of 
the resin. The amount of Rh(II) metal remaining in solution after scavenging 
was calculated to be ca 1 nmol per 100 μL of reaction mixture which would 
be diluted down to 1 nM when screening at a total product concentration of 
10 μM (see Chapter 4). An approximate amount of 30 mg of was 
QuadraPure TU resin thus added to the actual microreaction mixtures during 
the reaction arrays. 
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Plot 3.3: Scavenging of Rh(II) catalysts from various solvents using the 
QuadraPure Thiourea resin. 
3.4. Determination of the activity of the diazo 
precursors 
It was essential to determine that the potential diazo precursors’ activity 
would not interfere with the activity displayed by the microreaction mixtures 
that would be generated later during the progress of the project. Dose 
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response curves of the all 16 diazo precursors were recorded in a similar 
manner to TE and CPA (Plot 3.4). As it can be observed all of the diazo 
precursors were essentially inactive below 100 μM. This concentration would 
serve as an initial starting point for the screening of the microreaction 
mixtures and hence no interference from residual unreactive precursors 
would be observed. 
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Plot 3.4: Dose response curves of the 16 diazo precursors used in the 
reaction arrays. TE curve for comparison. 
3.5. Summary 
 The applicability of the TR-FRET assay for the purposes of this 
project was confirmed by testing the plate reader setup and recording dose-
response curves for two literature compounds, a natural agonist TE and a 
synthetic antagonist CPA. The EC50 and IC50 values determined for these 
compounds are consistent with reported literature values.30 The ability to 
remove the Rh metal from the microreaction mixtures using the QuadraPure 
TU resin was successfully determined. A quantity of ca. 30 mg was 
determined to be ideal for the removal of the metal. Lastly, the diazo 
precursors were found to be inactive against the androgen receptor at 
concentrations lower than 100 μM. All the above findings provided 
confidence that the experimental setup used was optimised and  could be 
used successfully for the purposes of the project. 
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4. Chapter 4 
Exploitation of intramolecular reactions in the Activity-
Directed Synthesis of androgen receptor agonists 
This chapter describes the details of the activity-directed synthesis of 
androgen receptor agonists using intramolecular reactions. Subsequently, 
the isolated products were elucidated and biologically evaluated. In addition, 
the basis of the emergence of the syntheses were evaluated retrospectively. 
The results described in this chapter have been published in Karageorgis et 
al. in Nature Chemistry, 2014, 6, 872-876. 
4.1. Reaction array 1 
For the first reaction array, the initial twelve α-diazo-amides 17a – 18f 
described in Chapter 2 were used. Dichloromethane was chosen as a 
generic solvent along with three commonly used Rh(II) catalysts: Rh2(OAc)4, 
Rh2(S-DOSP)4 and Rh2(5S-MEPY)4 (Figure 4.1). Rh2(OAc)4 is the most 
common Rh(II) catalyst, and Rh2(S-DOSP)4 and Rh2(5S-MEPY)4 are also 
commonly exploited with α-diazo-amides.43 Reactions were carried out in 
custom made 96-well PTFE plates. Briefly, the appropriate catalyst (4 μL of 
25 mM solution in THF) was added to each well containing a solution of the 
relevant diazo-substrate (8 μL of 1.25 M solution in CH2Cl2) in the 
appropriate solvent (88 μL) and subsequently sealed. This mixture resulted 
in a final solution with the diazo-amide substrate at a concentration of 
100 mM and the metal catalyst at a concentration of 1 mM. The product 
mixtures were mixed by pipetting occasionally, resealed and left to react at 
room temperature for 48 hours. 
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Figure 4.1: Structures of metal catalysts used in intramolecular reactions for 
activity-directed synthesis on androgen receptor agonists using 
intramolecular reactions. 
 
After scavenging for Rh(II) (see Chapter 3 for metal scavenging studies), 
the solvent was removed by evaporation at rt and then under reduced 
pressure and the reaction mixture was rediluted in dimethyl sulfoxide to give 
a solution of total product concentration of 100 mM. The product mixtures 
were then diluted further in DMSO and assay buffer and screened at an 
initial screened total product concentration of 10 μM (10 μM 1% DMSO in 
buffer, see experimental for full details). The TR-FRET ratio (520 nm/495 
nm) was then normalised to a percentage using the positive control 
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(Testosterone, TE 5 μM) as 100% and the negative control (1% DMSO in 
buffer, no ligand) as 0%. The results are shown in Figure 4.2. 
 
Figure 4.2: Percentage of activity (relative to 5 μM TE) of product mixtures 
from reaction array 1 at a total concentration of 10 μM (1% DMSO, in buffer). 
Different colours represent different catalysts: black Rh2(OAc)4, yellow 
Rh2(S-DOSP)4 and blue Rh2(5S-MEPY)4. Red boxes show which product 
mixtures were selected to inform the design of the subsequent reaction 
array. 
 
Product mixtures derived from the substrates 17a, 17b, 18c and 17e 
(Figure 4.3) exhibited the most promising results. These product mixtures 
retained  the high levels of activity at the screened concentration as well as 
across two of the catalysts used, Rh2(OAc)4 and Rh2(4S-DOSP)4.  The 
activity of these product mixtures informed the design of the reaction array 2. 
4.2. Reaction array 2 
For the second array, four solvents of increasing polarity44 and eight 
catalysts were chosen. CH2Cl2, THF, toluene and EtOAc have been 
previously used for metal carbenoid reactions.25b Rh2(OAc)4, Rh2(4S-
MEOX)4, Rh2(cap)4, Rh2(tfa)4, and Rh2(4S-MPPIM)4 (Figure 4.1) were 
chosen as readily available and reliable Rh(II) catalysts that could enable a 
wide range of carbenoid reactivity. Reports of using Cu(I), Pd(II) and Co(III) 
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based catalysts for carbenoid chemistry28 prompted the use of CuOTf–bis-
oxazoline, PdCl2–bis-oxazoline and Co(III)–salen complexes as well.  
The diazo substrates 17a, 17b, 18c and 17e (Figure 4.3) were used in 
reaction array 2 as these substrates that yielded the most promising product 
mixtures in reaction array 1. The diazo substrates 17f and 18f were also 
used in reaction array 2 in order to investigate whether it would be possible 
to resurrect any activity from substrates that did not yield any promising 
product mixtures in reaction array 1.   
 
Figure 4.3 Diazo substrates exploited in reaction array 2. Substrates 17a, 
17b, 18c and 17e were found to give the most active product mixtures. 
Substrates 17f and 18f were also used in the second reaction array as a 
control to investigate if it would be possible to resurrect any levels of activity. 
 
The microreactions were conducted in a similar fashion as for 
reaction array 1: the appropriate catalyst (4 μL of 25 mM solution in THF) 
was added to each well containing a solution of the relevant diazo-substrate 
(8 μL of 1.25 M solution in CH2Cl2) in the appropriate solvent (88 μL) and 
subsequently sealed. They were mixed by pipetting occasionally, resealed 
and left to react at room temperature for 48 hours. The product mixtures 
were diluted accordingly in DMSO and buffer and screened using the TR-
FRET AR assay at a total concentration of 10 μM as well as at a total 
concentration of 1 μM (10 μM and 1 μΜ 1% DMSO in buffer, see 
experimental for full details). Screening at a lower concentration was used 
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as a way of imposing selection pressure onto the system as well probing any 
effect dilution would have on the activity displayed by each reaction mixture. 
As before, the TR-FRET ratio (520 nm/495 nm) was normalised to a 
percentage using the positive control (TE 5 μM) as 100% and the negative 
control (1% DMSO in buffer, no ligand) as 0%. The results are shown in 
Figure 4.4. 
 
Figure 4.4: Percentage of activity (relative to 5 μM TE) of product mixtures 
from reaction array 2 at a total concentration of 10 μM (above) and a total 
concentration of 1 μM (below) (1% DMSO , in buffer). Different colours 
represent different catalysts (black Rh2(OAc)4, bright green Rh2(tfa)4 and 
blue Rh2(cap)4) and different shapes represent different solvents (squares 
CH2Cl2, triangles PhMe, circles THF, pentagons EtOAc). Red boxes show 
which product mixtures were selected to inform the design of the subsequent 
reaction array. Error bars omitted for clarity. Typical error 2-5%. 
As it can be observed in Figure 4.4, screening at a lower concentration 
revealed that only few product mixtures displayed high activities. This 
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observation might suggest that the reactions are only steered towards the 
formation of active products under specific combinations of diazo substrate, 
catalyst and solvent. This effect is more striking in the case of substrate 17a, 
where most of the product mixtures display very low activities, and only 
under some conditions combinations high activities are observed. Product 
mixtures from substrates 17a and 17c in combination with carboxylate Rh(II) 
catalysts in CH2Cl2, toluene or EtOAc, gave consistently better results 
compared to substrates 18c and 17e. The Cu(I), Pd(II) and Co(III) catalysts 
were found to yield weakly active product mixtures which lost their activity 
once diluted by a factor of ten. As expected, substrates 17f and 18f  did not 
yield any promising product mixtures suggesting that no active products 
were derived from these substrates. These results informed the design of 
the subsequent reaction array three. 
4.3. Reaction array 3 
Using the above results, a focused library of four additional substrates 
was synthesised, based on the structural features of substrates 17a and 
17b. The diazo substrate 17g was a heteroaromatic analogue of diazo 
substrate 17a, whilst diazo substrates 17h–17j were functionalised 
analogues of diazo substrate 17b. Substrates 17g–17j were synthesised 
using the established synthetic route as described in Chapter 2 (Figure 4.5). 
 
Figure 4.5: Diazo substrates exploited in reaction array 3. Substrates 17g-
17j were inspired by substrates 17a and 17b.  
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A third reaction array was carried out using the substrates 17a, 17b 
and 17g - 17j as well. A focused set of carboxylate Rh(II) catalysts was used 
as this type of catalyst had been shown to give the most active product 
mixtures in the previous reaction array. The reactions were conducted in 
CH2Cl2, toluene and EtOAc as all three solvents gave consistently good 
results in the previous array. The appropriate catalyst (4 μL of 25 mM 
solution in THF) was added to each well containing a solution of the relevant 
diazo-substrate (8 μL of 1.25 M solution in CH2Cl2) in the appropriate solvent 
(88 μL) and subsequently sealed. They were mixed by pipetting 
occasionally, resealed and left to react at room temperature for 48 hours. 
The product mixtures were subsequently diluted in DMSO and buffer 
accordingly and screened using the TR-FRET AR assay total concentrations 
of both 1 μM as well as 100 nM, As before, the TR-FRET ratio (520 nm/495 
nm) was normalised to a percentage using the positive control (TE 5 μM) as 
100% and the negative control (1% DMSO in buffer, no ligand) as 0%. The 
results are shown in Figure 4.6. 
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Figure 4.6: Percentage of activity (relative to 5 μM TE) of products mixtures 
from reaction array 3 at a total concentration of 1 μM (above) and 100 nM 
(below) (1% DMSO, in buffer). Different colours represent different catalysts 
(black Rh2(OAc)4, purple Rh2(esp)2 and orange Rh2(oct)4) and different 
shapes represent different solvents (squares: CH2Cl2, triangles: PhMe, 
pentagons: EtOAc). Red boxes show which product mixtures were selected 
to inform the selection of reactions to scale-up. Error bars omitted for clarity. 
Typical error 2-5%. 
 
Once more, it can be observed that only specific reaction conditions 
yield product mixtures which displayed promising activities. At this point the 
most promising combinations of substrate, catalyst and solvent were 
selected for scale up. Their selection was based on maintaining their activity 
even at the lowest level of dilution, total concentration of 100 nM when 
screened using the TR-FRET AR assay.  
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4.4. Scale up 
A total of eight reactions was selected for scale up; three reaction 
conditions using substrate 17a, three reaction conditions using substrate 
17b and two reaction conditions using substrate 17i. The conditions for 
these reactions are summarised in Table 4.1.  
Table 4.1: The eight most promising reactions were selected for scale-up. 
The details of the combinations regarding the substrate, catalyst and solvent 
are shown below. 
Entry Substrate Solvent Catalyst 
1 
 
CH2Cl2 Rh2(oct)4 
2 CH2Cl2 Rh2(OAc)4 
3 EtOAc Rh2(esp)2 
4 
 
CH2Cl2 Rh2(oct)4 
5 CH2Cl2 Rh2(esp)2 
6 CH2Cl2 Rh2(OAc)4 
7 
 
EtOAc Rh2(esp)2 
8 PhMe Rh2(tpa)4 
 
The selected reactions were performed in a similar manner as the 
microreactions on a 50-fold larger scale. The appropriate diazo substrates 
(400 μL of a 1.25 M solution in CH2Cl2) and the metal catalyst (200 μL of a 
25 mM in THF) were mixed in the appropriate solvent (4.4 mL). The final 
concentration for the diazo substrate was 0.1 M and for the catalyst 1 mM, in 
5 mL of solvent. The reactions were sealed and left to react for 48 h, 
followed by TLC and LC-MS. After scavenging they were filtered, 
concentrated in vacuo and the crude mixture purified by column 
chromatography. 
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4.4.1. Reactions from diazo substrate 17a 
The diazo butanamide 17a was treated with 1 mol% Rh2(OAc)4, 
Rh2(oct)4 or Rh2(esp)2 in CH2Cl2 or EtOAc. The outcome of each reaction is 
summarised in Table 4.2. The major product isolate in all three reactions 
was the β-lactam 25 formed by a C-H insertion at the benzylic position. The 
structure was confirmed by the IR peak at 1705 cm-1, indicative for a β-
lactam as well as the characteristic splitting patterns of the protons at 
positions 3 and 4 of the azetidinone ring. The relative trans configuration 
around the ring was determined by nOe spectroscopy, observing the 
correlation between the proton at the 4-position of the azetidinone ring (5.55 
ppm) and the methyl protons (2.40 ppm) (Figure 4.7) as well as 
characteristic trans azetidinone coupling constants of the protons at the 3- 
and 4- positions. 
Table 4.2: Scaled-up reactions from the diazo substrate 17a. 
Entry Catalyst Solvent Product  Yield (%) 
1 Rh2(oct)4 CH2Cl2 
 
71 
2 Rh2(OAc)4 CH2Cl2 68 
3 Rh2(esp)2 EtOAc 75 
 
 
Figure 4.7: Structural confirmation about the trans configuration of the 
azetidinone ring came from the nOe correlation between the proton at the 4- 
position and the methyl protons. 
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4.4.2. Reactions from diazo substrate 17b 
The diazo butanamide 17b was treated with 1 mol% Rh2(OAc)4, 
Rh2(oct)4 or Rh2(esp)2 in CH2Cl2. The outcome of each reaction is 
summarised in Table 4.3. The major product isolated was in all cases,the γ-
lactam 26 which was formed by a C-H insertion at the 2- position of the ethyl 
group. Structural confirmation was, once more provided by nOe 
spectroscopy to determine the trans configuration around the five-membered 
lactam ring. The correlation between the proton at the 3-position of the 
lactam ring (3.48 ppm) and the protons of methyl group at the 4-position 
(1.25 ppm) was observed (Figure 4.8). 
Table 4.3: Scaled-up reactions from diazo substrate 17b. 
Entry Catalyst Solvent Product  Yield (%) 
1 Rh2(oct)4 CH2Cl2 
 
88 
2 Rh2(esp)2  CH2Cl2 90 
3 Rh2(OAc)4 CH2Cl2 55 
 
 
Figure 4.8: Determination of the relative configuration around the lactam 
ring: a nOe correlation between the proton at the 3-position and the protons 
of the methyl group at the 4-position was observed. 
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4.4.3. Reactions from diazo substrate 17i 
Diazo butanamide 17i was treated with 1 mol% Rh2(esp)2 and Rh2(tpa)4 
in EtOAc or toluene respectively. The outcome of the two reactions is 
summarised in Table 4.4.The major product isolated from both reactions the 
β-lactam 27 formed by a C-H insertion at the 2-position of the N-appended 
group. As in the case of β-lactam 25, structural confirmation was provided by 
IR (1716 cm-1) and observation of nOe interactions (Figure 4.9) between the 
proton at 4.42 ppm (3-position) and the protons at 3.06 ppm (methylene 
cyano group) as well as characteristic trans azetidinone coupling constants 
of the protons at the 3- and 4- positions. 
Table 4.4: Scaled-up reactions from diazo substrate 17i. 
Entry Catalyst Solvent Product  Yield (%) 
1 Rh2(esp)2 EtOAc 
 
78 
2 Rh2(tpa)4 PhMe 70 
 
 
Figure 4.9: Structural confirmation about the trans- geometry of the 
azetidinone ring came from the nOe correlation between the proton at the 3- 
position and the protons at the 2- position of the methylene cyano group. 
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4.5. Evaluation of the isolated products 
The three isolated products – the β-lactam 25, the γ-lactam 26  and the 
β-lactam 27 were assayed in dose-dependent manner. Stock solutions of the 
compounds in DMSO were prepared (20 mM for 25 and 26 and 50 mM for 
27) and diluted accordingly with DMSO and assay buffer in a 12-step, 3-fold 
serial dilution manner. The initial assayed concentration was 50 μM for 
compounds 25 and 26 and 200 μM for compound 27 (1% DMSO in buffer) 
(Figure 4.10 and experimental for details).  
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Figure 4.10: Dose-response curves obtained by assaying the isolated 
products from the scaled reactions β-lactam 25, γ-lactam 26  and the β-
lactam 27.  
 
From the dose-response curves obtained, the EC50  value for each of 
the compounds was extracted by applying a non-linear fitting (logistic fit, 
OriginPro v. 8.6); β-lactam 25 350 (±60) nM, γ-lactam 26 470 (±78) nM and 
β-lactam 27 440 (±56) nM.  The two β-lactams 25 and 27, were found to be 
full agonists of the Androgen Receptor, whilst the γ-lactam 26 was found to 
be a partial agonist meaning that it will display a lower maximum activity 
compared to the maximum activity displayed by a full agonist such as 
testosterone. It had been previously observed that bicalutamide also acted 
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as a partial agonist when using this assay.45 All three products were found to 
be active modulators of the Androgen Receptor with chemotypes with no 
previously annotated biological activity. 
4.6. Synthesis of β-lactam 25 via an alternative route 
An alternative synthesis of the most active compound, the β-lactam 25, 
was undertaken. The alternative synthesis would prove beyond reasonable 
doubt that the activity observed from the isolated compound using the Rh-
catalysed reaction was indeed attributed to the β-lactam 25, and not to 
undetected minor impurities. 
To this extent, the commercially available racemic β-phenyl alanine 28 
was treated with methanesulfonyl chloride and NaHCO3 in acetonitrile46 to 
give the β-lactam 29. The β-lactam 29 was subsequently arylated by 
treatment with the aryl iodide 13, CuI, a diamine ligand and K3PO4 in 
refluxing dioxane47 to yield the N-arylated β-lactam 30. Subsequently the β-
lactam 30 was successfully acylated at the 3’ position by treatment with LDA 
and then methyl acetate48 to afford the desired β-lactam 25 as a single 
diastereomer (Scheme 4.1). The NMR spectra of the product, were identical 
to those previously obtained. 
 
Scheme 4.1: Alternative, synthesis of the β-lactam 25. 
 
A sample of the re-synthesised compound was assayed alongside a 
sample of the original β-lactam and the two were found to display almost 
identical activities within experimental error (Figure 4.11). The activity of the 
- 64 - 
resynthesised molecule demonstrated beyond reasonable doubt that the β-
lactam 25 was responsible for the activity observed. 
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Figure 4.11: The resynthesised β-lactam was found to give an almost 
identical dose-response curve as the original sample. Resynthesised (black 
squares) 320 ± 67 nM; Original (red circles) 340 ± 42 nM. 
 
4.7. Retrospective exploration of the basis of the 
emergence of Activity-Directed Synthesis 
Having proved that the active components in the product mixtures 
mixtures were the same as the products isolated from the scaled reactions, 
a retrospective exploration was undertaken in order to understand the basis 
for the emergence of the activity-directed synthesis. 
 
4.7.1. Quantitative HPLC 
To begin, the yield of the active component 25 and the activity 
displayed by the crude product mixtures was correlated. Quantitative HPLC 
analysis of the product mixtures generated in reaction array 3 with the diazo 
substrate 17a was performed, to determine the yield of the β-lactam 25 
formed in each reaction (Figure 4.12). Samples of each micro-reaction were 
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analysed using HPLC conditions determined by HPLC analysis of a pure 
sample of the β-lactam 25. 
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Figure 4.12: Correlation of the yield (%) of the β-lactam 25 and the activity 
displayed by product mixtures (relative to 5 μM TE) from reaction array 3, 
screened at Σ[Pn] = 100 nM (1% DMSO in buffer). 
 
The yield of the β-lactam 25 correlated very well with the activity 
displayed by the product mixtures (Figure 4.12). This analysis demonstrated 
that the direct assaying of the product mixtures gave an indication of the 
yield of the most active product i.e. by maximising the activity of the product 
mixtures,  the yield of the most active product would also be optimised. 
 
4.7.2. Diversity of products 
In order to investigate whether diverse products had been generated 
throughout the reaction arrays, some reactions that did not display 
sufficiently promising activity were also scaled-up. One reaction from each 
reaction array was selected: from reaction array 1 the diazo substrate 17e 
with Rh2(OAc)4 in CH2Cl2; from reaction array 2 diazo substrate 17a with 
Rh2(tfa)4 in CH2Cl2; and finally, from reaction array 3 diazo substrate 17h 
with Rh2(OAc)4 in CH2Cl2. In each reaction, the appropriate diazo substrate 
(400 μL of a 1.25 M solution in CH2Cl2) and the necessary metal catalyst 
(200 μL of a 25 mM in THF) were mixed in the appropriate solvent (4.4 mL). 
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The final concentration for the diazo substrate was 0.1 M and for the catalyst 
1 mM, in 5 mL of solvent. The reactions were sealed and left to react for 48 
h and as before followed by TLC and LC-MS. After scavenging, the crude 
was filtered, concentrated in vacuo and purified by column chromatography. 
The diazo substrate 17e afforded three different products when treated with 
1 mol% Rh2(OAc)4 in CH2Cl2 at room temperature: two oxindoles, 31 and 32, 
formed by C-H insertions, and a δ-lactam 33 formed by a cyclopropanation 
(Scheme 4.2). The diazo substrate 17a was treated with 1 mol% Rh2(tfa)4 in 
CH2Cl2 at room temperature: the reaction yielded  the oxindole 34, again via 
a C-H insertion. Similarly, treatment of the diazo substrate 17h with 1 mol% 
Rh2(OAc)4 in CH2Cl2 at room temperature yielded the oxindole 35. 
 
Scheme 4.2: Outcome of some reactions that did not yield product mixtures 
with sufficient activity for prioritisation. 
 
Stock solutions of the purified products in DMSO (100 mM for 
compounds 31-33, 25 mM for compound 34 and 50 mM for compound 35) 
were prepared and used to assay compounds 31-25 in a dose-response 
manner. These solutions were further diluted in buffer resulting at an initial 
assayed concentration of 1 mM for compounds 31-33, 110 μM for compound 
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34 and 200 μM for compound 35 (1% DMSO in buffer). When assayed all 
products, apart from the oxindole 32, were found to be partial agonists of the 
androgen receptor. Their EC50 values were determined by using a logistic fit 
on the dose-response curve: oxindole 31 10.0 ± 0.9 μΜ; δ-lactam 33 0.7 ± 
0.1 μΜ; oxindole 34 2.4 ± 0.4 μΜ; and oxindole 35 12.0 ± 3.7 μΜ. Their EC50 
values were found to be significantly higher than the products isolated from 
the original eight scaled-up reactions (Figure 4.13 and Table 4.5). 
 
 
Figure 4.13: Dose-response activity of the products 31, 33, 34 and 35. 
Compound 32 was not found to be active when assay for agonistic activity. 
All compounds were found to be partial agonists of the androgen receptor. 
Initial assayed concentrations 1 mM for compounds 31-33, 110 μM for 
compound 34 and 200 μM for compound 35 (1% DMSO in buffer).  
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Table 4.5: EC50 values of some products obtained from reactions whose 
product mixtures did not display significantly promising activity for 
prioritisation. 
Entry Product EC50 (μΜ) 
1 
 
10.0 ± 0.9 
2 
 
0.7 ± 0.1 
3 
 
>200 μΜ 
4 
 
2.4 ± 0.4 
5 
 
12.0 ± 3.7 
 
From these additional reactions, four chemotypes were identified: the 
oxindole 31, the isomeric oxindole 32, the δ-lactam 33 and the acetyl-
oxindoles 34 and 35. Apart from compound 32, all the compounds were 
found to be partial agonists with higher EC50 values compared to compounds 
25-27. These results may retrospectively rationalise the reason for not 
prioritising these reactions for the design of the subsequent reaction array. 
From reaction array 1, which was screened at a total product concentration 
of 10 µM, product mixtures stemming from diazo-substrate 17e displayed 
borderline activity presumably stemming from oxindole 31 the δ-lactam 33. 
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From reaction array 2, which was screened at total product concentrations of 
10 µM and 1 µM,  only some of the product mixtures stemming from diazo-
substrate 17a displayed promising activities whilst a few displayed only 
moderate activity, insufficient for prioritisation, possibly stemming from 
oxindole 34. Finally in reaction array 3, which was screened at total product 
concentrations of 1 µM and 100 nM, product mixtures stemming from diazo-
substrate 17h, did not display promising  activities, attributed to the 
formation of the weakly active oxindole 35. These results  indicate that the 
chemical space arising from each of the diazo substrates was sufficiently 
explored yet ultimately discarded due to either the low activity displayed by 
the products or the low yield in which they were formed.  
4.8. Summary 
Three arrays of intramolecular reactions were performed and the 
product mixtures from each array were screened for agonism of the 
Androgen Receptor, in progressively lower concentrations. This technique 
facilitated the selection of reaction conditions to be carried forward to the 
subsequent reaction array, based on the activity of product mixtures. A total 
of 272 micro-reactions were performed. This process allowed for the 
selection of eight reaction conditions for scale-up (Figure 4.14). Purifying, 
characterising and evaluating the biological activity of the products led to the 
rapid and efficient discovery of three sub-micromolar modulators of the 
Androgen Receptor with chemotypes with no previously annotated biological 
activity (Figure 4.15).  
Figure 4.14: A total of 272 reactions were
arrays. Eight reaction conditions were selected to be scaled
 
Figure 4.15: Three
with no previously annotated biological activity.
The retrospective exploration also provided evidence about the 
overall development of the approach and that the optimisation of activity
directed synthesis might lead to the simultaneous optimisation of both the 
yield and the structure of an active chemotype. In reaction array 1, the 
carbenoid reactivity was probed, evidenced by the formation of products 
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 performed over three reaction 
 modulators of the Androgen Receptor with chemotypes 
 
 
-up. 
 
-
31, 
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32, 33 and the β-lactam 25. In reaction array 2, the combination of solvent 
and catalyst resulted in yielding the active component in a similar or higher 
yield.  In  some cases the formation of a different less active product e.g. 
oxindole 34 was observed. Finally, in reaction array 3, a new, functionally 
similar diazo-substrate e.g. 17i was used to yield a novel compound, 27, but 
of a similar chemotype i.e. a β-lactam (Figure 4.16). 
 
Figure 4.16: Overall development of the methodology elucidated by the 
retrospective exploration. 
  The  alternative synthesis confirmed the activity of the β-lactam 25 
both quantitatively and qualitatively. The HPLC analysis combined with 
scaling up three additional reactions elucidated the progression and overall 
development of the methodology demonstrating its versatility and 
effectiveness as a novel tool for the discovery of small bioactive molecules. 
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5. Chapter 5 
Exploitation of Intermolecular Reactions in the Activity-
Directed Synthesis of Androgen Receptor Agonists 
A limitation of intramolecular reactions is that the outcome is largely 
determined by the diazo-substrate. Furthermore, synthetic effort was 
invested in the individual preparation of each substrate. For these reasons, it 
was decided to exploit intermolecular reactions for the activity-directed 
synthesis of Androgen Receptor agonists. Intermolecular reactions could, in 
principle, enable a far wider range of possible outcomes. In each round, a 
collection of possible co-substrates which were inactive against the 
androgen receptor, was used with diazo-amide substrates to yield product 
mixtures. Subsequently, selected reactions from each round were scaled-up 
and the isolated products from were elucidated and evaluated biologically in 
order to understand rationalise the emergence of activity-directed syntheses. 
5.1. Synthesis of diazo amide substrates for 
intermolecular reactions 
The diazo amide substrates for intermolecular reactions followed a 
similar design to the diazo amides for intramolecular reactions. However, it 
was decided that the N-appended group would be chosen such that it would 
minimise the possibility for intramolecular reactions. Limiting the 
consumption of the diazo substrate in intramolecular reactions would, in 
principle, promote the participation in intermolecular reactions. Four diazo 
amide substrates were initially used for intermolecular reactions: two diazo 
butanamides and two diazo acetamides (Figure 5.1). The N-appended group 
was chosen to be either methyl or cyclopropyl, as C-H insertions on 
unactivated methyl groups or tertiary carbon atoms have been shown to be 
unfavoured,49 minimising the possibilities of intramolecular reactions.  
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Figure 5.1: The design of the four diazo amides 17k–18l, used in 
intermolecular reactions. The N-appended groups were selected such that 
possible intramolecular reactions would be minimised.  
 
The four diazo amides were prepared using a synthetic route similar 
the diazo amides for intramolecular reactions (see Chapter 2). The aryl 
iodide 13 was heated with either the N-methyl amine hydrochloride 14k or 
the cyclopropylamine 14l, and CuI, L-proline and K2CO3 in DMSO to afford 
the anilines 15k and 15l. The anilines 15k and 15l were acylated under 
microwave irradiation using the dioxinone 4 and subsequently diazonated by 
treatment with p-ABSA and triethyl amine in acetonitrile to yield the diazo 
butanamides 17k and 17l. Subsequently, 17k and 17l were deacylated by 
treatment with NaOMe in methanol and afforded the diazo amides 18k and 
18l. 
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Table 5.1: Synthesis of diazo amide substrates 17k–18l from available 
amines. 
 
Entry Amine 
Aniline 
(Yield) 
Diazo-
butanamide 
(Yield) b 
Diazo-
acetamide 
(Yield) c 
1 
 
 
14k 
 
15kd 
(85%) 
17k 
(88%) 
18k  
(64%) 
2 
 
14l 
 
15l 
(81%) 
17l  
(83%) 
18l  
(48%) 
a: CuI (10 mol%), L-proline (20 mol%), K2CO3 (3 eqiuv.), DMSO, 90 °C, 20 h; b: i) Dioxinone 
4, microwave irradiation, 100 W, 50 psi, PhMe, 110 °C , 45 min, ii) p-ABSA, Et3N, MeCN, rt, 
1 h; c: NaOMe, MeOH, 0 °C, 3 h; d: amount of K2CO3 increased to five equivalents. 
 
Prior to being used in intermolecular microreaction arrays, the four 
diazo amides (17k, 17l, 18k and 18l) were tested in a dose-dependent 
manner against the androgen receptor using the TR-FRET assay from at an 
initial concentration of 500 μM (1% DMSO, in buffer) (Figure 5.2).  As it can 
be observed, all four diazo amide substrates were not active at 
concentrations lower than 50 μΜ, indicating that they could be used in the 
subsequent intermolecular microreaction arrays.  
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Figure 5.2: Normalised TR-FRET ratio (520 nm/495 nm) of the four diazo 
amide substrates 17k-18l assayed in a dose-dependent manner from an 
initial concentration of 500 μM (1 % DMSO, in buffer). The diazo substrates 
were found to be inactive at concentrations lower than 50 μM.  
 
5.2. Selection of co-substrates for the  intermolecular 
reactions  
Alongside the four initial diazo substrates, an initial set of 26 potential 
co-substrates was selected on the basis of generally being able to undergo 
more than one carbenoid transformations with the same diazo-substrate 
(Figure 5.3). To demonstrate that any unreacted co-substrate would not 
interfere with the assay, mock microreactions with these potential co-
substrates were performed. Stock solutions of the co-substrates (8 μL of 
12.5 M solution in CH2Cl2) were added to the wells of the custom made 96-
well PTFE plates with the appropriate solvent (92 μL, either CH2Cl2 or 
toluene) to give a final concentration of 1.0 M of each co-substrate. The 
microreactions were mixed by pipetting sealed and left for 48 h. After 
scavenging for 24 h, the solutions were left to evaporate and the crude 
dissolved in dimethyl sulfoxide to give a final solution of 1.0 M of co-
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substrate. These stock solutions were subsequently further diluted in DMSO 
and buffer and screened at a concentration of 1 mM (1% DMSO in buffer 
see experimental for details). The TR-FRET ratio (520 nm/495 nm) was then 
normalised to a percentage using the positive control (Testosterone, TE 5 
μM) as 100% and the negative control (1% DMSO in buffer, no ligand) as 
0%. The results are shown in Table 5.2. 
 
Figure 5.3: Structures of 26 commercially available potential co-substrates 
for intermolecular reactions. The potential co-substrates were selected on 
the basis of being able to undergo multiple chemical transformations with 
metal-carbenoid species.  
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Table 5.2: Percentage of activity at 1 mM of potential co-substrates. 
Entry Structure 
% of activity 
at 1 mM 
Entry Structure 
% of activity 
at 1 mM 
1 
 
2% 14 
 
2% 
2 
 
3% 15 
 
23% 
3 
 
5% 16 
 
7% 
4 
 
6% 17 
 
1% 
5 
 
5% 18 
 
5% 
6 
 
2% 19 
 
6% 
7 
 
8% 20 
 
8% 
8 
 
7% 21 
 
18% 
9 
 
24% 22 
 
0% 
10 
 
7% 23 
 
9% 
11 
 
0% 24 
 
1% 
12 
 
6% 25 
 
42% 
13 
 
2% 26 
 
12% 
Percentage of activity (relative to 5 μM TE) of product mixtures from mock  
microreactions at a total concentration of  1 mM (1% DMSO, in buffer) 
Typical error 1-7%. 
Most of the potential co-substrates were found to have minimal 
activities (lower than 7%) against the androgen receptor at a concentration 
of 1 mM. However some, such as p-nitro benzaldehyde (Table 5.2, entry 9) 
or tetrahydrocarbazole (Table 5.2, entry 25), were found to display moderate 
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activities arising either from biological effects or, more likely, interference 
with the assay read-out. Hence it was decided that these potential co-
substrates were not to be used in the intermolecular reaction arrays. Out of 
the total 26 potential co substrates, nine were selected to be used as 
intermolecular reaction co-substrates (Figure 5.4). Their selection was based 
on their low activities against the androgen receptor as well as their 
structural features that would possibly enable more than one chemical 
transformations with the same diazo-substrate. For example, indole (Table 
5.2, entry 17) can potentially undergo C-H insertion reactions at position 349 
or 7,50 or an N-H insertion51 to yield more than one potentially active 
products within the same product mixture. 
 
Figure 5.4: Structures of the nine selected co-substrates for the first 
intermolecular reaction array. Their selection was based on their low activity 
against the androgen receptor as well as that their structures may enable 
more than one carbenoid transformations. 
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5.3. Intermolecular reaction array 1 
 For the first reaction array, the four diazo amide substrates 17k-18l 
and the nine co-substrates were used, in combinations with six Rh(II) 
catalysts (Rh2(S-DOSP)4 Rh2(TFA)4 Rh2(5R-MEPY)4 Rh2(Oct)4 Rh2(4S-
MEOX)4 Rh2(cap)4, Figure 5.5) in two solvents (CH2Cl2 and toluene). An 
additional combination of diazo substrates without co-substrate was also 
used as a control.  It would also be possible that a pair of diazo substrate 
and co-substrate might have yielded the same product irrespective of the 
combination of solvent and catalyst used. Hence, in order to minimise 
redundancy, and because there was a total of 480 possible combinations, it 
was decided to perform a sparse array of reactions. Random combinations 
were investigated, covering ca. 40% of all possibilities (192 combinations) in 
an attempt to further the limits of small molecule discovery by activity-
directed synthesis. 
 
Figure 5.5: Structures of metal catalysts used in reaction arrays for activity-
directed synthesis on androgen receptor agonists using intermolecular 
reactions. 
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Reactions were, as before, carried out in custom made 96-well PTFE 
plates. The appropriate catalyst (4 μL of 25 mM solution in THF) was added 
to each well containing a solution of the relevant diazo-substrate (8 μL of 
1.25 M solution in CH2Cl2) and the appropriate co-substrate (8 μL of 12.5 M 
solution in CH2Cl2) in the appropriate solvent (80 μL) and subsequently 
sealed. This mixture resulted in a final solution with the diazo-amide 
substrate at a concentration of 0.1 M, the co-substrate at a concentration of 
1.0 M and the metal catalyst at a concentration of 1 mM. The product 
mixtures were mixed by pipetting occasionally, resealed and left to react at 
room temperature for 48 hours. After scavenging for Rh(II) (see Chapter 3 for 
metal scavenging studies), the solvent was removed by evaporation at rt and 
then under reduced pressure and the product mixtures were rediluted in 
dimethyl sulfoxide to give a solution of total product concentration of 
100 mM. The product mixtures were then diluted further in DMSO and assay 
buffer and screened initially at a total product concentration 10 μM (10 μM 
1% DMSO in buffer, see experimental for full details). The TR-FRET ratio 
(520 nm/495 nm) was then normalised to a percentage using the positive 
control (Testosterone, TE 5 μM) as 100% and the negative control 
(1% DMSO in buffer, no ligand) as 0%. The results are shown in Figure 5.6. 
It was observed that only specific combinations of catalyst, diazo-
substrate, co-substrate and solvent yielded any promising product mixtures, 
since only two out of 192 product mixtures displayed any promising activity 
at the concentration screened. These mixtures were derived from diazo 
substrate 18k with either cyclohexene 36a or indole 36f with Rh2(S-DOSP)4 
in CH2Cl2 (Figure 5.6). The results suggested that it was possible that the 
active product in each case was the result of an intermolecular reaction as 
the combinations of the diazo-substrate with no co-substrate present did not 
display any promising activity. These results formed the basis for the design 
of the second intermolecular reaction array. 
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Figure 5.6: Percentage of activity (relative to 5 μM TE) of product mixtures 
from intermolecular reaction array 1 at a total concentration of 10 μM (1% 
DMSO, in buffer). Different colours represent different catalysts: black, 
Rh2(S-DOSP)4; red, Rh2(tfa)4. Different shapes represent different solvents: 
squares, CH2Cl2; circles Toluene. Red circles indicate combinations with 
promising activity. Error bars omitted for clarity. Typical error 3-7%.  
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5.4. Intermolecular reaction array 2 
 For the second reaction array, the two deacylated diazo substrates 
18k and 18l were used. Promising activities in reaction array 1 were 
observed from product mixtures derived from diazo substrate 18k only. 
Diazo substrate 18l was used to investigate whether it would be possible to 
resurrect and activity from product mixtures derived from that substrate. The 
co-substrates used in this reaction array were inspired by cyclohexene and 
indole which were prioritised in the previous reaction array (Figure 5.7). 
Unsaturated and aromatic heterocycles with different ring sizes were used, 
again to enable more than possible reaction outcomes. Where possible, an 
acetyl of methyl group was incorporated on certain co-substrates such 36v 
and 36w or 36j and 36u. This derivatisation was incorporated to probe the 
effect such a group could have on the outcome of the product mixture, by 
either  blocking a possible reaction, e.g. an N-H insertion, or enabling a 
different reaction, e.g. a C-H insertion.  
 
Figure 5.7: Structures of the 18 potential co-substrates selected for the 
second intermolecular reaction array. The structures were inspired by 
cyclohexene and indole.  
Whilst most of these co-substrates were readily commercially 
available, some were prepared in one or two steps. The amide 36v was 
prepared by treating 36x with acetic anhydride in triethylamine and CH2Cl2 
(Scheme 5.1). The methyl hydrochloride 36w was prepared in two steps. 
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The amine 36x was treated with benzyl chloroformate and Na2CO3 in 
aqueous CH2Cl2 which was subsequently reduced by treatment with LiAlH4 
in refluxing THF. Treatment of the crude mixture with a 1 M aqueous HCl 
solution afforded the hydrochloride salt of the methyl amine 36w in 65% 
yield over two steps. 
 
Scheme 5.1: Preparation of co-substrates 36v and 36w from the readily 
available amine 36x. 
 
Before they could be used, these potential co-substrates were tested 
as mock product mixtures similar to the potential co-substrates of the 
previous reaction array. Stock solutions of the co-substrates (8 μL of 12.5 M 
in CH2Cl2) were added in the wells of the custom made 96-well PTFE plates 
with the appropriate solvent (92 μL), either CH2Cl2 or toluene. This mixture 
resulted in a final concentration of 1.0 M of the co-substrate. The 
microreactions were mixed by pipetting sealed and left for 48 h. After 
scavenging for 24 h, the solutions were left to evaporate and the crude re-
diluted in dimethyl sulfoxide to give a final solution of 1.0 M of co-substrate. 
These stock solutions were subsequently further diluted in DMSO and buffer 
and screened at a concentration of 1 mM (1% DMSO in buffer, see 
experimental for details). The TR-FRET ratio (520 nm/495 nm) was then 
normalised to a percentage using the positive control (Testosterone, TE 5 
μM) as 100% and the negative control (1% DMSO in buffer, no ligand) as 
0%. The results are shown in Table 5.3. As it can be seen from Table 5.3, it 
was possible to use all of the potential co-substrates for the second 
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intermolecular reaction array as they did not display any significant activity 
against the androgen receptor at a concentration of 1 mM. 
Table 5.3: Percentage of activity at 1 mM of potential co-substrates for 
intermolecular reaction array 2.  
Entry Structure 
% of activity 
at 1 mM 
Entry Structure 
% of activity 
at 1 mM 
1 
 
2% 8  0% 
2 
 
1% 9 
 
1% 
3 
 
1% 10  0% 
4 
 
0% 11 
 
0% 
5 
 
1% 12 
 
4% 
6 
 
0% 13 
 
1% 
7 
 
1% 14 
 
0% 
Percentage of activity (relative to 5 μM TE) of product mixtures from mock  
microreactions at a total concentration of  1 mM (1% DMSO, in buffer). 
Typical error 0.5-2%. 
 
With the two diazo substrates and the 18 co-substrates at hand, the 
second reaction array was performed. Since the most promising activities 
from the previous reaction array arose from carboxylate type catalysts, it 
was decided to focus on five commonly used, Rh(II) carboxylate catalysts 
(Rh2(S-DOSP)4, Rh2(OAc)4, Rh2(pfb)4, Rh2(tpa)4 and Rh2(esp)2). Again, 
instead of conducting exhaustive arrays, random combinations covering 86 
of 380 possible reactions were investigated. The appropriate catalyst (4 μL 
of 25 mM solution in THF) was added to each well containing a solution of 
the relevant diazo-substrate (8 μL of 1.25 M solution in CH2Cl2) and the 
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appropriate co-substrate (8 μL of 12.5 M solution in CH2Cl2) in the 
appropriate solvent (80 μL CH2Cl2 or Toluene) and subsequently sealed. 
This mixture resulted in a final solution with the diazo-amide substrate at a 
concentration of 0.1 M, the co-substrate at a concentration of 1.0 M and the 
metal catalyst at a concentration of 1 mM. The product mixtures were mixed 
by pipetting occasionally, resealed and left to react at room temperature for 
48 hours. After scavenging for Rh(II) (see Chapter 3 for metal scavenging 
studies), the solvent was removed by evaporation at rt and then under 
redused pressure and the product mixtures were dissolved in dimethyl 
sulfoxide to give a solution of total product concentration of 100 mM. The 
product mixtures were then diluted further in DMSO and assay buffer and 
screened at total product concentrations of both 10 μM and 5 μΜ (10 μM 
and 5 μΜ 1% DMSO in buffer, see experimental for full details). The TR-
FRET ratio (520 nm/495 nm) was then normalised to a percentage using the 
positive control (Testosterone, TE 5 μM) as 100% and the negative control 
(1% DMSO in buffer, no ligand) as 0%. The results are shown in Figure 5.8. 
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Figure 5.8: Percentage of activity (relative to 5 μM TE) of product mixtures 
from intermolecular reaction array 2 at a total concentration of 10 μM 
(above) and 5 μM (below) (1% DMSO, in buffer). Different colours represent 
different catalysts: black Rh2(S-DOSP)4, red Rh2(OAc)4; different shapes 
represent different solvents: squares CH2Cl2, circles Toluene. Red circles 
indicate combinations with promising activity. Error bars omitted for clarity. 
Typical error 1-7%. 
 
Similar, to the intramolecular reaction arrays (see Chapter 4), 
screening at a lower concentration revealed that promising activities arose 
only from a few product mixtures. This trend might suggest that reactions are 
steered towards active products only when the specific combination of 
reactants (diazo- and co-substrate) and conditions (catalyst and solvent) 
was used. Diazo substrate 18k was observed to yield more promising 
product mixtures compared to diazo substrate 18l. Product mixtures using 
diazo substrate 18k, co-substrates 36m, 36n, 36o and 36r (Figure 5.9) with 
either Rh2(S-DOSP)4 or Rh2(esp)2 in CH2Cl2 displayed the most promising 
activities and were used to inform the design of the third reaction array.  
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5.5. Intermolecular reaction array 3 
 For the third reaction array, it was decided to focus on a single diazo 
substrate and solvent in order to investigate the scope of co-substrate and 
catalyst further. Promising product mixtures arose mostly from diazo 
substrate 18k in CH2Cl2, and was thus also chosen for reaction array 3. Both 
enantiomers of the DOSP based catalyst were used in order to investigate 
the effect of catalyst configuration on the biological activity of the product 
mixtures. Rh2(OAc)4 and Rh2(esp)2 were also exploited as their use resulted 
in some promising activities in the previous reaction array. The co-substrates 
used in this reaction array were structurally inspired by co-substrates  36m, 
36n, 36o and 36r  which were prioritised from the previous reaction array 
(Figure 5.9). These co-substrates incorporated various substitution patterns 
on different positions of similar central scaffolds as co-substrates  36m, 36n, 
36o and 36r.  
 
Figure 5.9: The structures of the potential co-substrates used in the third 
reaction array were inspired by co-substrates  36m, 36n, 36o and 36r The 
potential co-substrates incorporated various substitution patterns on different 
positions of similar central scaffolds. 
Before they could be used, these potential co-substrates were tested 
as mock product mixtures similar to the potential co-substrates of the 
previous reaction array. Stock solutions of the co-substrates (8 μL of 12.5 M 
in CH2Cl2) were added in the wells of the custom made 96-well PTFE plates 
with CH2Cl2 (92 μL). This mixture resulted in a final concentration of 1.0 M of 
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the co-substrate. The microreactions were mixed by pipetting sealed and left 
for 48 h. After scavenging for 24 h, the solutions were left to evaporate and 
then dissolved in dimethyl sulfoxide to give a final solution of 1.0 M of co-
substrate. These stock solutions were subsequently further diluted in DMSO 
and buffer and screened at a concentration of 1 mM (1% DMSO in buffer, 
see experimental for details). The TR-FRET ratio (520 nm/495 nm) was then 
normalised to a percentage using the positive control (Testosterone, TE 5 
μM) as 100% and the negative control (1% DMSO in buffer, no ligand) as 
0%. The results are shown in Table 5.4. 
Table 5.4: Percentage of activity at 1 mM of potential co-substrates for 
intermolecular reaction array 3. 
Entry Structure 
% of activity at 1 
mM 
1 
 
36% 
2 
 
5% 
3 
 
12% 
4 
 
7% 
5 
 
5% 
6 
 
9% 
7 
 
3% 
Percentage of activity (relative to 5 μM TE) of product mixtures from mock  
microreactions at a total concentration of  1 mM (1% DMSO, in buffer). 
Typical error 0.5-3%. 
As it can be observed from Table 5.4, six of the potential co-
substrates could be used in the third intermolecular reaction array as they 
did not display any significant activity against the androgen receptor at a 
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concentration of 1 mM. 4-Azaindole, 36a’, displayed a moderate activity 
using the TR-FRET assay and it was decided not to be used. 
With the diazo substrate 18k the co-substrates identified in the first 
two reaction arrays (36a, 36f, 36m, 36n, 36o and 36r) as well as the six 
additional co-substrates at hand, the third reaction array was performed. For 
this reaction array, all the possible combinations were performed  resulting in 
48 microreactions (one diazo-substrate, 12 co-substrates, four catalysts, all 
in CH2Cl2). The appropriate catalyst (4 μL of 25 mM solution in THF) was 
added to each well containing a solution of the relevant diazo-substrate (8 
μL of 1.25 M solution in CH2Cl2) and the appropriate co-substrate (8 μL of 
12.5 M solution in CH2Cl2) in the appropriate solvent (80 μL) and 
subsequently sealed. This mixture resulted in a final solution with the diazo-
amide substrate at a concentration of 0.1 M, the co-substrate at a 
concentration of 1.0 M and the metal catalyst at a concentration of 1 mM. 
The product mixtures were mixed by pipetting occasionally, resealed and left 
to react at room temperature for 48 hours. After scavenging for Rh(II) (see 
Chapter 3 for metal scavenging studies), the solvent was removed by 
evaporation at rt and then under reduced pressure and the product mixtures 
were dissolved in dimethyl sulfoxide to give a solution of total product 
concentration of 100 mM. The product mixtures were then diluted further in 
DMSO and assay buffer and screened at total product concentrations of 
both 5 μM and 1 μΜ (5 μM and 1 μΜ 1% DMSO in buffer, see experimental 
for full details). The TR-FRET ratio (520 nm/495 nm) was then normalised to 
a percentage using the positive control (Testosterone, TE 5 μM) as 100% 
and the negative control (1% DMSO in buffer, no ligand) as 0%. The results 
are shown in Figure 5.10. 
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Figure 5.10: Percentage of activity (relative to 5 μM TE) of product mixtures 
from intermolecular reaction array 3 at a total concentration of 5 μM (above) 
and 1 μM (below) (1% DMSO, in buffer). Different colours represent different 
catalysts: black, Rh2(S-DOSP)4; red, Rh2(OAc)4. Red circles indicate 
combinations with promising activity. Error bars omitted for clarity. Typical 
error 1-6%. 
 
As it can be observed in Figure 5.10, only specific reaction conditions 
yield product mixtures which displayed promising activities. Furthermore, in 
some cases, product mixtures from the R-DOSP ligand were observed o be 
more active than those from the S-DOSP, suggesting that the reaction is 
enantioselective and the product is chiral. At this point the most promising 
combinations of diazo substrate, co-substrate, catalyst and solvent were 
selected for scale up. Their selection was based on maintaining their activity 
even at the lowest level of dilution, total concentration of 1 μM when 
screened using the TR-FRET AR assay. 
5.6. Scale-up 
A total of seven reactions were selected for scale up; two reactions 
from reaction array 1, three reactions from reaction array 2 and two 
reactions from reaction array 3. The conditions for these reactions are 
summarised in Table 5.5. 
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Table 5.5: The seven promising reactions selected for scale-up. The details 
of the combinations regarding the diazo substrate, co-substrate catalyst and 
solvent are shown below. 
Entry 
Reaction 
Array 
Diazo substrate Co-substrate Catalyst Solvent 
1 1 
 
 
36f 
Rh2(S-DOSP)4 CH2Cl2 
2 1 18k  
36a 
Rh2(S-DOSP)4 CH2Cl2 
3 2 18k  
36m 
Rh2(S-DOSP)4 CH2Cl2 
4 2 18k  
36o 
Rh2(S-DOSP)4 CH2Cl2 
5 2 18k  
36r 
Rh2(esp)2 CH2Cl2 
6 3 18k  
36f’ 
Rh2(OAc)4 CH2Cl2 
7 3 18k  
36g’ 
Rh2(R-DOSP)4 CH2Cl2 
 
The selected reactions were performed in a similar manner as the 
microreactions on a 50-fold larger scale. The appropriate diazo substrates 
(400 μL of a 1.25 M solution in CH2Cl2) co-substrate (400 μL of a 12.5 M 
solution in CH2Cl2) and the metal catalyst (200 μL of a 25 mM in THF) were 
mixed in the appropriate solvent (4.0 mL). The final concentration for the 
diazo substrate was 0.1 M, co-substrate 1.0 M and for the catalyst 1 mM, in 
5 mL of solvent. The reactions were sealed and left to react for 48 h, 
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followed by TLC and LC-MS. After scavenging the reactions were filtered, 
concentrated in vacuo and the crude mixture purified by column 
chromatography. 
5.6.1. Reactions identified in reaction array 1 
 For the scale-up of the two reactions highlighted from reaction array 
1, the diazo substrate 18k was treated with 1 mol% Rh2(S-DOSP)4, in 
CH2Cl2 in the presence of either the co-substrate 36f or 36a. The outcome of 
the reactions can be seen in Scheme 5.2. The major product isolated when 
using co-substrate 36f was the product 37a, of a C-H insertion at the 3’ 
position of the indole ring. In the case of co-substrate 36a, the major product 
36c, was formed by a cyclopropanation across the cyclohexene double 
bond. The trans configuration around the cyclopropyl ring was determined by 
careful analysis of the coupling constants of the protons around the 
cyclopropyl ring. The intramolecular products 37b and 37d, formed by the C-
H insertion on either position 2- or 6- of the N-aryl ring were, also observed. 
 
Scheme 5.2: Isolated products from the scale-up of reactions highlighted in 
reaction array 1. The major products isolated were formed by with a C-H 
insertion on the 3- position of the indole ring, 37a, or a cyclopropanation 
across the cyclohexene double bond 37c. 
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5.6.2. Reactions identified in reaction array 2 
Three reactions from reaction array 2 were prioritised for scale-up. The 
diazo substrate 18k was treated with 1 mol% Rh2(S-DOSP)4 or Rh2(esp)2 in 
CH2Cl2 in the presence of three distinct co-substrates: dihydronaphthalene 
36m, dihydropyran 36o, or indene 36r. The outcome of the reactions can be 
seen in Scheme 5.3. In all cases the major product was determined to be the 
result of a cyclopropanation reaction across the double bond of the co-
substrate, yielding products 37e, 37f and 37g. The trans configuration of the 
cyclopropyl rings was determined by careful analysis of the coupling 
constants of the protons around the cyclopropyl ring in each product. The 
formation of the intramolecular products 37b and 37d was also observed. 
 
Scheme 5.3: Isolated products from the scale-up of reactions highlighted in 
reaction array 2. The major products isolated, 37e, 37f and 37g were formed 
by a cyclopropanation reactions double bond of co-substrate used. 
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5.6.3. Reactions identified in reaction array 3 
For the scale-up of the two reactions highlighted in the third reaction 
array, the diazo substrate 18k was treated with 1 mol% Rh2(S-DOSP)4 or  
Rh2(OAc)4 in CH2Cl2 in the presence of co-substrate 36f’ or  36g’. The 
outcome of the reactions can be seen in Scheme 5.4. In the presence of co-
substrate 36f’, diazo substrate 18k afforded the oxazole 37h, formed by a 
condensation between the carbenoid acetamide group of the diazo substrate 
and the nitrile group of the co-substrate.52 Key for the elucidation of the 
product’s structure was the singlet at 6.95 ppm in its NMR spectrum, 
attributed to C4 proton of the oxazole ring. In the case of co-substrate 36g’, 
the major product was formed by an O-H insertion of the hydroxyl group 
affording the acetamide 37i. The presence of the dihydropyran ring double 
bond protons as well as the appearance of two diastereotopic acetamide 
protons (4.27 ppm and 4.23 ppm) confirmed the structure of the product. 
The formation of the intramolecular products 37b and 37d was also 
observed, in addition to the aniline 15k, which was possibly formed by partial 
hydrolysis of the diazo substrate 18k. 
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Scheme 5.4: Isolated products from the scale-up of reactions highlighted in 
reaction array 3. The oxazole 37h was formed by a condensation and 
acetamide 37i by an O-H insertion. 
5.7. Biological and structural assessment of isolated 
compounds 
5.7.1. Biological evaluation of isolated compounds 
 The intermolecular products as well as the minor intramolecular side-
produts isolated from the scaled-up reactions were assayed in a dose-
dependent manner. Stock solutions of the compounds were prepared in 
DMSO and these were subsequently diluted accordingly with DMSO and 
assay buffer in a 12-step, 3-fold serial dilution manner (Figure 5.11 and 
experimental for details). 
 From the dose-response curves obtained, the EC50  value for each of 
the compounds was extracted by applying a non-linear fitting (logistic fit, 
OriginPro v. 8.6); the acetamide 37a 8.8 (± 0.73) μM, the cyclopropane 37c 
7.3 (± 0.29) μM, the cyclopropane 37e 4.9 (± 0.08) μM, the cyclopropane 37f 
4.7 (± 0.07) μM, the cyclopropane 37g 3.7 (± 0.18) μM, the oxazole 37h 730 
(± 28) nM,  the acetamide 37i 1.1 (± 0.07) μM. EC50 values for the 
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intramolecular minor products, 37b and 37d, were not determined as a full 
dose-responce curve was not obtained. However these values are predicted 
to be greater than 150 μM for oxindole 37b and greater than 500 μM for 
oxindole 37d (Figure 5.11). 
 All major products isolated from the reactions identified through the 
intermolecular reaction arrays, proved to be active modulators of the 
Androgen Receptor. These findings provide additional confirmation that 
Activity-Directed Synthesis is a methodology that is able to focus on active 
molecules. 
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Figure 5.11: Dose-response curves obtained by assaying the isolated 
compounds: intermolecular products 37a, 37c, 37e, 37f, 37g, 37h and 37i 
and intramolecular products 37b and 37d. Ar = 4-Cyano-3-(trifluoro)methyl-
phenyl. 
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5.7.2. Structural evaluation of active modulators 
The major products isolated from the scaled-up reactions could be 
classed in four distinct chemotypes stemming from different transformations: 
C-H insertion (37a); cyclopropanation (37c, 37e, 37f and 37g); condensation 
(37h) and O-H insertion (37i). Oxazoles such as 37h, have been used as 
biological isosteres of amide groups in drug discovery53 and drug design 
before.54 It is interesting that such a chemotype arose from the 
intermolecular activity-directed synthesis of androgen receptor modulators, 
as it is possible that such compounds could mimic existing chemotypes such 
as flutamide or bicalutamide analogues (Figure 5.12).  
 
Figure 5.12: As oxazoles have been known to act as biological isosteres of 
amide groups, the condensation product 37h, likely mimics existing 
chemotypes such as flutamide and bicalutamide. 
 
Whilst cyclopropyl rings are often incorporated in lead or hit 
compounds, usually substituting a methyl group,55 cyclopropanation 
reactions are rarely used in drug discovery or medicinal chemistry 
programmes. In this regard, the cyclopropanation products 37c, 37e, 37f 
and 37g, would be highly unlikely to be discovered by conventional small 
molecule discovery approaches.  This case is emphasised by the fact that 
the corresponding cyclopropyl acids (Figure 5.13) in order to prepare these 
compounds via amide couplings are not commercially available. Finally, 
whilst compounds 37a and 37i, could be prepared using a less sophisticated 
chemical toolbox, it would be highly unlikely that they would be designed as 
potentially active androgen receptor modulators. 
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Figure 5.13: Although the cyclopropanation products 37c, 37e, 37f and 37g, 
could be readily prepared via simple amide couplings, the corresponding 
acids are not commercially available. 
5.8. Summary 
Three intermolecular reactions arrays have been performed and the 
product mixtures from each array screened at progressively lower 
concentrations. The biological results from one reaction array were used to 
select readily available co-substrates, the diazo-substrates and reaction 
conditions which would inform the design of the subsequent reaction array. 
Contrary to the intramolecular arrays, sparse combinations of reaction 
conditions were performed in the first two intermolecular reaction arrays. 
Sparse combinations minimised the possibility of redundant reactions whilst 
increasing the efficiency of the approach. A total of 326 reactions was 
performed, seven of which were prioritised for scale-up. Purifying and 
characterising the isolated products from each reaction, revealed  that the 
major products formed, could be classed in four distinct chemotypes 
stemming from different transformations. Biological evaluation of these 
products revealed that these molecules are active modulators of the 
Androgen Receptor. 
 It is interesting to consider how the methodology might have 
developed through the intermolecular reaction arrays. Two chemotypes were 
identified in round 1; the acetamide, 37a from a C-H insertion,  and the 
cyclopropanation product 37c. The cyclopropantion chemotype gave rise to 
structurally-related products 37e, 37f and 37g, all formed by an 
intermolecular cyclopropanation, in round 2. The structural information from 
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co-subsrates dihydronaphthalene 36m, dihydropyran 36o and indene 36r 
inspired the use of co-substrate 36f' and 36g' amongst others. The use of 
36f' and 36g' led to the formation of products 37h and 37i, which proved to 
have chemotypes not found in the previous rounds. This result suggests that 
in addition to optimising an identified molecular scafford, occasionally 
making leaps through chemical space is another possible mechanism for the 
evolution of activity-directed synthesis (Figure 5.14).  
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Figure 5.14: Developement of Activity-Directed Synthesis through the 
intermolecular reaction arrays. Leaps through chemical space provide an 
additional mechanism for the evolution of activity-directed synthesis. Ar = 4-
Cyano-3-(trifluoro)methyl-phenyl. 
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6. Chapter 6 
Conclusions and Future Work 
6.1. Conclusions  
6.1.1. Activity-Directed Synthesis exploiting intramolecular 
reactions 
 The Activity-Directed Synthesis of sub-micromolar Androgen 
Receptor modulators with chemotypes with no previously annotated activity 
has been successfully developed and demonstrated. By exploiting 
promiscuous metal-carbenoid reactions with multiple possible outcomes, 
generating mixtures of products allowed the rapid and facile identification of 
small biologically active molecules, in a more efficient manner compared to 
conventional approaches. A key aspect of Activity-Directed Synthesis was 
the utilisation of evolutionary feedback, through the analysis of the 
information from the screening of one reaction array to design a subsequent 
reaction array. The development of the approach was retrospectively 
analysed and rationalised in the case of intramolecular reactions, 
demonstrating that Activity-Directed Synthesis is able to focus on active 
molecules rather than treating molecules in large collections with the same 
significance. The approach was demonstrated to facilitate the optimisation of 
both the structure of the active component as well as a route for its synthesis 
simultaneously.  
6.1.2. Activity-Directed Synthesis exploiting intermolecular 
reactions 
A limiting factor when exploiting intramolecular reactions was the 
necessity to synthetically incorporate the various reactive groups on the 
same substrate, increasing the synthetic effort required for their preparation 
and diminishing the number of possible combinations used. These issues 
were addressed by exploiting intermolecular reactions, as demonstrated by 
the greater diversity of structures and chemotypes of the major products 
isolated from the scale-up of selected intermolecular reactions. It was also 
shown that exhaustive combinations of reaction arrays were not needed, as 
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sparse combinations were enough to provide sufficient information for the 
design of a subsequent reaction array. In addition, it was demonstrated that 
structural leaps through chemical space provide an additional mechanism for 
the evolution Activity-Directed Syntheis. 
6.2. Future work 
6.2.1. Retrospective exploration of the intermolecular 
reaction arrays 
 In order to fully rationalise and understand the development of 
Activity-Directed Synthesis using intermolecular reactions a retrospective 
exploration, similar to the case of intramolecular reactions, is needed. 
Initially, reactions which were not prioritised from each reaction array should 
be scaled-up and the products isolated, characterised and evaluated 
biologically, in order to investigate whether products of different structural 
scaffolds were formed.  
 In the case of diazo-substrate 18k, with co-substrate 36g’ (Scheme 
6.1), two significantly different activities were observed with the use of the 
two enantiomers of the Rh2(DOSP)4 catalyst. These results suggested that 
that the reaction was enantioselective and the product was chiral. As the 
major product formed, 37i is indeed chiral, it is possible that the catalyst is 
kinetically resolving the two enantiomers of the racemic co-substrate used, 
resulting in an enantiomerically enriched bioactive product. Performing the 
same reaction using the S enantiomer instead of the R, and  isolating, 
characterising and evaluating the isolated products will aid to the verification 
of this hypothesis. The enantioselectivity can be determined by determining 
the enantiomeric excess using chiral HPLC analysis. This analysis will also 
help verify the above hypothesis, as well as add to the overall understanding 
of the methodology. 
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Scheme 6.1: Scaled reaction of diazo-substrate 18k with co-substrate 36g’ 
with Rh2(R-DOSP)4 in CH2Cl2.  
 
6.2.2. Crystallographic Studies 
 There is currently no evidence for the structural basis of the novel 
Androgen Receptor modulators discovered through this project. Although it 
is hypothesised that these molecules bind in the same cavity of the AR LBD 
as other flutamide or bicalutamide analogues,56 it would not be surprising if 
the binding conformation or orientation is different. It would also be possible 
that these molecules act through covalent binding, as these has been 
previously reported for other β-lactam based molecules.57 A crystallographic 
study to obtain an X-Ray crystal structure with the isolated molecules co-
crystallised with the AR LBD would provide additional information and 
elucidate the binding site and orientation, as well as provide evidence of 
potentially new interactions which could be used to further optimise the 
activity of these molecules.    
6.2.3. Further Future Work 
 The general applicability of Activity-Directed Synthesis as an efficient 
approach for the discovery of novel small bioactive molecules could be 
effectively demonstrated by applying this methodology on different biological 
targets exploiting different chemical toolbox.  
The TR-FRET assay has proven to be an effective, high throughput 
and reliable screening method once it was established. Similar assays are 
commercially available for different biological targets such as PDK1 or 
VEGFR-2 or other kinases.58 As they as very well studied and understood, 
with limited novel inhibitors reported, kinases provide an attractive target to 
demonstrate the applicability of Activity-Directed Synthesis. 
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When choosing a different chemical toolbox the same considerations 
should be taken into account. The chemistry needs to be equally versatile 
and tunable, with a demonstrated record of applicability. In this regards, both 
Au catalysis and N-heterocyclic carbene (NHC) catalysis are very attractive. 
Au-catalysed chemistry can be considered complementary to carbenoid 
chemistry as shown in Scheme 6.2A. Both intra- and intermolecular 
applications of this chemistry have been reported, leading to the formation of 
diverse molecular scaffolds with the reaction outcome critically depended on 
conditions used (Scheme 6.2B).59 Similarly, NHC-catalysed cascades have 
been reported, where the use of either NHC-I or NHC-II type catalysed may 
result in different products with the use of the same starting materials 
(Scheme 6.2C).60 
Finally, however, in order to demonstrate the versatility, efficiency and 
greater potential of Activity-Directed Synthesis, it would be ideal to turn to 
unbiased libraries. Such an application would allow the same library of 
starting materials and its respective chemical toolbox to be exploited against 
different biological targets and ultimately turn Activity-Directed synthesis into 
a general methodology. This application would be far more efficient, as any 
synthetic preparations would need to be undertaken to a minimal extend 
whilst the starting materials could be used for more than one assays. 
Furthermore, it would be possible to extract multivariant information which 
would in turn facilitate SAR deduction and add to the subsequent 
optimisation of small molecules discovered by such an application of 
Activity-Directed Synthesis. 
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Scheme 6.2: Representative examples of the potentially attractive chemical 
transformations to be exploited for Activity-Directed Synthesis. A: Au-
catalysed chemistry can be considered complementary to metal-carbenoid 
chemistry considering the reactive species. B: Representative examples of 
Au-catalysed transformations to prepare molecules with diverse scaffolds 
through either intra- or intermolecular reactions. C: Representative example 
of NHC-catalysed transformation where different molecular scaffolds are 
obtained by treating the same starting materials with different types of NHC 
catalysts. 
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7. Chapter 7 
Experimental Section 
7.1. Instrumentation and General Information 
All non-aqueous reactions were carried out under an atmosphere of 
nitrogen.  Water-sensitive reactions were performed in oven- or flame-dried 
glassware cooled under nitrogen before use.  Solvents were removed under 
reduced pressure using a Büchi rotary evaporator and a Vacuubrand 
PC2001 Vario diaphragm pump.   
Ether refers to diethyl ether and petrol refers to petroleum spirit (b.p. 40-
60 °C) unless otherwise stated.  All other solvents and reagents were of 
analytical grade and used as supplied.  Commercially available starting 
materials were obtained from Sigma–Aldrich and Alfa Aesar. 
Flash column chromatography was carried out using silica (35-70 μm 
particles).  Thin layer chromatography was carried out on commercially 
available pre-coated glass or aluminium plates (Merck silica 2 8 8 0 
Kieselgel 60F254). 
  Analytical LC-MS was performed using an Agilent 1200 series LC system 
comprising of a Bruker HCT Ultra ion trap mass spec, a high vacuum 
degasser, a binary pump, a high performance autosampler and micro well 
plate autosampler, an autosampler thermostat, a thermostated column 
compartment and diode array detector.  The system used Phenomenex 
Luna C18 50 x 2mm 5 micron column and two solvent systems:. MeCN/H2O 
+ 0.1% Formic acid or MeCN/H2O. 
Proton (1H) and carbon-13 (13C) NMR spectra were recorded on a Bruker 
Avance DPX 300, Avance 500 or DRX500 spectrophotometer using an 
internal deuterium lock.  13C NMR spectra were recorded with composite 
pulse decoupling using the waltz 16 pulse sequence.  DEPT, COSY, HMQC 
and HMBC pulse sequences were routinely used to aid the assignment of 
spectra.  Chemical shifts are quoted in parts per million downfield of 
tetramethylsilane, and coupling constants (J) are given in Hz.  NMR spectra 
were recorded at 300 K unless otherwise stated.  
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Melting points were determined on a Reichert hot stage microscope and are 
uncorrected.  
Infrared spectra were recorded on a Perkin Elmer spectrum One FT-IR 
spectrophotometer. 
Nominal mass spectrometry was routinely performed on a Bruker HCT Ultra 
spectrometer using electrospray (+) ionization.  Nominal and accurate mass 
spectrometry using electrospray ionisation on a Bruker MicroTOF or a 
Bruker MaXis Impact spectrometer. 
EC50 values were obtained by performing logistic fits to the appropriate 
dose-response curves using the OriginPro v.8.6 software. 
7.2. Experimental Procedures 
7.2.1. Experimental procedures for organic compounds 
 
General procedure A: Amination of 4-iodo-2(trifluoro)methyl benzonitrile 
with primary amines. 
The amine (3 equiv.) was added to a stirred solution of 4-iodo-2-
(trifluoro)methyl benzonitrile (1 equiv.), CuI (10 mol%), L-proline (20 mol%) 
and K2CO3 (3 equiv.) in DMSO (0.5 M) and the reaction mixture was heated 
to 80 °C. After 20 h the reaction mixture was allowed to cool to rt. Water (10 
mL) was added and the resulting mixture was extracted with EtOAc (4 × 10 
mL). The combined organic layers were washed with brine (sat. aq. sol., 20 
mL), dried (Na2SO4), filtered and concentrated in vacuo to give a crude 
product. 
General procedure B: Acylation of secondary anilines with 2,2,6-trimethyl-
4H-1,3-dioxin-4-one via microwave irradiation and diazotisation of the crude 
reaction mixture. 
2,2,6-Trimethyl-4H-1,3-dioxin-4-one (1.5 equiv.) was added to a solution of 
the appropriate secondary aniline (1 equiv.) in toluene (1 mL). The reaction 
mixture was irradiated under microwave conditions (100 Watts, 50 psi) at 
110 °C for 45 min. The reaction mixture was concentrated in vacuo to give a 
crude product. Et3N (1.1 equiv.) was added to a stirred solution of the crude 
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product in MeCN (0.5 M) at rt. p-ABSA (1.1 equiv.) was added portionwise to 
the reaction mixture. After 2 h the reaction mixture filtered through a celite 
pad eluting with a 1:1 mixture of CH2Cl2–Et2O and concentrated in vacuo to 
give a crude product. 
General Procedure C: Deacylation of diazo-butanamides. 
NaOMe (1.1 equiv) was added portionwise to a stirred solution of the 
appropriate diazo-butanamide (1 equiv.) in MeOH (0.5 M) at 0 °C, and the 
reaction mixture was stirred at 0 °C. After 2-4 h the reaction mixture was 
poured into ice-water (10 mL), saturated with solid NaCl and extracted with 
Et2O (4 × 10 mL). The combined organic layers were dried (Na2SO4), filtered 
and concentrated in vacuo to give a crude product. 
General Procedure D: Implementation of intramolecular reaction arrays 
The reaction arrays were carried out in 96-well plates (8 × 12) custom made 
out of PTFE (well volume ~300 µl). Diazo-substrates were dissolved in 
CH2Cl2, to give a final solution of 1.25 M. Rh(II) catalysts were dissolved in 
THF to give a 25 mM solution. 8 μL of the diazo-substrate solution were 
added to the appropriate well followed by 88 μL of the appropriate reaction 
solvent and 4 μL of the appropriate catalyst solution. The final volume of the 
reaction mixture was 100 μL; the final concentration of diazo-substrate was 
100 mM and the final concentration of catalyst was 1 mM. The reaction wells 
were sealed using disposable sealing caps (Qiagen, Part No. 1051163) and 
left to react for 48 h at rt and mixed occasionally (ca. 2 h) by pipetting. The 
product mixtures were transferred to scavenging wells pre-loaded with 
QuadraPure TU resin (30 mg). Each reaction well was washed with the 
reaction solvent (3 × 50 μL) and the washes transferred to the corresponding 
scavenging well. The wells were sealed and left for 24 h. The scavenged 
product mixtures were transferred in Eppendorf tubes (500 μL). Each well 
was washed with the reaction solvent (3 × 100 μL) and the washes 
transferred to the corresponding Eppendorf tube. The product mixtures were 
left to evaporate at rt for 48 h. After evaporation the tube rack was placed in 
a desiccator and placed under vacuum for a further 24 h. The residue was 
re-dissolved in 100 μL of DMSO to give a product mixture solution of Σ[Pn] = 
100 mM. 
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General Procedure E: Implementation of intermolecular reaction arrays 
The reaction arrays were carried out in 96-well plates (8 × 12) custom made 
out of PTFE (well volume ~300 µl). Diazo-substrates were dissolved in 
CH2Cl2, to give a final solution of 1.25 M. Co-substrates were dissolved in 
CH2Cl2, to give a final solution of 12.5 M.  Rh(II) catalysts were dissolved in 
THF to give a 25 mM solution. 8 μL of the diazo-substrate solution were 
added to the appropriate well followed by 80 μL of the appropriate reaction 
solvent, 8 μL of the appropriate co-substrate and finally, 4 μL of the 
appropriate catalyst solution. The final volume of the reaction mixture was 
100 μL; the final concentration of diazo-substrate was 100 mM, the final 
concentration of the co-substrate was 1 M and the final concentration of 
catalyst was 1 mM. The reaction wells were sealed using disposable sealing 
caps (Qiagen, Part No. 1051163) and left to react for 48 h at rt and mixed 
occasionally (ca. 2 h) by pipetting. The product mixtures were transferred to 
scavenging wells pre-loaded with QuadraPure TU resin (30 mg). Each 
reaction well was washed with the reaction solvent (3 × 50 μL) and the 
washes transferred to the corresponding scavenging well. The wells were 
sealed and left for 24 h. The scavenged reaction mixtures were transferred 
in Eppendorf tubes (500 μL). Each well was washed with the reaction 
solvent (3 × 100 μL) and the washes transferred to the corresponding 
Eppendorf tube. The product mixtures were left to evaporate at rt for 48 h. 
After evaporation the tube rack was placed in a desiccator and placed under 
vacuum for a further 24 h. The crude was dissolved in 100 μL of DMSO to 
give a product mixture solution of Σ[Pn] = 100 mM. 
General Procedure F: Reaction scale-up process for intramolecular 
reactions. 
The scale-up process was identical to the reaction array method (General 
Procedure D), performed on a 50-fold larger scale. Diazo-substrates were 
dissolved in CH2Cl2, to give a final solution of 1.25 M. Rh(II) catalysts were 
dissolved in THF to give a 25 mM solution. 400 μL of the diazo-substrate 
solution were added to a round-bottom flask followed by 4.4 mL of the 
appropriate reaction solvent and 200 μL of the appropriate catalyst solution 
and the reaction mixture was stirred at rt. The final volume of the reaction 
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mixture was 5.0 mL; the final concentration of the diazo-substrate was 
100 mM and the final concentration of catalyst was 1 mM. After 48 h 
QuadraPure TU resin (500 mg) was added and the mixture stirred at rt. After 
24 h the mixture was filtered washing with the reaction solvent (3 × 10 mL) 
and concentrated in vacuo to give a crude product. 
General Procedure G: Reaction Scale-up process for intermolecular 
reactions. 
The scale-up process was identical to the reaction array method (General 
Procedure E), performed on a 50-fold larger scale. Diazo-substrates were 
dissolved in CH2Cl2, to give a final solution of 1.25 M. Co-substrates were 
dissolved in CH2Cl2, to give a final solution of 12.5 M.  Rh(II) catalysts were 
dissolved in THF to give a 25 mM solution. 400 μL of the diazo-substrate 
solution were added to a round-bottom flask followed by 4.0 mL of the 
appropriate reaction solvent, 400 μL of the co-substrate solution and finally, 
200 μL of the appropriate catalyst solution and the reaction mixture was 
stirred at rt. The final volume of the reaction mixture was 5.0 mL; the final 
concentration of the diazo-substrate was 100 mM and the final concentration 
of catalyst was 1 mM. After 48 h QuadraPure TU resin (500 mg) was added 
and the mixture stirred at rt. After 24 h the mixture was filtered washing with 
the reaction solvent (3 × 10 mL) and concentrated in vacuo to give a crude 
product. 
7.2.2. Compound Data 
Benzyl(prop-2-en-1-yl)amine, 3 
 
Benzaldehyde (2.0 mL, 20.0 mmol) was added to a stirred suspension of 
allylamine (1.0 mL, 13.3 mmol) with 4 Å molecular sieves (2.50 g) in MeOH 
(53.0 mL) at rt and the resulting mixture was heated at 35 °C for 24 h. The 
reaction mixture was cooled to rt and filtered through a pad of celite, eluting 
with MeOH (20 mL). The solution was concentrated to half volume in vacuo, 
cooled to 0 °C, NaBH4 (1.01 g, 26.7 mmol) was added, the reaction mixture 
was allowed to warm to rt and stirred for 1.5 h. The reaction mixture was 
acidified to pH 2 by addition of aq. 2M HCl, concentrated to half volume in 
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vacuo and extracted with EtOAc (3 × 15 mL). The aqueous phase was 
basicfied to pH 12 by addition of aq. sat. sol. K2CO3 and extracted with 
EtOAc (3 × 20 mL). The combined organic layers, after basification were 
dried (MgSO4) and concentrated in vacuo to give the amine 3 (1.77 g, 89%) 
as a pale yellow oil which required no further purification. Rf: 0.79 (85:14:1 
DCM—EtOH—NH4OH); δH (500 MHz; CDCl3) 7.34-7.31 (3H, m, Ar), 7.27-
7.23 (2H, m, Ar), 5.93 (1H, ddt, J 17.2, 10.4 and 6.9, propenyl 2-H), 5.20 
(1H, dd, J 17.2 and 6.9, propenyl 3-HA), 5.11 (1H, dd, J 10.4 and 6.9, 
propenyl 3-HB), 3.79 (2H, s, PhCH2-), 3.28 (2H, d, J 6.9, propenyl 1-H2), 1.50 
(1H, s, b, N-H); δC (125 MHz; CDCl3) 140.3 (Ar), 136.9 (propenyl C-2), 128.4 
(Ar), 128.2 (Ar), 126.7 (Ar), 116.0 (propenyl C-3), 53.3 (PhCH2-), 51.8 
(propenyl C-1); νmax/cm-1 (film) 3311, 2816, 1949, 1872, 1811;  m/z  (EI) [M+] 
146.1 (100%, M+); HRMS Found: 146.0961 (C10H13N  requires M 146.0967).  
N-Benzyl-3’-oxo-N-(prop-2-en-1-yl)butanamide, 5 
 
2,2,6-Trimethyl-4H-1,3-dioxin-4-one (1.08 mL, 8.2 mmol) was added to a 
stirred solution of the amine 3 (400 mg, 2.8 mmol) in toluene (9.00 mL) and 
the reaction mixture was heated at reflux for 1 h. The reaction mixture was 
allowed to cool to rt and concentrated in vacuo to give a crude product. 
Purification by flash chromatography, eluting with CH2Cl2—Et2O (90:10), 
gave the amide 5 (508 mg, 84%) (3:2 keto:enol tautomers, 1:1 rotamers) as 
a bright yellow oil. Rf: 0.42 (9:1, CH2Cl2—Et2O); δH (500 MHz; CDCl3)  7.39-
7.34 (20H, m, Ph), 7.34-7.22 (20H, m, Ph), 7.22-7.14 (10H, m, Ph), 5.83-
5.69 (10H, m, propenyl 2-H1 rot A and B), 5.26-5.10 (24H, m, propenyl 3-H2 
rot A and B and butanamide 2-H1enol rot A and B), 4.62 (6H, s, PhCH2-keto rot 
A), 4.62 (4H, s, PhCH2-enol rot A), 4.48 (6H, s, PhCH2-keto rot B) 4.47 (4H, s, 
PhCH2-enol rot B), 4.02 (5H, d, J 5.8, propenyl 1-H2 rot A), 3.80 (5H, d, J 5.8, 
propenyl 1-H2 rot B), 3.58 (6H, s, butanamide 2-H2keto rot A), 3.56 (6H, s, 
butanamide 2-H2keto rot B), 2.30 (9H, s, butanamide 4-H3keto rot A), 2.26 (9H, 
s, butanamide 4-H3keto rot B), 1.97 (6H, s, butanamide 4-H3enol rot A), 1.91 
(6H, s, butanamide 4-H3enol rot B); δC (75 MHz; CDCl3) 202.5 (butanamide C-
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3keto rot A), 202.4 (butanamide C-3keto rot B), 175.6 (butanamide C-3enol rot 
A), 175.4 (butanamide C-3enol rot B), 172.4 (butanamide C-1enol rot A), 172.4 
(butanamide C-1enol rot B), 167.2 (butanamide C-1keto rot A), 167.0 
(butanamide C-1keto rot B), 136.9 (Ph rot A), 136.1 (Ph rot B), 132.4 (propenl 
C-2 rot A), 132.3 (propenl C-2 rot B). 129.0 (Ph rot A), 128.7 (Ph rot B), 
128.1 (Ph rot A), 127.8 (Ph rot B), 127.5 (Ph rot A), 126.3 (Ph rot B), 117.6 
(1-C (enol-)), 117.9 (propenyl C-3keto rot A), 117.4 (propenyl C-3enol rot A), 
117.2 (propenyl C-3keto rot B), 117.1 (propenyl C-3enol rot B), 87.0 
(butanamide C-2enol), 50.8 (PhCH2-keto rot B), 50.0 (butanamide C-2keto rot 
B), 49.9 (butanamide C-2keto rot A), 49.7 (propenyl C-3keto rot B), 49.0 
(PhCH2-enol rot B), 48.4 (PhCH2-keto rot A), 48.1 (propenyl C-3keto rot A), 47.9 
(PhCH2-enol rot A), 47.5 (propenyl C-3enol rot A), 30.4 (butanamide C-4keto rot 
A), 30.3 (butanamide C-4keto rot B), 22.0 (30.4 (butanamide C-4enol rot A and 
B); νmax/cm-1 (film) 3498, 3086, 2556, 1859, 1724, 1631; m/z (ES) [MNa+] 
254.11 (100%, MNa+); HRMS Found: 254.1155, (C14H17NNaO2 requires 
MNa 254.1151). 
6α-Acetyl-5-benzyl-1H,3αH,4H,5H,6H,6αH-pyrrolo[3,4-c]pyrazol-6-one, 7 
 
Triethylamine (0.23 mL, 1.65 mmol) was added to a stirred solution of the 
amide 5 (346.0 mg, 1.5 mmol) in MeCN (2.00 mL) at 0°C. p-
Acetamidobenzenesulfonyl azide (396.0 mg, 1.65 mmol) was added portion 
wise, the reaction mixture was allowed to warm to rt and stirred for a further 
22 h. The reaction mixture was concentrated in vacuo to give a crude 
product. Purification by flash chromatography, eluting with Petrol—EtOAc 
(30:70), gave the pyrazolone 7 (289.5 mg, 75%) as a colourless amorphous 
solid, m.p. 89-92 ºC (from Petrol); Rf: 0.32 (30:70, Petrol—EtOAc); δH (500 
MHz; CDCl3) 7.36-7.28 (3H, m, Ar), 7.15 (2H, d, J 7.6, Ar), 6.70 (1H, s, N-H), 
6.64 (1H, s, 3-H), 4.51 (1H, d, J 14.8, PhCHAHB), 4.38 (1H, d, J 14.8, 
PhCHAHB), 3.81 (1H, d, J 7.5, 3α-H), 3.60 (1H, dd, J 7.5 and 2.5, 4-HA), 3.24 
(1H, d, J 2.5, 4-HB), 2.44 (3H, s, Acetyl-CH3); δC (125 MHz; CDCl3) 203.5 
(Acetyl CO), 170.3 (6-C), 144.3 (3-C), 135.0 (Ar), 129.1 (Ar), 128.0 (Ar), 
127.4 (Ar), 80.8 (6α-C), 48.2 (4-C), 47.4 (3α-C), 46.8 (PhCH2-), 27.4 (Acetyl-
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CH3); νmax/cm-1 (film) 3285, 2943, 2131, 1989, 1971, 1665, 1602; m/z  (ES) 
[MNa+] 280.1 (100%, MNa+); HRMS Found: 280.1056 (C14H15N3NaO2 
requires MNa 280.1056). 
Benzyl(propyl)amine, 9 
 
Benzaldehyde (1.22 mL, 12 mmol) was added to a stirred solution of 
propylamine (0.66 mL, 8 mmol) and 4 Å molecular sieves (2.50 g)in MeOH 
(32 mL) and the resulting mixture was stirred at rt. After 19 h the reaction 
mixture was filtered though a pad of celite, eluting with MeOH (50 mL). The 
solution was concentrated to half volume in vacuo, cooled to 0 °C, NaBH4 
(605 mg, 16 mmol) was added and the reaction mixture was allowed to 
warm to rt and stirred. After 2 h the reaction mixture was acidified to pH 2 by 
addition of aq. 2M HCl, concentrated to half volume in vacuo and extracted 
with EtOAc (4 × 10 mL). The aqueous layer was basified to pH 12 by 
addition of sat. aq. sol. K2CO3 and extracted with EtOAc (7 × 20 mL). The 
combined organic layers, after basification were dried (Na2SO4), filtered and 
concentrated in vacuo to give the amine 961 (1.0 g, 84%) as a colourless oil 
which required no further purification. Rf: 0.39 (9:1, CH2Cl2—MeOH); δH (500 
MHz; CDCl3) 7.32 (4H, m, Ph), 7.26-7.22 (1H, m, Ph), 3.79 (2H, s, PhCH2), 
2.60 (2H, t, J 7.3, propyl 1-H2), 1.58-1.49 (3H, m, propyl 2-H2 and NH), 0.92 
(3H, t, J 7.7, propyl 3-H3); δC (125 MHz; CDCl3) 140.7 (Ph), 128.4 (Ph), 
128.1 (Ph), 126.7 (Ph), 54.0 (PhCH2), 51.4 (propyl C-1), 23.2 (propyl C-2), 
11.8 (propyl C-3); νmax/cm-1 (film) 3310, 2958, 1604, 1494, 1454; m/z (EI) 
149.1 (M+, 85%), 120.1 (77%), 91 (100%); (Found: 149.1208, C10H15N 
requires M 149.1204). 
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N-Benzyl-3-oxo-N-propylbutanamide, 10 
 
2,2,6-Trimethyl-4H-1,3-dioxin-4-one (1.08 mL, 8.2 mmol) was added to a 
stirred solution of the amine 9 (298 mg, 2.0 mmol) in toluene (7 mL) and the 
reaction mixture was heated at reflux for 2 h. The reaction mixture was 
allowed to cool to rt and concentrated in vacuo to give a crude product. 
Purification by flash chromatography, eluting with CH2Cl2—Et2O (95:5), gave 
the amide 10 (400 mg, 86%) (3:1 keto:enol tautomers, 1:1 rotamers) as a 
yellow viscous oil. Rf: 0.28 (9:1, CH2Cl2—Et2O); δH (500 MHz; CDCl3)  7.39-
7.29 (16H, m, Ph), 7.29-7.21 (16H, m, Ph), 7.17 (8H, d, J 6.4, Ph), 5.14 (1H, 
s, butanamide 2-H1enol rot A), 5.07 (2H, s, butanamide 2-H1enol rot B), 4.62 
(8H, s, PhCH2 rot A), 4.52 (8H, s, PhCH2 rot B), 3.60 (6H, s, butanamide 2-
H2keto rot A), 3.50 (6H, s, butanamide 2-H2keto rot B), 3.36 (4H, t, J 7.7 propyl 
1-H2 rot A), 3.13 (4H, t, J 7.7 propyl 1-H2 rot B), 2.31 (9H, s, butanamide 4-
H3keto rot A), 2.25 (9H, s, butanamide 4-H3keto rot B), 1.98 (3H, s, butanamide 
4-H3enol rot A), 1.90 (3H, s, butanamide 4-H3enol rot B), 1.62-1.50 (16H, m, 
propyl 2-H2 rot A and B), 0.94-0.83 (24H, m, propyl 3-H3 rot A and B); δC 
(125 MHz; CDCl3) 202.5 (butanamide C-3keto), 175.2 (butanamide C-3enol), 
171.9 (butanamide C-1enol), 167.1 (butanamide C-1keto rot A) 166.8 
(butanamide C-1keto rot B), 137.1 (Ph rot A), 136.6 (Ph rot B), 129.0 (Ph rot 
A), 128.6 (Ph rot B), 127.9 (Ph rot A), 127.8 (Ph rot B), 127.4 (Ph rot A), 
127.2 (Ph rot B), 126.3 (Ph rot A), 126.2 (Ph rot B), 87.2 (butanamide C-2enol 
rot A), 86.9 (butanamide C-2enol rot B), 51.6 (PhCH2 rot B), 50.2 (butanamide 
C-2keto rot B), 49.9 (butanamide C-2keto rot A), 49.2 (propyl C-1 rot B), 48.3 
(propyl C-1 rot A), 48.0 (PhCH2 rot A), 30.3 (butanamide C-4keto rot A and B), 
22.2 (butanamide C-4enol rot A), 21.6 (propyl C-2 rot A), 21.1 (butanamide C-
4enol rot B), 20.7 (propyl C-2 rot B), 11.3 (propyl C-3 rot A), 11.3 (propyl C-3 
rot B); νmax/cm-1 (film) 3030, 2965, 1722, 1639, 1591; m/z (ES) [MNa+] 
256.11 (100%, MNa+); HRMS Found: 256.1341 (C14H19NNaO2 requires MNa 
256.1347). 
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N-Benzyl-2-diazo-3-oxo-N-propylbutanamide, 11 
 
Et3N (131 μL) was added to a stirred solution of the butanamide 10 (200 mg) 
in MeCN (0.8 M) at 0 °C. p-ABSA (1.1 equiv.) was added portionwise to the 
reaction mixture at 0 °C and the resulting mixture was allowed to warm to rt. 
After 20 h the reaction mixture was concentrated in vacuo to give a crude 
product. Purification by flash chromatography eluting with CH2Cl2—Et2O 
(95:5), gave the diazo-butanamide 11 (185 mg, 83%) as a bright yellow 
viscous oil. Rf:  0.32 (95:5, CH2Cl2—Et2O); δH (500 MHz; CDCl3) 7.38-7.33 
(2H, m, Ph), 7.31-7.27 (1H, m, Ph), 7.25 (2H, d, J 6.8, Ph), 4.59 (2H, s, 
PhCH2), 3.25 (2H, t, J 7.6, propyl 1-H2), 2.35 (3H, s, butanamide 4-H3), 1.61 
(2H, ap. hex, J 7.5, propyl 2-H2), 0.88 (3H, t, J 7.4, propyl 3-H3); δC (125 
MHz; CDCl3) 190.1 (butanamide C-3), 161.5 (butanamide C-1), 136.3 (Ph), 
128.9 (Ph), 127.7 (Ph), 127.3 (Ph), 73.7 (butanamide C-2), 50.6 (PhCH2), 
49.2 (propyl C-1), 27.3 (butanamide C-4), 20.9 (propyl C-2), 11.2 (propyl C-
3); νmax/cm-1 (film) 3585, 3518, 2965, 2358, 1634, 1418; m/z (ES) [MNa+] 
282.1212 (100%, MNa+); HRMS Found: 282.1212 (C14H17N3NaO2 requires 
MNa 282.1213). 
N-Benzyl-2-diazo-3-oxo-N-propylacetamide, 12 
 
By general procedure C, butanamide 11, gave the diazo-acetamide 12 (129 
mg, 89%) as a bright yellow liquid which required no further purification. Rf: 
0.63 (95:5, CH2Cl2—MeOH); δH (500 MHz; CDCl3) 7.34-7.28 (2H, m, Ph), 
7.27-7.23 (1H, m, Ph), 7.21 (2H, d, J 7.7, Ph), 4.94 (1H, s, diazo-acetamide 
2-H1), 4.48 (2H, s, b, PhCH2), 3.16 (2H, s, b, propyl 1-H2), 1.55 (2H, ap. hex, 
J 7.5,  propyl 2-H2), 0.87 (3H, t, J 7.5, propyl 3-H3); δC (125 MHz; CDCl3) 
166.2 (acetamide C-1), 137.4 (Ph), 128.7 (Ph), 127.4 (Ph), 50.3 (propyl C-1), 
48.9 (PhCH2), 46.7 (acetamide C-2), 21.3 (propyl C-2), 11.3 (propyl C-3); 
νmax/cm-1 (film) 3463, 3066, 2334, 2104, 1748, 1603; m/z (ES) [MNa+] 240.11 
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(100%, MNa+); HRMS Found: 240.1113 (C12H15N3NaO requires MNa 
240.1107). 
4-(Benzylamino)-2-(trifluoromethyl)benzonitrile, 15a 
 
By general procedure A, benzylamine, followed by purification by flash 
chromatography eluting with Petrol—EtOAc (80:20), gave the aniline 15a 
(240 mg, 87%) as pale yellow needles, m.p. 152-155 ºC (Petrol); Rf: 0.72 
(80:20, Petrol—EtOAc); δH (500 MHz; CDCl3) 7.50 (1H, d, J 8.5, Ar 6-H), 
7.37 (1H, m, Ph), 7.33 (2H, m, Ph), 7.30 (2H, m, Ph), 6.91 (1H, d, J 3.3, Ar 
3-H), 6.69 (1H, dd, J 8.5 and 3.3, Ar 5-H), 5.02 (1H, s, br, NH), 4.40 (2H, s, 
PhCH2); δC (125 MHz; CDCl3) 150.9 (Ar C-4), 136.2 (Ar C-6), 135.9 (Ph), 
134.0 (q, 2JFC 32, Ar C-2), 129.0 (Ph), 127.9 (Ph), 127.2 (Ph), 122.0 (q, 1JFC 
274, CF3); 117.7 (CN), 113.8 (Ar C-5), 110.2 (Ar C-3), 95.6 (Ar C-1), 47.3 
(PhCH2); νmax/cm-1 (film) 3348, 2641, 2592, 2228, 1895, 1819;  m/z (ES) 
[MNa+] 299.1 (100%, MNa+); HRMS Found: 299.0755 (C15H11F3N2 requires 
MNa 299.0767). 
4-[(Prop-2-en-1-yl)amino]-2-(trifluoromethyl)benzonitrile, 15a’ 
 
By general procedure A, allyl amine followed by purification by flash 
chromatography, eluting with Petrol—EtOAc (90:10), gave the aniline 15a’ 
(105 mg, 98%) as pale yellow needles, m.p. 128-134 ºC (Petrol); Rf: 0.76 
(80:20, Petrol—EtOAc); δH (500 MHz; CDCl3) 7.54 (1H, d, J 8.5, Ar 6-H), 
6.87 (1H, d, J 2.7, Ar 3-H), 6.70 (1H, dd, J 8.5 and 2.7, Ar 5-H), 5.89 (1H, 
ddt, J 17.3, 10.2 and 7.3, propenyl 2-H1), 5.29 (1H, dd, J 17.3 and 2.7, 
propenyl 3-HA), 5.24 (1H, dd, J 10.2 and 2.7, propenyl 3-HB), 4.79 (1H, s, b, 
NH), 3.86 (2H, d, J 7.3, propenyl 1-H); δC (125 MHz; CDCl3) 151.1 (Ar C-4), 
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136.1 (Ar C-6), 134.2 (q, 2JFC 32, Ar C-2), 132.9 (propenyl C-2), 
122.0 (q, 1JFC 276, CF3), 117.5 (propenyl C-3), 117.2 (CN); 113.9 (Ar C-5), 
110.1 (Ar C-3), 95.6 (Ar C-1), 45.7 (propenyl C-1);  νmax/cm-1 (film) 3370, 
2923, 2871, 2253, 2223, 1895; m/z (ES) [MNa+] 249.1 (100%, MNa+); HRMS 
Found: 249.0608, (C11H9F3N2Na requires MNa 249.061). 
N-Benzyl-N-[4-cyano-3-(trifluoromethyl)phenyl]-3-oxobutanamide, 16 
 
2,2,6-Trimethyl-4H-1,3-dioxin-4-one (103 μL, 0.77 mmol) was added to a 
solution of the aniline 7 (142 mg, 0.51 mmol) in toluene (1 mL). The reaction 
mixture was irratiated under microwave conditions (100 Watts, 50 psi) at 110 
°C for 30 mins. The crude product was concentrated in vacuo. Purification by 
flash chromatography, eluting with CH2Cl2—Et2O (98:2), gave the amide 16 
(155 mg, 84%) (1:1 keto:enol tautomers) as a pale yellow viscous oil. Rf: 
0.42 (95:5, CH2Cl2—Et2O); δH (500 MHz; CDCl3) 7.81-7.78 (2H, m, Ar 5-H), 
7.55-7.53 (2H, m, Ar 2-H), 7.39-7.47 (2H, m, Ar 6-H), 7.30-7.27 (6H, m, Ph), 
7.19-7.17 (4H, m, Ph), 4.97 (2H, s, PhCH2keto), 4.96 (2H, s, PhCH2enol), 4.73 
(1H, s, butanamide-2H1enol), 3.40 (2H, s, br, butanamide 2-H2keto), 2.18 (3H, 
s, butanamide 4-H3keto), 1.88 (3H, s, butanamide 4-H3enol); δC (125 MHz; 
CDCl3) 201.6 (butanamide C-3keto), 177.3 (butanamide C-3enol), 171.6 
(butanamide C-1enol), 165.9 (butanamide C-1keto), 146.1 (Ar C-1), 136.2 (Ar 
C-5), 135.8 (Ph), 134.1 (q, 2JFC 32, Ar C-3), 131.7 (Ar C-6), 128.9 (Ph), 128.4 
(Ph), 127.3 (Ph), 126.7 (Ar C-2), 121.8 (q, 1JFC 273, CF3), 114.8 (CN), 108.5 
(Ar C-4), 88.8 (butanamide C-2enol), 52.2 (PhCH2), 50.1 (butanamide C-2keto), 
30.6 (butanamide C-4keto), 21.9 (butanamide C-4enol);  νmax/cm-1 (film) 3374, 
3065, 2927, 2234, 1723, 1667, 1612; m/z (ES) [MNa+] 383.09 (100%, 
MNa+); HRMS Found: 383.0974 (C19H15F3N2NaO2 requires MNa 383.0978). 
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N-Benzyl-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-diazo-3-
oxobutanamide, 17a 
 
By general procedure B, aniline 15a, followed by purification by flash 
chromatography, eluting with Petrol—EtOAc (80:20), gave the amide 17a 
(133 mg, 80%) as a bright yellow viscous oil. Rf: 0.35 (90:10, CH2Cl2—Et2O); 
δH (500 MHz; CDCl3) 7.76 (1H, d, J 8.2, Ar 5-H), 7.52 (1H, d, J 2.1, Ar 2-H), 
7.39 (1H, dd, J 8.2 and 2.1, Ar 6-H), 7.33-7.27 (3H, m, Ph), 7.22-7.19 (2H, 
m, Ph), 5.04 (2H, s, PhCH2), 2.34 (3H, s, butanamide 4-H3); δC (125 MHz; 
CDCl3) 188.1 (butanamide C-3), 161.3 (butanamide C-1), 146.6 (Ar C-1), 
136.0 (Ar C-5), 135.6 (Ph), 134.3 (q, 2JFC 32, Ar C-3), 129.2 (Ph), 129.0 (Ar 
C-6), 128.3 (Ph), 128.0 (Ph), 123.8 (Ar C-2), 121.7 (q, 1JFC 274, CF3), 114.7 
(CN), 108.0 (Ar C-4), 75.9 (butanamide C-2), 54.1 (PhCH2), 27.8 
(butanamide C-4); νmax/cm-1  (film) 3087, 3066, 2933, 2232, 2114, 1660, 
1608; m/z (ES) [MNa+] 409.09 (100%, MNa+); HRMS Found: 409.0901, 
(C19H13F3N4NaO2 requires MNa 409.0883). 
N-Benzyl-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-diazo-acetamide, 18a 
 
By general procedure C, amide 17a, followed by purification by flash 
chromatography, eluting with CH2Cl2—EtOAc (90:10), gave the amide 18a 
(51 mg, 93%) as a bright yellow viscous oil. Rf: 0.47 (90:10, CH2Cl2—Et2O); 
δH (500 MHz; CDCl3) 7.78 (1H, d, J 8.7, Ar 5-H), 7.59 (1H, d, J 2.6, Ar 2-H), 
7.41 (1H, dd, J 8.7 and 2.6, Ar 6-H), 7.37-7.27 (3H, m, Ph), 7.19 (2H, d, J 
8.5, Ph), 4.97 (2H, s, PhCH2), 4.62 (1H, s, acetamide 2-H1); δC (125 MHz; 
CDCl3) 165.3 (acetamide C-1), 146.4 (Ar C-1), 136.1 (Ph), 135.9 (Ar C-5), 
134.1 (q, 2JFC 32, Ar C-3), 130.8 (Ar C-6), 129.0 (Ph), 128.1 (Ph), 127.7 
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(Ph), 125.6 (Ar C-2), 121.7 (q, 1JFC 275, CF3), 114.7 (CN), 108.5 (Ar C-4), 
52.8 (PhCH2), 48.5 (acetamide C-2); νmax/cm-1  (film) 3089, 2930, 2232, 
2106, 1631, 1607, 1502; m/z (ES) [MNa+] 367.08 (100%, MNa+); HRMS 
Found: 367.0770, (C17H11F3N4NaO requires MNa 367.0777). 
4-(Propylamino)-2-(trifluoromethyl)benzonitrile, 15b 
 
By general procedure A, propyl amine followed by purification by flash 
chromatography, eluting with Petrol—EtOAc (90:10), gave the aniline 15b 
(187 mg, 82%) as pale yellow needles, m.p. 116—119 ºC (Petrol); Rf: 0.55 
(50:50, Petrol—EtOAc); δH (500 MHz; CDCl3) 7.54 (1H, d, J 8.7, Ar 6-H), 
6.83 (1H, d, J 2.4, Ar 3-H), 6.67 (1H, dd, J 8.7 and 2.4, Ar 5-H), 4.46 (1H, s, 
br, NH), 3.16 (2H, t, J 7.2, propyl 1-H2), 1.68 (2H, ap. hex, J 7.3, propyl 2-
H2), 1.02 (3H, t, J 7.3, propyl 3-H3); δC (125 MHz; CDCl3) 151.1 (Ar C-4), 
136.2 (Ar C-6), 134.2 (q, 2JFC 31, Ar C-2), 122.0 (q, 1JFC 272, CF3), 117.4 
(CN), 113.7 (Ar C-5), 110.0 (Ar C-3), 95.4 (Ar C-1), 45.0 (propyl C-1), 22.2 
(propyl C-2), 11.4 (propyl C-3); νmax/cm-1 (film) 3357, 2878, 2224, 1893, 
1615; m/z (ES) [MNa+] 251.08 (100%, MNa+); HRMS Found: 251.0773, 
(C11H11F3N2Na requires MNa 251.0767). 
N-[4-Cyano-3-(trifluoromethyl)phenyl]-2-diazo-3-oxo-N-
propylbutanamide, 17b 
 
By general procedure B, aniline 15b, followed by purification by flash 
chromatography, eluting with Petrol—EtOAc (80:20), gave the amide 17b 
(129 mg, 89%) as  bright yellow needles. Rf: 0.83 (95:5, CH2Cl2—MeOH); δH 
(500 MHz; CDCl3) 7.88 (1H, d, J 8.4, Ar 5-H), 7.62 (1H, d, J 2.0, Ar 2-H), 
7.53 (1H, dd, J 8.4 and 2.0, Ar 6-H), 3.81 (2H, t, J 7.8, propyl 1-H2), 2.33 
(3H, s, butanamide 4-H3), 1.62 (2H, ap. hex, J 7.5, propyl 2-H2), 0.94 (3H, t, 
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J 7.5, propyl 3-H3); δC (125 MHz; CDCl3) 188.4 (butanamide C-3), 160.9 
(butanamide C-1), 146.8 (Ar C-1), 136.2 (Ar C-5), 134.4 (q, 2JFC 32, Ar C-3), 
129.2 (Ar C-6), 123.8 (Ar C-2), 121.7 (q, 1JFC 276, CF3), 114.7 (CN), 107.8 
(Ar C-4), 75.8 (butanamide C-2), 52.6 (propyl C-1), 27.7 (butanamide C-4), 
21.4 (propyl C-2), 11.1 (propyl C-3); νmax/cm-1  (film) 3084, 2934, 2235, 2095, 
1777, 1682, 1503; m/z (ES) [MNa+] 361.09 (100%, MNa+); HRMS Found: 
361.0890, (C15H13F3N4NaO2 requires MNa 361.0883). 
N-[4-Cyano-3-(trifluoromethyl)phenyl]-2-diazo-N-propylacetamide, 18b 
NC
CF3
N
O
N2
 
By general procedure C, amide 17b, followed by purification by flash 
chromatography, eluting with CH2Cl2—EtOAc (90:10), gave the amide 18b 
(65 mg, 91%) as a bright yellow viscous oil. Rf: 0.49 (95:5, CH2Cl2—MeOH); 
δH (500 MHz; CDCl3) 7.89 (1H, d, J 8.2, Ar 5-H), 7.67 (1H, d, J 2.1, Ar 2-H), 
7.57 (1H, dd, J 8.2 and 2.1, Ar 6-H), 4.61 (1H, s, acetamide 2-H), 3.74 (2H, t, 
J 7.6, propyl 1-H2), 1.58 (2H, ap. hex, J 7.6, propyl 2-H2), 0.92 (3H, t, J 7.6, 
propyl 3-H3); δC (125 MHz; CDCl3) 164.9 (acetamide C-1), 146.4 (Ar C-1), 
136.2 (Ar C-5), 134.4 (q, 2JFC 32,  Ar C-3), 131.0 (Ar C-6), 125.8 (Ar C-2), 
122.0 (q, 1JFC 276, CF3), 114.8 (CN), 108.3 (Ar C-4), 51.1 (propyl C-1), 48.4 
(acetamide C-2), 21.7 (propyl C-2), 11.1 (propyl C-1); νmax/cm-1  (film) 3110, 
2939, 2229, 2109, 1735, 1594, 1504; m/z  (ES) [MH+] 297.1 (100%, MH+); 
HRMS Found: 297.0951  (C13H11F3N4O requires MH 297.0958). 
4-[(2-Phenylethyl)amino]-2-(trifluoromethyl)benzonitrile, 15c 
 
By general procedure A, phenylethylamine followed by purification by flash 
chromatography, eluting with Petrol—EtOAc (80:20), gave the aniline 15c 
(203 mg, 87%) as pale yellow needles, m.p. 132-136 ºC (Petrol); Rf: 0.89 
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(95:5, CH2Cl2—MeOH); δH (500 MHz; CDCl3) 7.54 (1H, d, J 8.5, Ar 6-H), 
7.37-7.31 (2H, m, Ph), 7.29-7.24 (2H, m, Ph), 7.21 (1H, d, J 7.7, Ph), 6.82 
(1H, d, J 2.4, Ar 3-H), 6.66 (1H, dd, J 8.5 and 2.4, Ar 5-H), 4.48 (1H, s, br, 
NH), 3.48 (2H, t, J 6.8, CH2N), 2.95 (2H, t, J 6.8, PhCH2); δC (125 MHz; 
CDCl3) 150.8 (Ar C-4), 138.0 (Ph), 136.2 (Ar C-6), 134.2 (q, 2JFC 32, Ar C-2), 
128.9 (Ph), 128.7 (Ph), 127.0 (Ph), 122.6 (q, 1JFC 272,  CF3), 117.1 (CN), 
113.9 (Ar C-5), 110.1 (Ar C-3), 95.4 (Ar C-1), 44.3 (CH2N), 35.1 (PhCH2); 
νmax/cm-1 (film) 3351, 2925, 2224, 1615, 1528; m/z (ES) [MNa+] 313.1 
(100%, MNa+); HRMS Found: 313.0921 (C16H13F3N2Na requires MNa 
313.0923). 
N-[4-Cyano-3-(trifluoromethyl)phenyl]-2-diazo-3-oxo-N-(2-
phenylethyl)butanamide, 17c 
 
By general procedure B, aniline 15c, followed by purification by flash 
chromatography, eluting with Petrol—EtOAc (80:20), gave the amide 17c 
(125 mg, 76%) as a bright yellow viscous oil Rf: 0.49 (90:10, CH2Cl2—Et2O); 
δH (500 MHz; CDCl3)  7.75 (1H, d, J 8.4, Ar 5-H), 7.35-7.24 (3H, m, Ph and 
Ar 2-H), 7.22 (1H, d, J 8.4 and 2.2, Ar 6-H), 7.16-7.12 (3H, m, Ph), 4.06 (2H, 
t, J 7.8, CH2N), 3.00 (2H, t, J 7.8, PhCH2), 2.37 (3H, s, butanamide 4-H3); δC 
(125 MHz; CDCl3) 189.3 (butanamide C-3), 160.8 (butanamide C-1), 147.0 
(Ar C-1), 138.0 (Ph), 136.2 (Ar C-5), 134.1 (q, 2JFC 32, Ar C-3), 129.0 (Ar C-
6), 127.2 (Ph), 123.9 (Ar C-2), 121.5 (q, 1JFC 276, CF3), 114.6 (CN), 107.7 
(Ar C-4), 75.9 (butanamide C-2), 53.7 (CH2N), 34.2 (PhCH2), 28.2 
(butanamide C-4); νmax/cm-1  (film) 3029, 2232, 2113, 1660, 1607, 1501; m/z 
(ES) [MNa+] 423.11 (100%, MNa+); HRMS Found: 423.1057, 
(C20H15F3N4NaO2 requires MNa 423.1039). 
  
- 122 - 
N-[4-Cyano-3-(trifluoromethyl)phenyl]-2-diazo-N-(2-
phenylethyl)acetamide, 18c 
 
By general procedure C, amide 17c, followed by purification by flash 
chromatography, eluting with CH2Cl2—EtOAc (90:10), gave the amide 18c 
(36 mg, 89%) as a bright yellow viscous oil. Rf: 0.49 (90:10, CH2Cl2—Et2O); 
δH (500 MHz; CDCl3)  7.77 (1H, d, J 8.5, Ar 6-H), 7.32-7.20 (4H, m, Ph and 
Ar 2-H), 7.17-7.09 (3H, m, Ph and Ar 5-H), 4.51 (1H, s, acetamide 2-H), 4.03 
(2H, t, J 7.3, CH2N), 2.96 (2H, t, J 7.3, PhCH2); δC (125 MHz; CDCl3) 164.9 
(acetamide C-1), 138.0 (Ph), 146.8 (Ar C-1), 135.9 (Ar C-5), 134.3 (q, 
2JFC 32, Ar C-3), 130.9 (Ph and Ar C-6), 128.7 (Ph), 126.9 (Ph), 125.8 (Ar C-
2), 121.7 (q, 1JFC 278, CF3), 114.8 (CN), 108.2 (Ar C-4), 51.9 (CH2N), 48.5 
(acetamide C-2), 34.7 (PhCH2); νmax/cm-1 (film) 3500, 3086, 2232, 2108, 
1726, 1634, 1606;  m/z (ES) [MNa+] 381.09 (100%, MNa+); HRMS Found: 
381.0934, (C18H13F3N4NaO requires MNa 381.0934). 
4-[Isopentylamino]-2-(trifluoromethyl)benzonitrile, 15d 
 
By general procedure A, isopentyl amine, followed by purification by flash 
chromatography, eluting with Petrol—EtOAc (80:20) gave the aniline 15d, 
(460 mg, 90%) as pale yellow oil; Rf:  0.90 (95:5, CH2Cl2—MeOH); δH 
(500 MHz; CDCl3) 7.53 (1H, d, J 8.7, Ar 6-H), 6.83 (1H, d, J 2.5, Ar 3-H), 
6.67 (1H, dd, J 8.7 and 2.5, Ar 5-H), 4.47 (1H, s, b, NH), 3.19 (2H, dt, J 7.6 
and 2.2, ipentyl 1-H2), 1.72 (1H, ap. sept, J 6.7, ipentyl 3-H1), 1.54 (2H, q, J 
7.2, ipentyl 2-H2), 0.97 (6H, d, J 6.7, ipentyl 4-H3 and 4’-H3); δC (125 MHz; 
CDCl3) 151.2 (Ar C-4), 136.1 (Ar C-6), 134.3 (q,  2JFC 33, Ar C-2), 122.7 (q,  
1JFC 279, CF3), 117.2 (CN), 113.6 (Ar C-5), 110.0 (Ar C-3), 95.1 (Ar C-1); 
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41.5 (ipentyl C-1), 37.8 (ipentyl C-2), 25.9 (ipentyl C-3), 22.4 (ipentyl C-4); 
νmax/cm-1 (film) 3367, 2960, 2219, 1711, 1616, 1533; m/z (ES) [MNa+] 279.11 
(100%, MNa+); HRMS Found: 279.1087 (C13H15F3N2Na MNa  requires 
279.1080). 
N-(Isopentyl)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-diazo-3-
oxobutanamide, 17d 
 
By general procedure B, aniline 15d, followed by purification by flash 
chromatography, eluting with Petrol—EtOAc (80:20) gave the amide 17d 
(425 mg, 65 %) as a bright yellow oil;  Rf: 0.61 (90:10, CH2Cl2—Et2O); δH 
(500 MHz; CDCl3) 7.87 (1H, d, J 8.6, Ar 5-H), 7.58 (1H, d, J 2.5, Ar 2-H), 
7.49 (1H, dd, J 8.6 and 2.5, Ar 6-H), 3.84 (2H, t, J 8.1, ipentyl 1-H2), 2.33 
(3H, s, butanamide 4-H3), 1.59 (1H, ap. sept, J 6.8, ipentyl 3-H2), 1.47 (2H, 
dt, J 6.8 and 8.1, ipentyl 2-H), 0.92 (6H, d, J 6.8, ipentyl 4-H3 and 4’-H3); δC 
(125 MHz; CDCl3) 189.0 (butanamide C-3), 160.9 (butanamide C-1), 146.8 
(Ar C-1), 136.2 (Ar C-5), 134.8 (q, 2JFC 31, Ar C-3), 129.1 (Ar C-2), 123.8 (Ar 
C-6), 121.7 (q, 2JFC 276, CF3), 114.7 (CN), 107.1 (Ar C-4), 75.8 (butanamide 
C-2), 49.8 (ipentyl C-1), 36.8 (ipentyl C-2), 27.7 (butanamide C-4), 26.1 
(ipentyl C-3), 22.3 (ipentyl C-4); νmax/cm-1 (film) 3083, 2958, 2873, 2232, 
2111, 1675; m/z (ES) [MNa+] 389.12 (100%, MNa+); HRMS 
Found: 389.1207 (C16H13F3N4NaO2 requires, MNa 389.1196). 
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N-(Isopentyl)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-diazo-acetamide, 
18d 
 
By general procedure C, amide 17d, followed by purification by flash 
chromatography, eluting with Petrol—EtOAc (70:30) gave the amide 18d (87 
mg, 75 %) , as a bright yellow oil; Rf: 0.32 (70:30, Petrol—EtOAc); δH (500 
MHz; CDCl3) 7.89 (1H, d, J 8.4, Ar 5-H), 7.65 (1H, d, J 2.8, Ar 2-H), 7.55 
(1H, dd, J 8.4 and 2.8, Ar 6-H), 4.56 (1H, s, acetamide 2-H1), 3.78 (2H, t, J 
7.0, ipentyl-1H2), 1.59 (1H, ap. sept, J 6.7, ipentyl 3-H1), 1.43 (2H, dt, J 7.0 
and 6.7, ipentyl 2-H2), 0.91 (6H, d, J 7.0, ipentyl 4-H3 and 4’-H3); δC (125 
MHz; CDCl3) 164.9 (acetamide C-1), 146.5 (Ar C-1), 136.0 (Ar C-5), 134.6 
(q, 2JFC 31, Ar C-3), 130.9 (Ar C-6), 125.7 (Ar C-2), 121.8 (q, 1JFC 269, CF3), 
114.7 (CN), 108.3 (Ar C-4), 48.4 (acetamide C-2), 48.2 (ipentyl C-1), 37.2 
(ipentyl C-2), 26.0 (ipentyl C-3), 22.4 (ipentyl C-4); νmax/cm-1  (film) 3096, 
2959, 2236, 2107, 1630; m/z (ES) [MNa+] 347.11 (100%, MNa+); HRMS 
Found: 347.1093 (C15H15F3N4NaO requires MNa 347.1090). 
4-[(But-3-en-1-yl)amino]-2-(trifluoromethyl)benzonitrile, 15e 
 
By general procedure A, 3-butenylamine hydrochloride and two extra equiv. 
of K2CO3 followed by purification by flash chromatography, eluting with 
Petrol—EtOAc (80:20), gave the aniline 15e (197 mg, 87%) as a pale yellow 
viscous oil. Rf: 0.67 (50:50, Petrol—EtOAc); δH (500 MHz; CDCl3) 7.53 (1H, 
d, J 8.2, Ar 6-H), 6.86 (1H, d, J 2.1, Ar 3-H), 6.69 (1H, dd, J 8.2 and 2.1, Ar 
5-H), 5.81 (1H, ddt, J 17.0, 10.4 and 3.2, butenyl 3-H1), 5.18 (1H, dd, J 17.0 
and 3.2, butenyl 4-HA), 5.15 (1H, dd, J 10.4 and 3.2, butenyl 4-HB), 4.76 (1H, 
s, br, NH), 3.26 (2H, ap. q, J 6.5, butenyl 1-H2), 2.42 (2H, ap. q, J 6.8, 
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butenyl 2-H2); δC (125 MHz; CDCl3) 151.3 (Ar C-4), 136.1 (Ar C-6), 134.5 
(butenyl C-3), 134.1 (q, 2JFC  32, Ar C-2), 122.6 (q, 1JFC  274, CF3), 117.9 
(butenyl C-4), 117.8 (CN), 113.8 (Ar C-5), 110.2 (Ar C-3), 94.8 (Ar C-1), 42.0 
(butenyl C-1), 39.4 (butenyl C-2); νmax/cm-1 (film) 3367, 2926, 2220, 1615, 
1531; m/z (ES) [MNa+] 263.08 (100%, MNa+); HRMS Found: 263.0769 
(C12H11F3N2Na, requires MNa 263.0767). 
 
N-(But-3-en-1-yl)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-diazo-3-
oxobutanamide, 17e 
 
By general procedure B, aniline 15e, followed by purification by flash 
chromatography, eluting with Petrol—EtOAc (80:20), gave the amide 17e 
(162 mg, 91%) as bright yellow needles. Rf: 0.47 (90:10, CH2Cl2—Et2O); δH 
(500 MHz; CDCl3)  7.87 (1H, d, J 8.2, Ar 5-H), 7.61 (1H, d, J 2.3, Ar 2-H), 
7.51 (1H, dd, J 8.2 and 2.3, Ar 6-H), 5.75 (1H, ddt, J 17.3, 10.2 and 7.3, 
butenyl 3-H1), 5.09 (1H, dd, J 10.2 and 3.0, butenyl 4-HA), 5.06 (1H, dd, J 
17.3 and 3.0, butenyl 4-HB), 3.93 (2H, t, J 7.1, butenyl 1-H2), 2.37 (2H, dt, J 
7.3 and 7.1, butenyl 2-H2), 2.33 (3H, s, butenamide 4-H3); δC (125 MHz; 
CDCl3) 188.4 (butenamide C-3), 161.1 (butenamide C-1) 146.4 (Ar C-1), 
136.1 (Ar C-5), 134.7 (q, 2JFC 34, Ar C-3), 134.1 (butenyl C-3), 129.3 (Ar C-
6), 124.0 (Ar C-2), 121.7 (q, 1JFC 274, CF3), 118.0 (butenyl C-4), 114.6 (CN), 
108.0 (Ar C-4); 75.8 (butanamide C-2), 50.3 (butenyl C-1), 32.5 (butenyl C-
2), 27.7 (butenamide C-4); νmax/cm-1 (film) 3277, 3087, 2228, 2113, 1759, 
1645, 1503; m/z  (ES) [MNa+] 373.09 (100%, MNa+); HRMS Found: 
373.0892, (C16H13F3N4O2 requires MNa 373.0883). 
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N-(But-3-en-1-yl)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-diazo-
acetamide, 18e 
 
By general procedure C, amide 17e, followed by purification by flash 
chromatography, eluting with Petrol—EtOAc (80:20), gave the amide 18e 
(75 mg, 93%) as a bright yellow viscous oil. Rf: 0.56 (90:10, CH2Cl2—Et2O); 
δH (500 MHz; CDCl3),  7.91 (1H, d, J 8.5, Ar 5-H), 7.67 (1H, d, J 2.2, Ar 2-H), 
7.57 (1H, dd, J 8.5 and 2.2, Ar 6-H), 5.73 (1H, ddt, J 17.3, 10.4 and 7.3, 
butenyl 3-H1), 5.08 (1H, dd, J 10.4 and 2.3, butenyl 4-HA), 5.06 (1H, dd, J 
17.3 and 2.3, butenyl 4-HB), 4.57 (1H, s, b, acetamide 2-H1), 3.87 (2H, t, J 
7.4, butenyl 1-H2), 2.32 (2H, ap. q, J 7.4, butenyl 2-H2); δC (125 MHz; CDCl3) 
165.0 (acetamide C-1), 146.2 (Ar C-1), 136.0 (Ar C-5), 134.6 (q, 2JFC 32, Ar 
C-3), 134.3 (butenyl C-3), 131.4 (Ar C-6), 126.2 (Ar C-2), 121.9 
(q, 1JFC 274, CF3), 117.9 (butenyl C-4), 114.7 (CN), 108.6 (Ar C-4), 48.7 
(butenyl C-1), 48.5 (acetamide C-2), 32.8 (butenyl C-2); νmax/cm-1 (film) 
3083, 2934, 2233, 2112, 1633, 1503, 1393; m/z (ES) [MNa+] 331.08 (100%, 
MNa+); HRMS Found: 331.0778, (C14H11F3N4O requires MNa 331.0777). 
Benzyl but-3-enylcarbamate, 1962 
 
By the method of Taillier et al.,62 a solution of Na2CO3 in H2O (3 mL, 4 M) 
was added to a stirred suspension of 3-butenyl amine hydrochloride 
(403 mg, 3.75 mmol) in CH2Cl2 (40 mL) at rt and the reaction mixture was 
cooled to 0 °C. Benzyl chloroformate (0.85 mL, 6.0 mmol) was added 
dropwise to the reaction mixture and allowed to warm to rt. After 3 h H2O (50 
mL) was added and layers separated. The aqueous layer was extracted with 
CH2Cl2 (3 × 20 mL). The combined organic layers were washed with H2O 
(20 mL), dried over Na2SO4, filtered and concentrated in vacuo to give the 
carbamate 1962 as a clear oil (769 mg, 95 %) which required no further 
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purification. Rf: 0.52 (80:20, Petrol—EtOAc);  δH (500 MHz; CDCl3) 7.34 (5H, 
m, Ph), 5.74 (1H, ddt, J 17.1, 10.2, and 6.6, butenyl 2-H), 5.10 (4H, m, 
butenyl 1-H2 and PhCH2), 3.26 (2H, q, J 6.6, butenyl 3-H1), 2.26 (2H, q, J 
6.6, butenyl 4-H2); δH (125 MHz; CDCl3) 156.4 (carbamate C-1); 136.7 (Ph), 
135.1 (butenyl C-2), 133.3 (Ph), 128.8 (Ph), 128.1 (Ph), 117.3 (butenyl C-1); 
66.6 (PhCH2), 40.1 (butenyl C-3), 34.1 (butenyl C-4); νmax/cm-1 (film) 3332, 
2940, 1953, 1870, 1776, 1692, 1547; m/z (ES) [MNa+] 228.1 (100%, MNa+). 
N-Methyl but-3-enyl amine hydrochloride, 2063 
 
The carbamate 19 was added, as a solution in THF (4 mL) to a stirred 
suspension of LiAlH4 in THF (4 mL) at 0 °C. The syringe was washed with 
THF (2 mL) and the reaction mixture was allowed to warm to rt and then 
heated to reflux. After 4 h the reaction mixture was cooled to 0 °C and H2O 
(0.8 mL), NaOH (15% aq. sol., 0.8 mL) and H2O (2.4 mL) were added 
sequentially and the reaction mixture was allowed to warm to rt. After 2.5 h 
the reaction mixture was filtered through a pad of celite eluting with Et2O 
(100 mL). The organic layer was extracted with 1 M HCl (3 × 20 mL) and the 
combined aqueous layers were concentrated in vacuo to give the amine 
hydrochloride salt 2063 (395 mg, 65%) as a pale yellow amorphous solid. 
m.p. 164-167 °C (lit.63 178-180 °C); δH (500 MHz; D2O)  5.74 (1H, ddt, J 
17.4, 10.2 and 3.4, butenyl 3-H1), 5.18 (1H, dd, J 10.2 and 3.4, butenyl 4-
HA), 5.15 (1H, dd, J 17.4 and 3.4, butenyl 4-HB), 4.68 (2H, s, b, NH2+), 3.05 
(2H, t, J 7.0, butenyl 1-H2), 2.63 (3H, s, NMe), 2.39 (2H, ap. q, J 7.0, butenyl 
2-H2); δC (125 MHz; D2O) 132.8 (butenyl C-3), 119.0 (butenyl C-4), 48.1 
(butenyl C-1), 32.7 (NMe), 29.9 (butenyl C-2); m/z (ES) [MH+] 86.09 
(100%, MH+). 
Ethyl 2-[(4-cyano-3-(trifluoromethyl)phenyl)amino]acetate, 15k 
 
By general procedure A, glycine ethyl ester hydrochloride and two extra 
equiv. of K2CO3 followed by purification by flash chromatography, eluting 
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with Petrol—EtOAc (60:40), gave the aniline 42 (304 mg, 56%) as a 
colourless amorphous solid. Rf: 0.22 (70:30, Petrol—EtOAc); δH (500 MHz; 
CDCl3) 7.59 (1H, d, J 8.5, Ar 5-H), 6.88 (1H, d, J 2.4, Ar 2-H), 6.70 (1H, dd, J 
8.5 and 2.4, Ar 6-H), 5.13 (1H, s, b, NH), 4.29 (2H, q, J 7.1, ethyl 1-H2), 3.96 
(2H, d, J 5.1, glycinic 1-H2), 1.32 (3H, t, J 7.1, ethyl 2-H3); δH (125 MHz; 
CDCl3) 169.4 (glycinic C-2), 149.8 (Ar C-1), 136.6 (Ar C-5), 134.5 (q, 2JCF 33, 
Ar C-3), 122.3 (q, 1JCF 278, CF3), 116.7 (CN), 114.2 (Ar C-6), 110.4 (Ar C-2), 
96.8 (Ar C-4), 62.1 (ethyl C-1), 44.7 (glycinic C-1), 14.1 (ethyl C-2); νmax/cm-1 
(film) 3360, 2996, 2221, 1713, 1615; m/z (ES) [MH+] 273.09 (100%, MH+); 
HRMS Found: 273.0854, (C12H11F3N2O2 requires MH 273.0845).  
tert-Butyl N-[((but-3-en-1-yl)(methyl)carbamoyl)methyl]carbamate, 22 
 
DIPEA (1.4 mL, 8.9 mmol) was added to a stirred solution of EDCI∙HCl (468 
mg, 2.4 mmol) and HOBt∙H2O (324 mg, 2.4 mmol) in CH2Cl2 (20 mL). The 
amine 20 (392 mg, 2.4 mmol) and N-Boc glycine (385 mg, 2.2 mmol) were 
added sequentially to the reaction mixture. After 20 h the reaction mixture 
was concentrated in vacuo. Purification by flash chromatography eluting with 
Petrol—EtOAc (1:1) gave the amide 22 (494 mg, 93%; 1:1 mixture of 
rotamers) as a colourless oil. Rf:: 0.85 (90:10, CH2Cl2—MeOH); δH (500 
MHz; CDCl3) 5.75 (1H, m, butenyl 3-H1), 5.53 (1H, s, b, NH), 5.08 (2H, m, 
butenyl 4-HA and 4-HB), 3.97 (1H, d, J 4.3, glycinic-H rot A), 3.92 (1H, d, J 
4.3, glycinic-H rot B), 3.47 (1H, t, J 7.3, butenyl 1-H2 rot A), 3.28 (1H, t, J 7.3, 
butenyl 1-H2 rot B), 2.96 (1.5H, s, NMe rot A), 2.93 (1.5H, s, NMe rot B), 
2.31 (2H, m, butenyl 2-H2), 1.45 (9H, s, Boc); δH (125 MHz; CDCl3) 168.2 
(Boc C-1); 155.8 (glycine amide C-2), 135.1 (butenyl C-3 rot A), 133.7 
(butenyl C-3 rot B), 118.2 (butenyl C-4 rot A), 117.0 (butenyl C-4 rot B); 48.2 
(butenyl C-1 rot A), 47.6 (butenyl C-1 rot B), 42.4 (glycine amide C-1 rot A), 
42.2 (glycine amide C-1 rot B), 34.2 (NMe rot A), 33.5 (NMe rot B), 32.4 
(butenyl C-2 rot A), 31.8 (butenyl C-2 rot B), 28.4 (Boc C-3); νmax/cm-1 (film) 
3418, 3332, 2978, 2933, 1714, 1658, 1487; m/z (EI) [M+] 242.16 (100%, M+); 
HRMS Found: 242.1639, (C12H22N2O3 requires M 242.1630). 
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2-Amino-N-(but-3en-1-yl)-N-methylacetamide, 14f63 
 
HCl (4 M in Dioxane, 2 mL) was added dropwise over 5 min to a stirred 
solution of the amide 34 (506 mg, 2.1 mmol) in CH2Cl2 (10 mL). After 17 h 
the reaction mixture was concentrated in vacuo to give a crude product. The 
crude was diluted in Et2O—MeOH (20:1, 80 mL) and the organic layer was 
extracted with H2O (2 × 20 mL) and 1 M HCl (2 × 20 mL). The combined 
aqueous layers were concentrated in vacuo until half volume and basified by 
the addition of 2 M NaOH until pH 14. The aqueous layer was extracted with 
EtOAc (10 × 20 mL). The combined organic layers were dried over Na2SO4, 
filtered and concentrated in vacuo to give the amide 14f63 as a pale yellow 
oil (248 mg, 92%) which required no further purification (1:1 mixture of 
rotamers). Rf:: 0.21 (90:10, CH2Cl2—MeOH); δH (500 MHz; CDCl3) 5.52 (1H, 
m, butenyl 3-H1), 4.82 (2H, m, butenyl 4-H2), 3.21 (1H, t, J 7.1, butenyl 1-H2 
rot A), 3.19 (2H, s, acetamide 2-H2), 3.04 (1H, t, J 7.1, butenyl 1-H2 rot B), 
2.70 (1.5H, s, NMe rot A), 2.68 (1.5H, s, NMe rot B), 2.06 (2H, m, butenyl 2-
H2), 1.96 (2H, s, b, NH2); δH (125 MHz; CDCl3) 172.1 (acetamide C-1), 135.1 
(butenyl C-3 rot A), 133.9 (butenyl C-3 rot B), 117.6 (butneyl C-4 rot A), 
116.7 (butenyl C-4 rot B), 47.8 (butenyl C-1 rot A), 47.4 (butenyl C-1 rot B), 
43.0 (acetamide C-2 rot A), 42.7 (acetamide C-2 rot B), 33.9 (NMe rot A), 
33.3 (NMe rot B), 32.3 (butenyl C-2 rot A), 31.6 (butenyl C-2 rot B); m/z (EI) 
[MH+] 143.1 (100%, MH+); HRMS Found: 143.1181, (C12H22N2O3 requires 
MH 143.1148). 
N-(But-3-en-1-yl)-2-[(4-cyano-3-(trifluoromethyl)phenyl)amino]-N-
methylacetamide, 15f 
 
By general procedure A, amide 14f, followed by purification by flash 
chromatography eluting with CH2Cl2—Et2O (95:5), gave the aniline 15f (112 
mg, 72%) as a colourless amorphous solid (1:1 mixture of rotamers); Rf: 0.62 
(90:10, CH2Cl2—Et2O); δH (500 MHz; CDCl3) 7.55 (1H, d, J 8.3, Ar 5-H), 
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6.88 (1H, d, J 3.1, Ar 2-H), 6.72 (1H, dd, J 8.3 and 3.1, Ar 6-H), 5.93 (1H, s, 
b, NH), 5.79 (1H, m, butenyl 3-H1), 5.11 (2H, m, butenyl 4-H2), 3.93 (1H, d, J 
4.1, acetamide 2-H2 rot A), 3.89 (1H, d, J 4.1, acetamide 2-H2 rot B), 3.55 
(1H, t, J 7.1, butenyl 1-H2 rot A), 3.38 (1H, t, J 7.1, butenyl 1-H2 rot B), 3.04 
(1.5H, s, NMe rot A), 3.03 (1.5H, s, NMe rot B), 2.40 (1H, ap q, J 7.1, butenyl 
2-H2 rot A), 2.34 (1H, ap. q, J 7.1, butenyl 2-H2 rot B); δC (125 MHz; CDCl3)  
167.1 (acetamide C-1 rot A), 167.0 (acetamide C-1  rot B), 149.9 (Ar C-1), 
136.1 (Ar C-5), 134.8 (butenyl C-3 rot A), 134.2 (q, 2JFC = 279 Ar C-3), 133.5 
(butenyl C-3 rot B), 122.7 (q, 1JFC = 38 CF3); 118.6 (butenyl C-4 rot A), 117.1 
(butenyl C-4 rot B); 114.4 (CN), 114.3 (Ar C-6), 110.4 (Ar C-2), 95.6 (Ar C-
4), 48.1 (butenyl C-1 rot B), 47.8 (butenyl C-1 rot A), 44.1 (acetamide C-2 rot 
B), 43.9 (acetamide C-2 rot A), 34.1 (NMe rot A), 33.6 (NMe rot B), 32.3 
(butenyl C-2 rot A), 31.7 (butenyl C-2 rot B); m/z (ES) [MH+] 312.13 (100%, 
MH+); HRMS Found: 312.1312, (C15H16F3N2O requires MH 312.1318). 
N-(But-3-en-1-yl)-N-[4-cyano-3-(trifluoromethyl)phenyl]-N-
methylacetamide-2-diazo-3-oxobutanamide, 17f 
 
By general procedure B, aniline 15f, followed by purification by flash 
chromatography eluting with CH2Cl2—Et2O (90:10) gave the amide 17f (101 
mg, 63 %) as bright yellow oil (1:1 mixture of rotamres); Rf: 0.26 (90:10, 
CH2Cl2—Et2O); δH (500 MHz; CDCl3)  7.83 (1H, d, J 8.5, Ar 5-H), 7.69 (1H, 
d, J 2.4, Ar 2-H), 7.64 (1H, dd, J 8.5 and 2.4, Ar 6-H), 5.76 (1H, ddt, J 17.3, 
10.7 and 7.3, butenyl 3-H1), 5.12-5.07 (2H, m, butenyl 4-H2), 4.61 (1H, s, 
acetamide 2-H2 rot A), 4.57 (1H, s, acetamide 2-H2 rot B), 3.46 (1H, t, J 7.3, 
butenyl 1-H2 rot A), 3.36 (1H, t, J 7.3, butenyl 1-H2 rot B), 3.02 (1.5H, s, NMe 
rot A), 2.96 (1.5H, s, NMe rot B), 2.39 (1H, ap q, J 7.1, butenyl 2-H2 rot A), 
2.37 (3H, s, butanamide 4-H3), 2.30 (1H, ap q, J 7.1, butenyl 2-H2 rot B); δC 
(125 MHz; CDCl3) 188.9 (butanamide C-3), 166.4 (acetamide C-1), 161.3 
(butanamide C-1), 147.3 (Ar C-1), 136.0 (Ar C-5), 134.6 (q, 2JFC = 35, Ar C-
3), 133.6 (butenyl C-3 rot A), 132.8 (butenyl C-3 rot B), 128.9 (Ar C-6), 123.9 
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(Ar C-2), 121.6 (q, 2JFC = 275,CF3), 118.4 (butenyl C-4 rot A), 116.9 (butenyl 
C-4 rot B), 114.6 (CN), 108.1 (Ar C-4), 75.6 (butanamide C-2), 53.3 
(acetamide C-2 rot A), 51.9 (acetamide C-2 rot B), 48.8 (butenyl C-1 rot A), 
48.1 (butenyl C-1 rot B), 34.7 (NMe rot A), 33.8 (NMe rot B), 32.4 (butenyl C-
2 rot A), 31.7 (butenyl C-2 rot B), 27.7 (butanamide C-4); νmax/cm-1 (film) 
3320, 2926, 2232, 2117, 1653;  m/z (ES) [MNa+] 444.13 (100%, MNa+); 
HRMS Found: 444.1269, (C19H18F3N5NaO3 requires MNa 444.1254). 
 
N-(But-3-en-1-yl)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-diazo-
acetamide-N-methylglycineamide, 18f 
 
By general procedure C, amide 17f, followed by purification by flash 
chromatography eluting with Petrol—EtOAc (1:1) gave the amide 18f (84 
mg, 76%) as bright yellow oil (1:1 mixture of rotamers); Rf: 0.32 (90:10, 
CH2Cl2—Et2O); δH (500 MHz; CDCl3) 7.87 (1H, d, J 8.7, Ar 5-H), 7.84 (1H, d, 
J 2.9, Ar 2-H), 7.79 (1H, dd, J 8.7 and 2.9, Ar 6-H), 5.75 (1H, m, butenyl 3-H1 
rot A and B), 5.06 (2H, m, butenyl 4-H2 rot A and B), 4.62 (1H, s, acetamide 
2-H1), 4.53 (1H, s, glycineamide 1-H2 rot A), 4.49 (1H, s, glycineamide 1-H2 
rot B), 3.46 (1H, t, J 7.3, butenyl 1-H2 rot A), 3.36 (1H, t, J 7.3, butenyl 1-H2 
rot B), 3.01 (1.5H, s, NMe rot A), 2.96 (1.5H, s, NMe rot B), 2.39 (1H, ap. q, 
J 7.3, butenyl 2-H2 rot A), 2.30 (1H, ap. q, J 7.3, butenyl 2-H2 rot B); δC (125 
MHz; CDCl3) 168.8 (glycineamide C-2 rot A), 167.0 (glycineamide C-2 rot B), 
166.9 (acetamide C-1 rot A), 165.4 (acetamide C-1 rot B), 146.9 (Ar C-1); 
135.9 (Ar C-5), 134.9 (butenyl C-3 rot A), 134.3 (Ar C-3), 133.8 (butenyl C-3 
rot B), 131.5 (Ar C-6), 126.0 (Ar C-2), 121.7 (CF3); 118.1 (butenyl C-4 rot A), 
116.8 (butenyl C-4 rot B), 114.7 (CN), 108.7 (Ar C-4), 50.9 (glycine amide C-
1 rot A), 50.8 (glycine amide C-1 rot B), 48.9 (butenyl C-1 rot A), 48.3 
(acetamide C-2), 48.0 (butenyl C-1 rot B), 34.7 (NMe rot A), 33.8 (NMe rot 
B), 32.4 (butenyl C-2 rot A), 31.7 (butenyl C-2 rot B); νmax/cm-1 (film) 3084, 
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2926, 2232, 2110, 1654, 1606, 1501; m/z (ES) [MNa+] 402.12 (100%, 
MNa+); HRMS Found: 402.1159, (C17H16F3N5NaO2 requires MNa 444.1148). 
 
4-[(Pyridin-4-ylmethyl)amino]-2-(trifluoromethyl)benzonitrile, 15g 
 
By general procedure A, pyridinyl amine, followed by purification by flash 
chromatography, eluting with Petrol—EtOAc (50:50), gave the aniline 15g, 
(369 mg, 67%) as a colorless amorphous solid, Rf: 0.68 (80:20, CH2Cl2—
Et2O); δH (500 MHz; CDCl3) 8.59 (2H, d, J 6.0, pyr 3-H), 7.55 (1H, d, J 8.5, 
Ar 6-H), 7.25 (2H, d, J 6.0, pyr 2-H), 6.91 (1H, d, J 2.5, Ar 3-H), 6.67 (1H, dd, 
J 8.5 and 2.5, Ar 5-H), 5.19 (1H, s, b, NH), 4.48 (2H, d, J 6.0, pyrCH2NH); δC 
(125 MHz; CDCl3) 150.5 (Ar C-4), 150.4 (pyr C-3), 146.3 (pyr C-1), 136.4 (Ar 
C-6), 134.4 (q, 2JFC 33, Ar C-2), 122.4 (q, 1JFC 282, CF3), 121.8 (pyr C-2), 
116.7 (CN), 114.0 (Ar C-5), 110.8 (Ar C-3); 96.9 (Ar C-1), 46.3 (pyrCH2NH);  
νmax/cm-1 (film) 3236, 2253, 2220, 1945, 1615; m/z  (ES) [MH+] 278.09 
(100%, MH+); HRMS Found: 278.0912, (C14H10F3N3 MH requires 278.0900).  
N-[4-Cyano-3-(trifluoromethyl)phenyl]-N-(pyridin-4-ylmethyl)-2-diazo-3-
oxobutanamide, 17g 
 
By general procedure B, aniline 15g, followed by purification by flash 
chromatography, eluting with EtOAc—Et2O (75:25), gave the amide 17g 
(270 mg, 54%), as a colorless amorphous solid, Rf: 0.44 (95:5, EtOAc—
MeOH); δH (500 MHz; CDCl3) 8.59 (2H, d, J 6.0, pyr 2-H), 7.81 (1H, d, J 8.2, 
Ar 5-H), 7.57 (1H, d, J 2.3, Ar 2-H), 7.43 (1H, dd, J 8.2 and 2.3, Ar 6-H), 7.21 
(2H, d, J 6.0, pyr 3-H), 5.06 (2H, s, pyr-CH2), 2.30 (3H, s, butanamide 4-H); 
δC (125 MHz; CDCl3) 187.0 (butanamide C-3, verified in HMBC) 161.5 
(butanamide C-1), 150.2 (pyr C-2), 146.7 (Ar C-1), 144.9 (pyr C-4), 136.1 (Ar 
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C-5), 134.6 (q, 2JFC 30, Ar C-3), 128.5 (Ar C-6), 123.2 (Ar C-2), 122.4 (pyr C-
3), 121.5 (q, 1JFC 284, CF3), 114.5 (CN), 108.2 (Ar C-4), 74.7 (butanamide C-
2, verified in HMBC), 53.3 (pyr-CH2), 27.5 (butanamide C-4); νmax/cm-1  (film) 
3338, 2234, 2114, 1687, 1649; m/z (ES) [MH+] 388.11 (100%, MH+); HRMS 
Found: 388.1017, (C18H12F3N5O2 MH requires 388.1016).  
4-[(2-Methoxyethyl)amino]-2-(trifluoromethyl)benzonitrile, 15h 
 
By general procedure A, 2-methoxy ethyl amine, followed by purification by 
flash chromatography, eluting with CH2Cl2—Et2O (90:10), gave the aniline 
15h (218 mg, 89%) as pale yellow needles, m.p. 132-134 °C (Et2O); Rf: 0.51 
(50:50, CH2Cl2—Et2O); δH (500 MHz; CDCl3) 7.55 (1H, d, J 8.5, Ar 6-H), 
6.87 (1H, d, J 2.9, Ar 3-H), 6.70 (1H, dd, J 8.5 and 2.9, Ar 5-H), 4.83 (1H, s, 
b, NH), 3.62 (2H, t, J 5.3, ethyl 2-H), 3.41 (3H, s, methoxy-CH3), 3.36 (2H, 
ap. q, J 5.3, ethyl 1-H); δC (125 MHz; CDCl3) 151.0 (Ar C-4), 136.2 (Ar C-6), 
134.3 (q, 2JFC 32, Ar C-2), 122.6 (q, 1JFC 280, CF3), 117.0 (CN), 114.0 (Ar C-
5), 111.3 (Ar C-3), 95.8 (Ar C-1), 70.1 (ethyl C-2), 58.9 (methoxy-CH3), 42.7 
(ethyl C-1); νmax/cm-1  (film) 3340, 2226, 1618, 1542; m/z  (ES) [MH+] 245.09 
(100%, MH+); HRMS Found: 245.0886, (C11H11F3N2O MH requires 
245.0896).  
N-[4-Cyano-3-(trifluoromethyl)phenyl]-N-2-methoxyethyl)-2-diazo-3-
oxobutanamide, 17h 
 
By general procedure B, aniline 15h, followed by purification by flash 
chromatography, eluting with CH2Cl2—Et2O (95:5), gave the amide 17h (600 
mg, 97%) as a viscous bright yellow liquid, Rf: 0.47 (80:20, CH2Cl2—Et2O); 
δH (500 MHz; CDCl3) 7.86 (1H, d, J 8.4, Ar 5-H), 7.81 (1H, d, J 2.6, Ar 2-H), 
7.63 (1H, dd, J 8.4 and 2.6, Ar 6-H), 4.01 (2H, t, J 5.0, ethyl 1-H), 3.61 (2H, t, 
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J 5.0, ethyl 2-H), 3.34 (3H, s, methoxy-CH3), 2.37 (3H, s, butanamide 4-H); 
δC (125 MHz; CDCl3) 188.9 (butanamide C-3), 160.9 (butanamide C-1), 
147.5 (Ar C-1), 136.0 (Ar C-5), 134.4 (Ar C-3), 129.3 (Ar C-6), 124.3 (q, 2JFC 
35, Ar C-2), 121.7 (q, 1JFC 275, CF3), 114.8 (CN), 107.7 (Ar C-4), 75.8 
(butanamide C-2), 69.8 (ethyl C-2), 58.9 (methoxy-CH3), 51.4 (ethyl C-1), 
27.9 (butanamide C-4); νmax/cm-1 (film) 3083, 2898, 2232, 2115, 1659; m/z 
(ES) [MNa+] 377.09 (100%, MNa+); HRMS Found: 377.0850, 
(C15H13F3N4NaO3 MNa requires 377.0832).  
4-[(2-Cyanoethyl)amino]-2-(trifluoromethyl)benzonitrile, 15i 
 
By general procedure A, 3-amino propionitrile, followed by purification by 
flash chromatography, eluting with Petrol—EtOAc (50:50), gave the aniline 
15i (444 mg, 69%) as colorless needles, m.p. 146-150 °C (Petrol); Rf: 0.26 
(50:50, Petrol—EtOAc); δH (500 MHz; CDCl3) 7.62 (1H, d, J 8.7, Ar 6-H), 
6.91 (1H, d, J 2.4, Ar 3-H), 6.76 (1H, dd, J 8.7 and 2.4, Ar 5-H), 4.85 (1H, s, 
b, NH), 3.61 (2H, ap. q, J 6.3, ethyl 1-H), 2.71 (2H, t, J 6.3, ethyl 2-H); δC 
(125 MHz; CDCl3) 149.6 (Ar C-4), 136.5 (Ar C-6), 134.7 (q, 2JFC 31, Ar C-2), 
122.3 (q, 1JFC 273, CF3), 117.2 (CN), 116.5 (Ar CN), 114.2 (Ar C-5), 110.4 
(Ar C-3), 97.6 (Ar C-1), 39.0 (ethyl C-1), 18.1 (ethyl C-2); νmax/cm-1 (film) 
3391, 2252, 2222, 1905, 1791; m/z (ES) [MNa+] 262.06 (100%, MNa+); 
HRMS Found: 262.0562, (C11H8F3N3Na MNa requires 262.0563). 
N-(2-Cyanoethyl)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-diazo-3-oxo-
butanamide, 17i 
 
By general procedure B, aniline 15i, followed by purification by flash 
chromatography, eluting with Petrol—EtOAc (50:50), gave the amide 17i 
(444 mg, 69%), as a colorless needles. Rf: 0.58 (40:60, Petrol—EtOAc); δH 
(500 MHz; CDCl3) 7.92 (1H, d, J 8.3, Ar 5-H), 7.70 (1H, d, J 2.5, Ar 2-H), 
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7.63 (1H, dd, J 8.3 and 2.5, Ar 6-H), 4.08 (2H, t, J 6.4, ethyl 1-H), 2.82 (2H, t, 
J 6.4, ethyl 2-H), 2.33 (3H, s, butanamide 4-H); δC (125 MHz; CDCl3) 187.5 
(butanamide C-3, verified in HMBC), 161.5 (butanamide C-1), 145.9 (Ar C-
1), 136.5 (Ar C-5), 134.9 (q, 2JFC 30, Ar C-3), 129.7 (Ar C-6); 124.3 (Ar C-2), 
121.5 (q, 1JFC 280, CF3) 117.1 (CN), 114.4 (Ar CN), 109.1 (Ar C-4), 76.1 
(butanamide C-2, verified in HMBC), 47.3 (ethyl C-1), 27.8 (butanamide C-
4), 17.0 (ethyl C-2); νmax/cm-1 (film) 3336, 3085, 2252, 2234, 2123, 1632; m/z 
(ES) [MNa+] 372.07 (100%, MNa+); HRMS Found: 372.0690, 
(C15H10F3N5NaO2 MNa requires 372.0679).  
Prop-2-yn-1-yl methanesulfonate, 2464  
 
By the method of Girard et al.,64 methanesulfonyl chloride was added 
dropwise to a stirred solution of propargyl alcohol and Et3N in CH2Cl2 at 
0 °C, and the reaction mixture was allowed to warm to rt. After 30 min, the 
reaction mixture was diluted with CH2Cl2 (10 mL) and HCl (aq, 1 M, 10 mL) 
was added and layers separated. The aqueous layer was extracted with 
CH2Cl2 (3 × 10 mL). The combined organic layers were washed with with 
brine (sat. aq. sol 10 mL), dried (Na2SO4), filtered and concentrated in 
vacuo. Purification by flash chromatography eluting with Petrol—EtOAc 
(50:50) gave the sulfonate 24,64 at a quantitative yield, as a pale yellow oil 
which required no further purification. Rf: 0.87 (90:10, CH2Cl2—MeOH); δH 
(500 MHz; CDCl3) 4.86 (2H, d, J 2.5, propynyl 1-H), 3.13 (3H, s, methyl), 
2.71 (1H, t, J 2.5, propynyl 3-H); δC (125 MHz; CDCl3) 75.8 (propynyl C-3), 
57.2 (methyl), 46.1 (propynyl C-2), 39.1 (propynyl C-1); m/z (EI) [MH+] 
135.01 (100%, MH+). 
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4-[(Prop-2-yn-1-yl)amino]-2-(trifluoromethyl)benzonitrile, 15j 
 
4-amino-2(trifluoromethyl)benzonitrile (930 mg, 5 mmol) was added to a 
stirred solution of sulfonate 24 (335 mg, 2.5 mmol), in MeCN (0.5M) at rt and 
the reaction mixture was heated to reflux. After 3 h, the reaction mixture was 
allowed to cool to rt and quenched by the addition of K2CO3 (sat. aq. sol. 
10 mL). CH2Cl2 (10 mL) was added and layers separated. The oerganic 
layer was triturated using a glass rod and he precipitate was removed by 
filtration through a pad of celite, eluting with a CH2Cl2–MeOH (50:50) 
mixture. The solution was concentrated in vacuo. Purification by flash 
chromatography eluting with Petrol—Et2O (50:50) gave the aniline 15j, as 
bright yellow needles (531 mg, 60%). m.p. 126-127 °C; Rf: 0.32 (80:20, 
Petrol—Et2O); δH (500 MHz; CDCl3) 7.62 (1H, d, J 8.2, Ar 6-H), 6.96 (1H, d, 
J 2.6, Ar 3-H), 6.81 (1H, dd, J 8.2 and 2.6, Ar 5-H), 4.77 (1H, s, b, NH), 4.03 
(2H, dd, J 3.5 and 2.4, propynyl 1-H), 2.30 (1H, t, J 2.4, propynyl 3-H); δC 
(125 MHz; CDCl3) 149.8 (Ar C-4), 136.2 (Ar C-6), 134.3 (q, 2JFC 32, Ar C-2), 
122.3 (q, 1JFC 276, CF3), 116.8 (CN), 114.6 (Ar C-5), 110.9 (Ar C-3), 91.2 (Ar 
C-1), 78.4 (propynyl C-2), 72.7 (propynyl C-3), 32.9 (propynyl C-1); νmax/cm-1 
(film) 3362, 3299, 2226, 1902, 1617; m/z (ES) [MNa+] 247.05 (100%, MNa+); 
HRMS Found: 247.0461, (C11H7F3N2Na MNa requires 247.0454). 
N-[4-Cyano-3-(trifluoromethyl)phenyl]-N-(prop-2-yn-1-yl)-2-diazo-3-
oxobutanamide, 17j 
 
By general procedure B, aniline 15j, followed by purification by flash 
chromatography, eluting with Petrol—Et2O (40:60), gave the amide 17j (444 
mg, 69%), as pale yellow needles. Rf: 0.53 (60:40, EtOAc—Petrol); δH (500 
MHz; CDCl3) 7.92 (1H, d, J 8.3, Ar 5-H), 7.74 (1H, d, J 2.2, Ar 2-H), 7.63 
(1H, dd, J 8.3 and 2.2, Ar 6-H), 4.60 (2H, d, J 2.5, propynyl 1-H), 2.37 (3H, s, 
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butanamide 4-H), 2.34 (1H, t, J 2.5, propynyl 3-H); δC (125 MHz; CDCl3) 
188.2 (butanamide C-3), 161.0 (butanamide C-1), 145.7 (Ar C-1), 136.2 (Ar 
C-5), 134.5 (2JFC 32, Ar C-3), 129.7 (Ar C-6), 124.4 (Ar C-2), 121.7 (q, 1JFC 
277, CF3), 114.6 (CN), 108.7 (Ar C-4), 77.3 (propynyl C-2), 75.9 
(butanamide C-2), 74.2 (propynyl C-3), 39.9 (propynyl C-1), 27.9 
(butanamide C-4); νmax/cm-1  (film) 3287, 2221, 2118, 1689, 1647; m/z (ES) 
[MNa+] 357.06 (100%, MNa+); HRMS Found: 357.0573, (C15H9F3N4NaO2 
MNa requires 357.0570). 
4-(Methylamino)-2-(trifluoromethyl)benzonitrile, 15k 
 
By general procedure A, methylamine HCl salt with two additional equiv of 
K2CO3 followed by purification by flash chromatography eluting with 50:50 
Petrol—EtOAc to yield the aniline 15k (860 mg, 86%) as a yellow solid. Rf: 
0.53 (50:50, Petrol—EtOAc); δH (500 MHz; CDCl3) 7.56 (1H, d, J 8.5, Ar 2-
H), 6.84 (1H, d, J 2.1, Ar 5-H), 6.68 (1H, dd, J 8.5 and 2.1, Ar 3-H), 4.54 (1H, 
s, NH), 2.93 (3H, d, J 5.5, Me);  δC (125 MHz; CDCl3) 151.8 (Ar C-4), 136.1 
(Ar C-2), 134.0 (q, 2JFC 31, Ar C-6), 122.0 (q, 1JFC 274, CF3), 117.1 (CN), 
113.5 (Ar C-3), 109.7 (Ar C-5), 95.0 (Ar C-1), 29.9 (Me);  vmax/cm-1 (film) 
3357, 2218; m/z (ES) [MH+] 201.1 (100%, MH+); HRMS Found: 201.0630, 
(C9H8F3N2 requires MH 201.0634). 
N-[4-Cyano-3-(trifluoromethyl)phenyl]-2-diazo-3-oxo-N-
methylbutanamide, 17k 
 
By general procedure B, aniline 15k, followed by purification by flash 
chromatography, eluting with 90:10 CH2Cl2—Et2O, to yield the butanamide 
17k (1.15 g, 88%), as a yellow amorphous solid, Rf: 0.46 (90:10 CH2Cl2—
Et2O); δH (500 MHz; CDCl3) 7.86 (1H, d, J 8.4, Ar 5-H), 7.65 (1H, d, J 2.2, Ar 
2-H), 7.54 (1H, dd, J 8.4 and 2.2, Ar 6-H), 3.45 (3H, s, NMe), 2.35 (3H, s, 
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butanamide 4-H); δC (125 MHz; CDCl3) 187.9 (butanamide C-3), 161.5 
(butanamide C-1), 147.7 (Ar C-1), 136.1 (Ar C-6), 134.4 (q, 2JCF 32, Ar C-3), 
128.0 (Ar C-5), 122.9 (Ar C-2), 121.8 (q, 1JCF 274, CF3), 114.7 (CN), 107.6 
(Ar C-4), 75.9 (butanamide C-2), 38.3 (NMe), 27.7 (butanamide C-4); 
vmax/cm-1 (film) 2231, 2115, 1643, 1606; m/z  (ES) [MNa+] 333.1 (100%, 
MNa+); HRMS Found: 333.0573, (C13H9F3N4NaO2 requires MNa 333.0570). 
N-[4-Cyano-3-(trifluoromethyl)phenyl]-2-diazo-N-(methyl)acetamide, 
18k 
 
 By general procedure C, amide 17k, followed by purification by flash 
chromatography eluting with  90:10 CH2Cl2—Et2O, to yield the acetamide 
18k,  (276 mg, 64%) as a pale yellow solid, Rf: 0.40 (90:10 CH2Cl2—Et2O); 
δH (500 MHz; CDCl3) 7.87 (1H, d, J 8.4, Ar 5-H), 7.71 (1H, d, J 2.4, Ar 2-H), 
7.60 (1H, dd, J 8.4 and 2.4, Ar 6-H), 4.80 (1H, s, acetamide 2-H), 3.37 (3H, 
s, NMe); δC (125 MHz; CDCl3) 165.0 (acetamide C-1), 147.4 (Ar C-1), 135.8 
(Ar C-5), 134.0 (q, 2JCF 33, Ar C-3), 129.2 (Ar C-6), 124.2 (Ar C-2), 122.0 (q, 
1JCF 288, CF3), 114.9 (CN), 108.0 (Ar C-4); 448.3 (acetamide C-2), 
28.6 (NMe); vmax/cm-1 (film) 2235, 2115, 1604; m/z (ES) [MNa+] 291.0 
(100%, MNa+); HRMS Found: 291.0465, (C11H7F3N4NaO requires MNa 
291.0464). 
4-(Cyclopropylamino)-2-(trifluoromethyl)benzonitrile, 15l 
 
By general procedure A, cyclopropyl amine, followed by purification by flash 
chromatography, eluting with 70:30 Petrol—EtOAc, gave the aniline 15l (910 
mg, 81%) as a pale yellow solid, m.p. 80-84 °C; Rf: 0.75 (50:50 Petrol—
EtOAc); δH (500 MHz; CDCl3) 7.56 (1H, d, J 8.7, Ar 6-H), 7.03 (1H, d, J 2.1, 
Ar 3-H), 6.89 (1H, dd, J 8.7 and 2.1, Ar 5-H), 4.96 (1H, s, b, NH), 2.51 (1H, 
ttd, J 6.8, 3.6 and 1.4, cp 1-H), 0.87 (2H, td, J 6.8 and 4.9, cp 2-Ha), 0.58 
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(2H, td, J 4.9 and 3.6, cp 2-Hb); δC (125 MHz; CDCl3) 151.8 (Ar C-4), 135.9 
(Ar C-6), 134.0 (q, 2JCF 34, Ar C-2), 122.7 (q, 1JCF 284, CF3), 117.2 (CN), 
114.6 (Ar C-5), 110.6 (Ar C-3), 96.1 (Ar C-1), 24.6 (cp C-1), 7.7 (cp C-2);  
vmax/cm-1 (film) 3351, 2213; m/z (ES) [MH+] 227.1 (100%, MH+); HRMS 
Found: 227.0795, (C11H10F3N2 requires MH 227.0790). 
N-(Cyclopropyl)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-diazo-3-
oxobutanamide, 17l 
 
By general procedure B, aniline 15l, followed by purification by flash 
chromatography, eluting with 70:30 Petrol—EtOAc, to yield the butanamide 
17l   (560 mg, 83%), as a pale yellow solid; Rf: 0.34 (50:50 Petrol—EtOAc);  
δH (500 MHz; CDCl3) 7.91 (1H, d, J 1.9, Ar 2-H), 7.83 (1H, d, J 8.6, Ar 6-H), 
7.77 (1H, dd, J 8.6 and 1.9, Ar 5-H), 3.09 (1H, tt, J 7.0 and 3.8, cp 1-H), 2.46 
(3H, s, butanamide 4-H), 1.15 (2H, td, J 7.0 and 1.4, cp 2-Ha), 0.80 (2H, td, 
J 3.8 and 1.4, cp 2-Hb); δC (125 MHz; CDCl3) 189.7 (butanamide C-3), 162.7 
(butanamide C-1), 146.4 (Ar C-1), 135.3 (Ar C-6), 133.5 (q, 2JCF 32, Ar C-3), 
127.4 (Ar C-5), 122.4 (Ar C-3), 121.6 (q, 1JCF 286, CF3), 115.1 (CN), 106.6 
(Ar C-4), 75.9 (butanamide C-2), 31.9 (cp C-1), 28.2 (butanamide C-4), 11.1 
(cp C2); vmax/cm-1 (film) 2228, 2114, 1642; m/z (ES) [MNa+] 359.1 (100%, 
MNa+); HRMS Found: 359.0729 (C15H11F3N4NaO2 requires MNa 359.0726).  
N-(Cyclopropyl)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-diazo- 
acetamide, 18l 
 
By general procedure C, amide 17l, followed by purification by flash 
chromatography eluting with  60:40 Petrol—EtOAc, to yield the acetamide 
18l,  (232 mg, 48%) as a pale yellow solid, Rf: 0.30 (60:40 Petrol—EtOAc); 
δH (500 MHz; CDCl3) 7.85 (1H, d, J 1.9, Ar 2-H), 7.79 (1H, d, J 8.4, Ar 6-H), 
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7.68 (1H, dd, J 8.4 and 1.9, Ar 5-H), 5.64 (1H, s, acetamide 2-H), 2.97 (1H, 
tt, J 6.9 and 3.8, cp 1-H), 1.13 (2H, td, J 6.9 and 1.2, cp 2-Ha), 0.71 (2H, td, 
J 3.8 and 1.2, cp 2-Hb); δC (125 MHz; CDCl3) 167.6 (acetamide C-1), 146.1 
(Ar C-1), 134.7 (Ar C-6), 133.1 (q, 2JCF 32, Ar C-3), 127.9 (Ar C-5), 123.1 (Ar 
C-2), 122.1 (q, 1JCF 276, CF3), 115.5 (CN), 105.5 (Ar C-4), 49.0 (acetamide 
C-2), 29.4 (cp C-1), 11.4 (cp C2); vmax/cm-1 (film) 2230, 2111, 1636; m/z (ES) 
[MNa+] 317.2 (100%, MNa+); HRMS Found: 295.0805 (C13H10F3N4O 
requires MH 295.0801). 
1-(1,2,3,6-Tetrahydropyridin-1-yl)ethan-1-one, 36v65 
 
By the method of Stille et al.,65 acetic anhydride (340 μL, 3.6 mmol) was 
added dropwise to a solution of 1,2,3,6-tetrahydropyridine (274 μL, 3 mmol) 
and Et3N (830 μL, 6 mmol) in CH2Cl2 (6 mL, 0.5 M) at 0 °C over ten min. 
After the addition was completed the mixture was allowed to warm to rt and 
stirred. After 30 min, sat. aq. NH4Cl solution (1 mL) was added and layers 
separated. The organic layer was washed with sat. aq. NaHCO3 solution 
(2 × 3 mL), dried (Na2SO4), filtered and concentrated in vacuo. Purification 
by flash chromatography eluting with 95:5 CH2Cl2—MeOH gave the 
ethanone 36v65 (223 mg, 60%) as a pale yellow oil, Rf: 0.45 (95:5 CH2Cl2—
MeOH); δH (500 MHz; CDCl3) 5.93-5.76 (1H, m, 5-H), 5.73-5.59 (1H, m, 4-
H), 4.03 (1H, q, J 2.7, 6-H rot A), 3.92 (1 H, q, J 2.7, 6-H rot B), 3.65 (1 H, t, 
J 5.7, 2-H rot A), 3.50 (1 H, t, J 5.7, 2-H rot B), 2.22-2.11 (2H, m, 3-H), 2.10 
(1.6H, s, N-acetyl), 2.08 (1.4H, s, N-acetyl); δC (125 MHz; CDCl3) 169.4 
(C=O rot A), 169.2 (C=O rot B), 126.5 (C-5 rot A), 124.8 (C-5 rot B), 124.5 
(C-4 rot A), 123.2 (C-4 rot B), 45.6 (C-6 rot A), 43.2 (C-2 rot A), 41.8 (C-6 rot 
B), 37.9 (C-2 rot A), 25.7 (C-3 rot A), 24.8 (C-3 rot B), 21.9 (N-acetyl rot A), 
21.4 (N-acetyl rot B); m/z (ES) [MNa+] 148.4 (100%, MNa+).  
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Benzyl 1,2,3,6-tetrahydropyridine-1-carboxylate, 3766 
 
By the method of Larock et al.,66 benzyl chloroformate (1.14 mL, 8.0 mmol) 
was added dropwise over ten min to a stirred solution of 1,2,3,6-
tetrahydropyridine (457 μL, 5.0 mmol) in CH2Cl2 (50 mL, 0.1 M) and 
aqueous NaHCO3 (10.5 mmol, 4 M) at 0 °C. After the addition was 
completed the mixture was allowed to warm to rt and stirred. After 2 h, H2O 
(40 mL) was added and layers separated. The aqueous layer was extracted 
with CH2Cl2 (3 × 40 mL) and the combined organic layers were dried 
(Na2SO4), filtered and concentrated in vacuo, to yield the carbamate 37,66 as 
a colourless oil which required no further purification. Rf: 0.42 (80:20 
Petrol—EtOAc); δH (500 MHz; CDCl3) 7.40-7.37 (2H, m, Ph), 7.36-7.30 (3H, 
m, Ph), 5.84 (1H, ap. s, b, 5-H), 5.67 (1H, app d, b, J 21, 4-H), 5.16 (2H, s, 
benzyl-H), 3.97 (2H, quint, J 3.2, 6-H), 3.58 (2H, t, J 5.9, 2-H), 2.16 (2H, s, b, 
3-H); δC (125 MHz; CDCl3) 155.6 (C=O), 136.9 (Ph), 135.2 (C-5), 128.7 (Ph), 
127.6 (Ph), 126.9 (Ph), 125.4 (C-4), 67.0 (C-6), 40.3 (C-2), 24.9 (C-3); m/z 
(ES) [MH+] 218.3 (100%, MH+).  
1-methyl-1,2,3,6-tetrahydropyridine hydrochloride, 36w67 
 
The carbamate 37 (650 mg, 3.0 mmol) in THF (1 mL) was added dropwise, 
over 30 min, to a solution of LiAlH4 in THF (6 mL, 1M) at 0 °C. The reaction 
mixture was allowed to warm to rt and then heated to reflux. After 2 h, the 
reaction mixture was cooled to 0 °C and H2O (0.5 mL), NaOH (aq, sol., 15% 
w/v, 0.5 mL) and H2O (0.5 mL) were sequentially added dropwise. The 
mixture was allowed to warm to rt and after 15 min filtered through a celite 
pad eluting with Et2O (30 mL). The organic layer was extracted with 1 M HCl 
aqueous solution (2 × 10mL) and H2O (2 × 10mL) and the combined 
aqueous layers were concentrated in vacuo to give the amine HCl salt 
36w,67 as a crystalline solid which required no further purification. δH (500 
MHz; MeOD) 6.06-5.98 (1H, m, 5-H), 5.83-5.74 (1H, m, 4-H), 3.90 (1H, d, J 
16.4, 6Ha), 3.70 (1H, d, J 16.4, 6-Hb), 3.59 (1H, dd, J 6.1, 2-Ha), 3.29 (1H, 
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dt, J 5.1 and 11.8, 2-Hb), 2.99 (3H, s, NMe), 2.71-2.59 (1H, m, 3-Ha), 2.44 
(1H, ap d, J 18, 3-Hb); δC (125 MHz; MeOD) 126.3 (C-5), 121.0 (C-4), 52.9 
(C-6), 51.6 (C-2), 43.2 (NMe), 23.5 (C-3); m/z (ES) [MNa+] 120.2 (100%, 
MNa+). 
4-(3-Acetyl-2-oxo-4-phenylazetidin-1-yl)-2-(trifluoromethyl)benzonitrile, 
25 
 
By general procedure F, diazo butanamide 17a with Rh2(Oct)4 in CH2Cl2 
followed by purification by flash chromatography, eluting with 30:70 Petrol—
Et2O gave the β-lactam 25 as a colourless amorphous solid (128 mg, 71%). 
Rf: 0.56 (80:20, Et2O-Hexane); δH (500 MHz; CDCl3) 7.79 (1H, d, J 2.1, Ar 3-
H), 7.69 (1H, d, J 8.4, Ar 6-H), 7.45-7.32 (6H, m, Ar 5-H and Ph), 5.55 (1H, 
d, J 2.8, azetidinyl 3-H), 4.29 (1H, d, J 2.8, azetidinyl 4-H), 2.40 (3H, s, 
acetyl H); δC (125 MHz; CDCl3) 197.5 (acetyl C=O), 160.9 (azetidinyl C=O), 
140.6 (Ar C-4), 136.0 (Ar C-6), 134.8 (Ph), 134.4 (q, 2JFC 33, Ar C-2), 129.7 
(Ph), 129.6 (Ph), 126.1 (Ph), 121.8 (q, 1JFC  277, CF3 ), 119.4 (Ar C-5), 115.3 
(Ar C-3), 115.2 (CN), 104.7 (Ar C1), 72.3 (azetidinyl C-3), 56.5 (azetidinyl C-
4), 29.9 (acetyl CH3); νmax/cm-1  (film) 3427, 2927, 2231, 1784, 1705, 1615;  
m/z (ES) [MNa+] 381.08 (100%, MNa+); HRMS Found: 381.0825, 
(C19H13F3N2O2 MNa requires 381.0821).  
By general procedure F, diazo butanamide 17a with Rh2(OAc)4 in CH2Cl2 
followed by purification by flash chromatography, eluting with 30:70 Petrol—
Et2O gave the β-lactam 25 as a colourless amorphous solid (122 mg, 68%). 
By general procedure F, diazo butanamide 17a with Rh2(esp)2 in EtOAc 
followed by purification by flash chromatography, eluting with 30:70 Petrol—
Et2O gave the β-lactam 25 as a colourless amorphous solid (134 mg, 75%). 
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4-(3-Acetyl-4-methyl-2-oxopyrrolidin-1-yl)-2-
(trifluoromethyl)benzonitrile, 26 
 
By general procedure F, diazo butanamide 17b with Rh2(Oct)4 in CH2Cl2 
followed by purification by flash chromatography, eluting with 80:20 Petrol—
EtOAc gave the γ-lactam 26 as a pale yellow amorphous solid (136 mg, 
88%). Rf: (90:10, CH2Cl2—Et2O); δH (500 MHz; CDCl3) 8.13 (1H, d, J 2.1, Ar 
3-H), 7.93 (1H, dd, J 8.6 and 2.1, Ar 5-H), 7.82 (1H, d, J 8.6, Ar 6H), 4.04 
(1H, dd, J 9.6 and 8.1, 5-Ha), 3.46 (2H, m, 5-Hb and 3-H), 3.04 (1H, ap. sept, 
J 7.2, 4-H), 2.47 (3H, s, acetyl CH3), 1.24 (3H, d, J 7.2, CH3); δC (125 MHz; 
CDCl3) 201.8 (acetyl C=O), 169.9 (C-2), 142.8 (Ar C-4), 135.5 (Ar C-6), 
133.7 (q, 2JFC 30, Ar C-2), 122.1 (q, 1JFC 275, CF3), 121.6 (Ar C-5), 117.0 (Ar 
C-3), 115.4 (CN), 106.1 (Ar C-5), 104.8 (Ar C-1), 64.5 (C-4), 53.4 (C-2), 30.5 
(acetyl CH3), 27.9 (C-3), 18.5 (methyl CH3); νmax/cm-1 (film) 2921, 2236, 
1696; m/z  (ES) [MNa+] 333.08 (100%, MNa+); HRMS Found: 333.08259, 
(C15H13F3N2O2 MNa requires 333.0821). 
By general procedure F, diazo butanamide 17b with Rh2(esp)2 in CH2Cl2 
followed by purification by flash chromatography, eluting with 80:20 Petrol—
EtOAc gave the γ-lactam 26 as a pale yellow amorphous solid (140 mg, 
90%). 
By general procedure F, diazo butanamide 17b with Rh2(OAc)4 in CH2Cl2 
followed by purification by flash chromatography, eluting with 80:20 Petrol—
EtOAc gave the γ-lactam 26 as a pale yellow amorphous solid (85 mg, 55%). 
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4-[3-Acetyl-2-(cyanomethyl)-4-oxoazetidin-1-yl]-2-
(trifluoromethyl)benzonitrile, 27 
 
By general procedure F, diazo butanamide 17i with Rh2(esp)2 in EtOAc 
followed by purification by flash chromatography, eluting with 50:50 Et2O—
CH2Cl2 gave the β-lactam 27 as a pale yellow viscous oil (122 mg, 78%). Rf: 
0.35 (50:50, CH2Cl2—Et2O); δH (500 MHz; CDCl3) 7.86 (1H, d, J 8.6, Ar 6-
H), 7.73 (1H, d, J 2.1, Ar 3-H), 7.62 (1H, dd, J 8.6 and 2.1, Ar 5-H), 4.93 (1H, 
ddd, J 4.6, 2.6 and 2.1, azetidinyl 4-H), 4.42 (1H, d, J 2.6, azetidinyl 3-H), 
3.06 (2H, ap dd, J 5.9 and 4.6, methylene CH2), 2.44 (3H, s, acetyl CH3); δC 
(125 MHz; CDCl3) 196.4 (acetyl C=O), 158.9 (azetidinyl C-2), 139.6 (Ar C-4), 
136.4 (Ar C-6), 134.8 (q, 2JFC 33, Ar C-2), 121.8 (q, 1JFC 277, CF3), 119.6 (Ar 
C-5), 114.9 (Ar C-3), 114.3 (Ar CN and CN), 105.7 (Ar C1); 67.9 (azetidinyl 
C-3), 48.7 (azetidinyl C-4), 29.7 (acetyl CH3), 20.3 (methylene CH2); νmax/cm-
1
 (film) 2922, 2851, 2231, 1767, 1716, 1611; m/z (ES) [MNa+] 344.06 (100%, 
MNa+); HRMS Found: 344.0616, (C15H10F3N3O2 MNa requires 344.0617).  
By general procedure F, diazo butanamide 17i with Rh2(tpa)4 in toluene 
followed by purification by flash chromatography, eluting with 50:50 Et2O—
CH2Cl2 gave the β-lactam 27 as a pale yellow viscous oil (109 mg, 70%). 
4-Phenylazetidin-2-one, 2946 
 
By the method of Lowew et al.,46 methane sulfonyl chloride (680 μL, 8.8 
mmol) was added to a suspension of NaHCO3 (4.4 g, 48 mmol) in MeCN (44 
mL) and the resulting mixture was heated to reflux. Solid (±)-3-amino 3-
phenyl propionic acid (1.3 g, 8 mmol) was added portionwise to the reaction 
mixture over a period of 3 h and the reaction mixture was stirred at 80 °C. 
After 2 h the reaction was allowed to cool to rt, filtered eluting with MeCN 
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(2 × 75 mL) and concentrated in vacuo to give the β-lactam 2946 as a light 
yellow amorphous solid (1.14 g, 97%) which required no further purification. 
δH (500 MHz; CDCl3)  7.40-7.35 (4H, m, Ph), 7.35-7.29 (1H, m, Ph), 6.40 
(1H, s, b, NH), 4.72 (1H, ap q, J 2.6, azetidinyl 4-H), 3.44 (1H, dq, J 14.8 and 
2.6, azetidinyl 3-Ha), 2.87 (1H, dd, J 14.8 and 2.6, azetidinyl 3-Hb); δC (125 
MHz; CDCl3) 168.1 (C=O), 140.2 (Ph), 128.9 (Ph), 128.3 (Ph), 125.6 (Ph), 
50.4 (azetidinyl C-4), 48.0 (azetidinyl C-3); νmax/cm-1 (film) 3203, 1737, 1704, 
1644; m/z (EI) [MH+] 148.19 (100%, MH+). 
4-(2-Oxo-4-phenylazetidin-1-yl)-2-(trifluoromethyl)benzonitrile, 30 
 
4-Iodo-2(trifluoro)methyl benzonitrile (594 mg, 2.0 mmol) as a solution in 
dioxane (1 mL) was added to a stirred suspension of the lactam 29 (353 mg, 
2.4 mmol), CuI (19 mg, 0.1 mmol), N,N’-dimethylethylenediamine (22 μL, 0.2 
mmol) and K3PO4 (849 mg, 4.0 mmol) in dioxane (1 mL). The reaction 
mixture was heated to reflux. After 23 h the reaction mixture was allowed to 
cool to rt and concentrated in vacuo. Purification by flash chromatography 
eluting with 50:40:10 CHCl3–Hexane–Et2O gave the arylated lactam 30 (481 
mg, 76%) as a pale yellow viscous oil. Rf: 0.48 (50:50, Hexane-EtOAc); δH 
(500 MHz; CDCl3) 7.82 (1H, d, J 2.1, Ar 3-H), 7.65 (1H, d, J 8.5, Ar 6-H), 
7.46-7.33 (6H, m, Ar 5-H and Ph), 5.12 (1H, ap q, J 2.8, azetidinyl 4-H), 3.69 
(1H, dd, J 15.9 and 6.0, azetidinyl 3-Ha), 3.11 (1H, dd, J 15.9 and 2.8, 
azetidinyl 3-Hb); δC (125 MHz; CDCl3) 165.1 (C=O), 141.1 (Ar C-4), 136.5 
(Ph), 135.9 (Ar C-6), 134.0 (q, 2JFC 32, Ar C-2), 129.6 (Ph), 129.3 (Ph), 
125.9 (Ph), 121.7 (q, 1JFC 278, CF3), 118.8 (Ar C-5), 115.5 (Ar C-3), 115.1 
(CN); 103.9 (Ar C-1), 54.9 (azetidinyl C-4), 47.82 (azetidinyl C-3); νmax/cm-1 
(film) 2224, 1767, 1605; m/z (ES) [MNa+] 339.07 (100%, MNa+); HRMS 
Found: 339.0718, (C17H11F3N2O, MNa requires 339.0716). 
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4-(3-Acetyl-2-oxo-4-phenylazetidin-1-yl)-2-trifluoromethyl)benzonitrile, 
25 (via alternative route) 
LDA (670 μL as a 2 M solution in THF/hexane, 1.3 mmol) was added to a 
stirred solution of the arylated β-lactam 30 (318 mg, 1.0 mmol) in THF at 
−78 °C. After 30 min, MeOAc (315 μL, 4 mmol) was added and the reaction 
mixture was stirred at −78 °C. After 1 h the reaction mixture was allowed to 
warm to rt. After 1.5 h, sat. aq. NH4Cl solution (16 mL) was added and the 
mixture extracted with Et2O (3 × 20 mL). The combined organic layers were 
dried (Na2SO4), filtered and concentrated in vacuo. Purification by flash 
chromatography eluting with 50:40:10 CHCl3–Hexane–Et2O  gave the β-
lactam 25 (208 mg, 58%) as a colourless amorphous solid. 
 
 
 
By general procedure F, diazo butanamide 17e with Rh2(OAc)4 in CH2Cl2 
followed by purification by flash chromatography, eluting with 95:5 CH2Cl2–
Et2O gave the oxindole  31 (17.9 mg, 13%), the oxindole 32 (16.6 mg, 12%) 
and the δ-lactam 33 (36.6 mg, 26%). Characterisation data for these 
compounds is given below. 
 
1-(But-3-en-1-yl)-2-oxo-4-(trifluoromethyl)-2,3-dihydro-1H-indole-5-
carbonitrile, 31 
 
Rf: 0.83 (90:10, CH2Cl2—Et2O); δH (500 MHz; CDCl3) 7.78 (1H, d, J 8.5, 6-
H), 7.05 (1H, d, J 8.5, 7-H), 5.78 (1H, ddt, J 16.6, 9.7 and 7.3, butenyl 3-H), 
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5.09 (1H, dd, J 16.6 and 3.4, butenyl 4-HA), 5.06 (1H, dd, J 9.7 and 3.4, 
butenyl 4-HB), 3.83 (2H, t, J 7.3, butenyl 1-H2), 3.74 (2H, indole 3-H2), 2.43 
(2H, ap q, J 7.3, butenyl 2-H2); δC (125 MHz; CDCl3) 173.8 (C-2), 149.0 (C-
7a), 135.9 (C-6), 133.5 (C-4), 129.5 (CF3), 124.3 (C-3a), 118.2 (butenyl C-4), 
116.0 (CN), 110.8 (Ar C-1), 102.9 (Ar C-5), 39.8 (butenyl C-1), 35.3 (C-3), 
31.5 (butenyl C-2); m/z (ES) [MNa+] 303.1 (100%, MNa+); HRMS Found: 
303.0713 (C14H11F3N2O  requires MNa 303.0716).  
 
1-(But-3-en-1-yl)-2-oxo-6-(trifluoromethyl)-2,3-dihydro-1H-indole-5-
carbonitrile, 32 
 
Rf: 0.52 (9:1, CH2Cl2—Et2O); δH (500 MHz; CDCl3) 7.65 (1H, s, 4-H), 7.15 
(1H, s, 7-H), 5.78 (1H, ddt, J 16.7, 9.7 and 7.9, butenyl 3-H1), 5.08 (1H, dd, J 
16.7 and 3.1, butenyl 4-HA), 5.06 (1H, dd, J 9.7 and 3.1, butenyl 4-HB), 3.84 
(2H, t, J 7.9, butenyl 1-H2), 3.62 (2H, s, indole 3-H2), 2.45 (2H, ap. q, J 7.4, 
butenyl 2-H2); δC (125 MHz; CDCl3) 173.8 (C-2), 148.7 (C-5), 133.6 (C-7), 
129.9 (C-3a), 128.4 (C-4), 118.4 (butenyl C-4), 115.8 (CN), 106.5 (C-6), 
102.9 (C-7a), 39.9 (butenyl C-1), 34.9 (C-3), 31.7 (butenyl C-2); m/z (ES) 
[MNa+] 303.1 (100%, MNa+); HRMS Found: 303.0707 (C14H11F3N2O  
requires MNa 303.0716). 
4-[2-Oxo-3-azabicyclo[4.1.0]heptanyl]3-2-(trifluoromethyl)benzonitrile, 
33 
 
Rf: 0.24 (9:1, CH2Cl2—Et2O); δH (500 MHz; CDCl3) 7.80 (1H, d, J 8.4, Ar 6-
H), 7.75 (1H, d, J 2.5, Ar 3-H), 7.64 (1H, dd, J 8.4 and 2.5, Ar 5-H), 3.62 (1H, 
ap. ddt J 6.6, 5.6 and 5.2, 4-HA), 3.54-3.49 (1H, m, 4-HB), 2.28-2.17 (2H, m 
5-HA and 5-HB), 1.96 (1H, dddd, J 4.4, 2.8 2.2 and 1.8, 6-HA), 1.84-1.78 (1H, 
m, 6-HB), 1.36 (1H, ap. q, J 4.4 7-HA), 1.18-1.12 (1H, m, 7-HB); δC (125 MHz; 
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CDCl3)  171.0 (C-2), 147.2 (Ar C-4), 135.1 (Ar C-6), 133.4 (q 2JFC 33, Ar C-
3), 128.2 (Ar C-5), 123.3 (Ar C-3), 121.4 (q 1JFC 273, CF3), 115.3 (CN), 106.3 
(Ar C-1), 44.6 (C-4), 21.4 (C-5), 18.0 (C-6), 14.6 (C-1), 7.4 (C-7); m/z (ES) 
[MNa+] 307.1 (100%, MNa+); HRMS Found: 307.0708, (C14H11F3N2O 
requires MNa 307.0716). 
3-Acetyl-1-benzyl-2-oxo-6-(trifluoromethyl)-2,3-dihydro-1H-indole-5-
carbonitrile, 34 
 
By general procedure F, diazo butanamide 17a with Rh2(tfa)4 in CH2Cl2 
followed by purification by flash chromatography, eluting with 90:10 
CH2Cl2—MeOH gave the dihydroindole 34 as a colourless amorfous solid 
(166 mg, 92%). Rf: 0.15 (95:5, CH2Cl2—MeOH); δH (500 MHz; CDCl3) 7.75 
(1H, s, 4-H), 7.37-7.29 (3H, m, Ph), 7.28-7.24 (2H, m, Ph), 7.20 (1H, s, 7-H), 
5.11 (2H, s, CH2-Ph), 2.58 (3H, s, acetyl CH3) (3-H not observed); δC (125 
MHz; CDCl3) 178.6 (acetyl C=O), 170.9 (NH-C=O), 140.2 (C-7a), 134.6 (Ph), 
130.4 (C-6), 129.2 (Ph), 128.3 (Ph), 127.6 (q, 1JFC  278, CF3), 127.3 (C-3a),  
124.7 (C-4), 116.4 (CN), 107.2 (C-7), 105.1 (Ph), 103.1 (C-5), 99.9 (C-3), 
43.8 (CH2-Ph), 21.1 (acetyl CH3); νmax/cm-1 (film) 3031, 2228, 1661, 1606, 
1455; m/z (ES) [MNa+] 376.1 (100%, MNa+); HRMS Found: 359.1001, 
(C19H13F3N2O2 MH requires 359.1002).  
3-Acetyl-1-(2-methoxyethyl)-2-oxo-6-(trifluoromethyl)-2,3-dihydro-1H-
indole-5-carbonitrile, 35 
 
By general procedure F, diazo butanamide 17h with Rh2(OAc)4 in CH2Cl2 
followed by purification by flash chromatography, eluting with 90:10 
CH2Cl2—MeOH gave the dihydroindole 35 as a pale yellow viscous oil (139 
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mg, 85%). Rf: 0.10 (95:5, CH2Cl2—MeOH); δH (500 MHz; CDCl3) 7.74 (1H, 
s, 4-H), 7.51 (1H, s, 7-H), 4.10 (2H, t, J 5.6, ethyl-2-H), 3.67 (2H, t, J 5.6, 
ethyl-1-H), 3.31 (3H, s, OMe), 2.56 (3H, s, acetyl-CH3) (3-H not observed); 
δC (300 MHz; CDCl3) 178.4 (acetyl C=O), 171.2 (NH-C=O), 141.1 (C-7a), 
129.5 (q, 2JFC 31, C-6), 125.3 (C-3a), 124.5 (C-4), 122.7 (q, 1JFC 278, CF3), 
116.5 (CN), 108.1 (C-7), 102.7 (C-5), 99.9 (C-3), 70.6 (ethyl-C-1), 58.9 
(OMe), 40.5 (ethyl-C-2), 20.8 (acetyl-CH3); νmax/cm-1 (film) 3057, 2923, 2230, 
1679, 1630; m/z (ES) [MH+] 327.1 (100%, MH+); HRMS Found: 327.0995, 
(C15H13F3N2O3 MH requires 327.0987). 
N-[4-Cyano-3-(trifluoromethyl)phenyl]-2-(1H-indol-3-yl)-N-
methylacetamide, 37a 
 
By general procedure G, the diazo-substrate 18k and co-substrate 36f with 
Rh2(S-DOSP)4 in CH2Cl2 followed by flash chromatography, eluting with 
90:10 CH2Cl2—Et2O gave the acetamide 37a as a brown viscous oil (143 
mg, 80%). Rf: 0.35 (90:10 CH2Cl2—Et2O); δH (500 MHz; CDCl3) 8.39 (1H, s, 
br, NH), 7.71 (1H, d, J 8.2, Ar 5-H), 7.48 (1H, s, br, Ar 6-H), 7.40 (2H, ap. d, 
J 8, Indole 7-H and Ar 2-H), 7.32 (1H, d, J 8.1, Indole 4-H), 7.19 (1H, dt, J 
8.2 and 1, Indole 5-H), 7.09 (1H, dt, J 7.5 and 1.0, Indole 6-H), 6.83 (1H, s, 
br, Indole 3-H), 3.79 (2H, s, CH2), 3.35 (3H, s, NMe); δC (125 MHz; CDCl3) 
171.3 (C=O), 148.0 (Ar C-1), 136.1 (Indole C-3a), 135.7 (Ar C-5), 133.8 (q, 
2JCF 33 Ar C-3), 130.1 (Ar C-2), 126.7 (Indole C-7a), 125.02 (Ar C-6), 122.9 
(Indole C-3), 122.4 (Indole C-5), 121.6 (q, 1JCF 276 CF3), 119.8 (Indole C-6), 
118.3 (Indole C-7), 114.9 (CN), 111.4 (Indole C-4), 108.0 (Ar C-4), 107.9 
(Indole C-2), 37.7 (NMe), 32.3 (CH2); νmax/cm-1 (film) 3466, 3055, 2234, 
1664, 1609; m/z (ES) [MH+] 358.1 (100%, MH+); HRMS Found: 358.1175 
(C19H14F3N3O MH requires 358.1162)  
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1-(Methyl)-2-oxo-6-(trifluoromethyl)-2,3-dihydro-1H-indole-5-
carbonitrile, 37b 
 
By general procedure G, the diazo-substrate 18k and co-substrate 36f with 
Rh2(S-DOSP)4 in CH2Cl2 followed by flash chromatography, eluting with 
90:10 CH2Cl2—Et2O gave the oxindole 37b as a colourless amorphous solid  
(13.1 mg, 11 %).  Rf: 0.62 (90:10 CH2Cl2—Et2O); δH (500 MHz; CDCl3) 7.66 
(1H, s, 4-H), 7.16 (1H, s, 7-H), 3.64 (2H, s, 3-H), 3.29 (3H, s, NMe); δC (125 
MHz; CDCl3) 174.0 (C-2), 150.0 (C-7a), 129.8 (C-3a), 135.0 (C4), 133.0 (q, 
2JCF 34 C-6), 124.0 (C-7), 121.0 (q, 1JCF 274, CF3), 116.0 (CN), 106.0 (C-5), 
34.9 (C-3), 26.6 (NMe); vmax/cm-1 (film) 2227, 1719; m/z (ES) [MH+] 146.0 
(100%, MH+); HRMS Found: 137.0025, (C11H6N2Na4O requires MH 
137.0029). 
N-[4-Cyano-3-(trifluoromethyl)phenyl]-N-methylbicyclo[4.1.0]heptane-7-
carboxamide, 37c 
 
By general procedure G, the diazo-substrate 18k and co-substrate 36a with 
Rh2(S-DOSP)4 in CH2Cl2 followed by flash chromatography, eluting with 
60:40 Petrol—EtOAc gave the carboxamide 37c (114 mg, 71%). Rf: 0.51 
(60:40 Petrol—EtOAc); δH (500 MHZ; CDCl3) 7.89 (1H, d, J 8.2, Ar 5-H), 
7.70 (1H, d, J 2.2, Ar 2-H), 7.57 (1H, dd, J 8.2 and 2.2, Ar 6-H), 3.40 (3H, s, 
NMe), 1.92 (2H, ap. q, 2-Ha and 2'-Ha), 1.77-1.71 (2H, m, 1-H and 1'-H), 
1.54 (2H, app quint, 2-Hb and 2'-Hb), 1.34-1.20 (2H, m, 3-Ha and 3-Ha), 
1.16 (1H, t, J 4.2, 7-H), 1.07-0.96 (2H, m, 3-Hb and 3'-Hb); δc (300 MHz; 
CDCl3) 173.7 (C=O), 148.6 (Ar C-1), 135.7 (Aryl C-5), 133.8 (q, 1JCF  32, Ar 
C-3), 129.2 (Ar C-6), 124.6 (Ar C-2), 121.9 (q, 1JCF 276 CF3), 115.0 (CN), 
107.0 (Ar C-4), 37.0 (NMe); 26.5 (C-7), 22.8 (C-1 and C-1'), 22.4 (C-2 and 
C-2'), 20.9 (C-3 and C-3'); νmax/cm-1 (film) 2928, 2855, 2230; m/z (ES) [MH+] 
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323.2 (100%, MH+); HRMS Found: 323.1373 (C17H18F3N2O requires MH 
323.1366). 
1-Methyl-2-oxo-4-(trifluoromethyl)-2,3-dihydro-1H-indole-5-carbonitrile, 
37d 
 
By general procedure G, the diazo-substrate 18k and co-substrate 36a with 
Rh2(S-DOSP)4 in CH2Cl2 followed by flash chromatography, eluting with 
60:40 Petrol—EtOAc gave the oxindole 37d as a yellow solid (14.2 mg, 
12 %). Rf: 0.28 (60:40 Petrol—EtOAc); δH (500 MHz; CDCl3) 7.81 (1H, d, J 
8.2, 6-H), 7.04 (1H, d, J 8.2, 7-H), 3.76 (2H, s, 3-H), 3.28 (3H, s, NMe); δC 
(125 MHz; CDCl3) 173.2 (C-2), 149.9 (C-7a), 136.2 (C-6), 128.2 (q, 2JCF 30, 
C4), 124.3 (C-3a), 115.8 (CN), 110.5 (C-7), 102.8 (C-5), 35.1 (C-3), 26.5 
(NMe) (CF3 not observed); vmax/cm-1 (film) 2921, 2229, 1752; m/z (ES) [MH+] 
145.1 (100%, MH+); HRMS Found: 145.1331 (C7H17F3N2O requires MH 
145.1335). 
N-[4-cyano-3-(trifluoromethyl)phenyl]-N-methyl-1H,1aH,2H,3H,7bH-
cyclopropa[a]naphthalene-1-carboxamide, 37e 
 
By general procedure G, the diazo-substrate 18k and co-substrate 36m with 
Rh2(S-DOSP)4 in CH2Cl2 followed by flash chromatography, eluting with 6:4 
Petrol—EtOAc gave the carboxamide 37e (141 mg, 76%) as a colourless 
amorphous solid. Rf: 0.39 (60:40 Petrol—EtOAc); δH (500 MHz; CDCl3) 7.79 
(1H, d, J 8.3, Ar 5-H), 7.66 (1H, d, J 2.0, Ar 2-H), 7.52 (1H, dd, J 8.3 and 2.0, 
Ar 6-H), 7.28 (1H, dd, J 7.5 and 1.4, Ph 7-H), 7.15 (1H, ddt, J 7.5, 1.4 and 
0.8, Ph 6-H), 7.10 (1H, dt, J 7.5 and 1.4, Ph 5-H), 6.97 (1H, d, J 7.5, Ph 4-
H), 3.42 (3H, s, NMe), 2.72 (1H, dd, J 8.7 and 3.5, 1-H), 2.63 (1H, dt, J 14.5 
and 4.5, 3-Ha), 2.35-2.29 (1H, m, 3-Hb), 2.18-2.10 (2H, m, 2-Ha and 1-aH), 
1.93-1.80 (2H, m, 7b-H and  and 2-Hb); δC (125 MHz; CDCl3) 171.6 (C=O), 
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148.1 (Ar C-1), 135.7 (Ar C-5), 134.6 (Ph C-3a), 133.9 (q, 2JCF 33, Ar C-3), 
133.4 (Ph-C-7a), 129.1 (Ar C-6), 128.7 (Ph C-7 and C-4), 126.5 (Ph C-6), 
126.2 (Ph C-5), 124.4 (Ar C-2), 121.8 (q, 1JCF 274, CF3), 114.9 (CN), 107.2 
(Ar C-4), 37.0 (NMe), 27.11 (C-1), 25.3 (C-2 and C-1a), 24.1 (C-7b), 18.3 (C-
3); νmax/cm-1 (film) 3022, 2924, 2231, 1661, 1608; m/z (ES) [MH+] 371.0 
(100%, MH+); HRMS Found: 371.1368 (C21H18F3N2O requires MH 
371.1366). 
N-[4-cyano-3-(trifluoromethyl)phenyl]-N-methyl-2-
oxabicyclo[4.1.0]heptane-7-carboxamide, 37f 
 
By general procedure G, the diazo-substrate 18k and co-substrate 36o with 
Rh2(S-DOSP)4 in CH2Cl2 followed by flash chromatography, eluting with 1:1 
Petrol—EtOAc gave the carboxamide 37f  (133 mg, 82%) as a pale yellow 
amorphous solid. Rf: 0.15 (60:40 Petrol—EtOAc); δH (500 MHz; CDCl3) 7.89 
(1H, d, J 8.5, Ar 5-H), 7.71 (1H, d, J 2.3, Ar 2-H), 7.60 (1H, dd, J 8.5 and 2.3, 
Ar 6-H), 3.96 (1H, dd, J 7.2 and 1.7, Heptane 1-H), 3.53 (1H, dt, J 10.9 and 
3.2, Heptane 3-Ha), 3.40 (3H, s, NMe), 3.35 (1H, td, J 11.3 and 1.7, Heptane 
3-Hb), 2.04-1.85 (3H, m, Heptane 4-Ha and 4-Hb and Heptane 6-H), 1.58 
(1H, d, J 4.7, Heptane 7-H), 1.53-1.46 (1H, m, Heptane 5-Ha), 1.29-1.20 
(1H, m, Heptane 5-Hb); δC (125 MHz; CDCl3) 171.0 (C=O), 148.2 (Ar C-1), 
135.7 (Ar C-5), 133.9 (q, 2JCF 32, Ar C-3); 129.4 (Ar C-6); 124.4 (Ar C-2), 
121.6 (q, 2JCF289, CF3), 114.9 (CN), 107.2 (Ar C-4), 64.4 (Heptane C-3), 
60.8 (Heptane C-1), 36.9 (NMe), 27.1 (Heptane C-7), 22.8 (Heptane C-6), 
21.9 (Heptane C-5), 18.6 (Heptane C-4) νmax/cm-1 (film) 2933, 2859, 2231, 
1655, 1608; m/z (ES) [MH+] 325.3 (100%, MH+); HRMS Found: 325.1166 
(C16H16F3N2O2 requires MH 325.1166). 
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N-[4-cyano-3-(trifluoromethyl)phenyl]-N-methyl-1H,1aH,6H,6aH-
cyclopropa[α]indene-1-carboxamide, 37g 
 
 
By general procedure G, the diazo-substrate 18k and co-substrate 36r with 
Rh2(esp)2 in CH2Cl2 followed by flash chromatography, eluting with 60:40 
Petrol—EtOAc gave the carboxamide 37g  (130.1 mg, 73%) as a colourless 
amorphous solid. Rf: 0.35 (60:40 Petrol—EtOAc); δH (500 MHz; CDCl3) 7.81 
(1H, d, J 8.3, Ar 5-H), 7.69 (1H, d, J 2.2, Ar 2-H), 7.55 (1H, dd, J 8.3 and 2.2, 
Ar 6-H), 7.34-7.30 (1H, m, Ph), 7.16-7.09 (3H, m, Ph), 3.41 (3H, s, NMe), 
3.31 (1H, dd, J 17.6 and 6.4, 6-Hb), 3.12 (1H, dq, J 6.4 and 1.3, 1a-H), 2.90 
(1H, d, J 17.6, 6-Ha), 2.59 (1H, tdd, J 6.5, 3.3 and 0.4, 1-H), 1.00 (1H, s, br, 
7-H); δC (125 MHz; CDCl3) 174.2 (C=O), 148.1 (Ar C-1), 143.4 (Ph), 141.8 
(Ph), 135.8 (Ar C-5), 133.9 (q, 2JCF 34, Ar C-3), 129.2 (Ar C-6), 126.5 (Ph), 
125.4 (Ph), 124.4 (Ar C-2), 123.8 (Ph), 121.8 (q, 1JCF 289, CF3), 114.9 (CN), 
107.4 (Ar C-4), 37.2 (NMe), 35.5 (C-6a), 35.1 (C-6), 31.8 (C-1a), 27.5 (C7); 
νmax/cm-1 (film) 2921, 2230, 1665, 1609; m/z (ES) [MH+] 357.4 (100%, MH+); 
HRMS Found: 379.1039 (C20H15F3N2NaO requires MNa 379.1029). 
 4-[(2-(2,2-Dimethyl-2H-chromen-6-yl)-1,3-oxazol-5-yl)(methyl)amino]-2-
(trifluoromethyl)benzonitrile, 37h 
 
By general procedure G, the diazo-substrate 18k and co-substrate 36f’ with 
Rh2(OAc)4 in CH2Cl2 followed by flash chromatography, eluting with 50:50 
Petrol—EtOAc gave the oxazole 37g  (159 mg, 75%) as a bright yellow oil. 
Rf: 0.62 (50:50 Petrol—EtOAc); δH (500 MHz; CDCl3) 7.74 (1H, dd, J 8.5 and 
2.1, chromene 7-H), 7.67 (1H, d, J 8.7, Ar 6-H), 7.62 (1H, d, J 2.1, chromene 
5-H), 7.18 (1H, d, J 2.6, Ar 3-H), 7.02 (1H, dd, J 8.7 and 2.6, Ar 5-H), 6.93 
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(1H, s, oxazole 4-H), 6.84 (1H, d, J 8.5, chromene 8-H), 6.36 (1H, d, J 9.8, 
chromene-4H), 5.69 (1H, d, J 9.8, chromene 5-H), 3.43 (3H, s, NMe), 1.46 
(6H, s, chromene 2-Me); δC (125 MHz; CDCl3) 159.4 (oxazole C-2), 155.4 
(chromene C-8a), 150.1 (Ar C-4), 148.7 (oxazole C-5), 135.9 (Ar C-6), 134.3 
(q, 2JCF 33, Ar C-2), 131.6 (chromene C-3), 127.3 (chromene C-7), 124.3 
(chromene C-5), 122.2 (q, 1JCF 276, CF3), 121.6 (chromene C-4), 121.5 
(chromene C-4a), 120.1 (oxazole C-4); 116.8 (chromene C-8), 116.5 (Ar C-
5), 116.2 (CN), 111.7 (q, 3JCF 5, Ar C-3), 105.0 (chromene C-6), 99.6 (Ar C-
1), 77.2 (chromene C-2), 39.6 (NMe), 28.2 (Chromene 2-Me); νmax/cm-1 (film) 
2976, 2923, 2224, 1602; m/z (ES) [MH+] 426.0 (100%, MH+); HRMS Found: 
426.1428 (C23H19F3NO2 requires MH 426.1424). 
N-[4-cyano-3-(trifluoromethyl)phenyl]-2-(3,4-dihydro-2H-pyran-2-
ylmethoxy)-N-methylacetamide, 37i 
 
By general procedure G, the diazo-substrate 18k and co-substrate 36g’ with 
Rh2(S-DOSP)4 in CH2Cl2 followed by flash chromatography, eluting with 95:5 
CH2Cl2—Et2O gave the carboxamide 37i (129.3 mg, 73%) as a colourless 
oil. Rf: 0.18 (50:50 Petrol—EtOAc); δH (500 MHz; CDCl3) 7.89 (1H, d, J 8.3, 
Ar 5-H), 7.75 (1H, d, J 1.7, Ar 2-H), 7.64 (1H, dd, J 8.3 and 1.7, Ar 6-H), 6.33 
(1H, d, J 6.2, pyran 6-H), 4.69 (1H, ddd, J 6.2, 1.4 and 3.2, pyran 5-H), 4.20 
(2H, ap. q, J 12.6, acetamide 2-H), 3.93 (1H, ddd, J 5.6, 3.3 and 2.5, pyran 
2-H), 3.58 (2H, ap d, J 5.6, methoxy CH2), 3.40 (3H, s, NMe), 2.14-2.04 (1H, 
m, pyran 4-Ha), 1.96 (1H, ap. d, J 17.4, pyran 4-Hb), 1.77 (1H, ap. dd, J 13.5 
and 5.8, pyran 3-Ha), 1.67-1.56 (1H, m, pyran 3-Hb); δC (125 MHz; CDCl3) 
168.9 (acetamide C-1), 147.2 (Ar C-1), 143.2 (Pyran C-6), 135.8 (Ar C-5), 
134.1 (q, 2JCF 34, Ar C-3), 129.3 (Ar C-6), 124.3 (Ar C-2), 121.9 (q, 1JCF 274, 
CF3), 114.9 (CN), 107.9 (Ar C-4), 100.6 (pyran C-5), 74.0 (methoxy CH2), 
73.9 (pyran C-2), 70.6 (acetamide C-2), 37.0 (NMe), 24.2 (pyran C-3), 19.3 
(pyran C-4); νmax/cm-1 (film) 3060, 2952, 2231, 1675, 1609; m/z (ES) [MNa+] 
377.0 (100%, MNa+); HRMS Found: 377.1094 (C17H17F3N2NaO3 requires 
MNa 377.1083). 
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7.2.3. Experimental procedures for assaying individual 
compounds or reaction mixtures from intra- or 
intermolecular reaction arrays 
 
General Procedure H: Assaying individual compounds using the Invitrogen 
TR-FRET Androgen Receptor co-activator assay kit – agonist mode. 
The assay kit was purchased from Invitrogen and used as instructed. The kit 
contained the protein, AR LBD-His-GST, the fluorescein-tagged peptide, the 
Tb3+-anti-GST-Ab, co-regulator buffer and DDT.  
The biochemical assay was performed in black 384-well plates from Corning 
(#3676).  The plate type was found to be important for high quality 
reproducible assay results. 
Reagents: 
Fluorescein-tagged peptide: 100 μM in 50 mM HEPES buffer, pH 7.5, 
sequence: VESGSSRFMQLFMANDLLT. 
AR LBD GST: Rat AR LBD in a buffer pH 7.5, containing protein, stabilising 
reagents and glycerol (batches were typically supplied at a concentration 
ranging between 450-550 nmol). 
Tb3+-anti-GST antibody: 3.3-3.7 μM in 10 mM HEPES buffered saline 137 
mM NaCl, 2.7 mM KCl, pH 7.5. 
TR-FRET Coregulator buffer: propertiary buffer, pH 7.5, 20% glycerol. 
DTT: 1 M in water. 
Complete co-regulator buffer A: A solution of 5 mM DTT in TR-FRET co-
regulator buffer was prepared freshly before each assay. This solution was 
then used as the dilution buffer for all materials. 
The assay includes three additions per well, in which AR-LBD is added to 
agonist dilutions or controls, followed by the addition of a pre-mixed 
fluorescein-tagged peptide/Tb3+-anti-GST antibody solution.  
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A solution of compound in DMSO at 100× the desired maximum assay 
concentration was prepared (e.g. for testosterone the 100x concentration 
was 500 µM giving a maximum assay concentration of 5 µM). 
A 12-step, 4-fold serial dilution of the compound stock was prepared in 
DMSO and 1µL of each dilution point was added to 49 μL of complete co-
regulator buffer A. 10 μL of the resulting solution were added to each well in 
rows A to C, columns 1-12 of a 384 well plate. 
Positive Control: A 10 µM solution of testosterone was prepared by adding 2 
μL of 500 µM of testosterone in DMSO to 98 µL of complete co-regulator 
buffer A and 5 μL of this solution were added to each well in row D columns 
5 to 8 of the 384 well plate. 
Negative Control: A solution of 2% DMSO in complete co-regulator buffer A 
was prepared and 5 μL of this solution were added to each well in row D, 
columns 1 to 4 and 9 to 12 of the 384 well plate. 
Diffusion TR-FRET baseline control: 10 μL of complete co-regulator buffer A 
were added to each well in row D, columns 9 to 12 of the 384 well plate. 
A 5 nM solution of the AR-LBD in complete co-regulator buffer A was 
prepared. 5 μL of this solution were added to each well rows A to C, columns 
1 to 12 and row D columns 1 to 8, of the 384 well plate. 
A solution with a final concentration of 500 nM of the fluorescein-tagged 
peptide and 5 nM of the Tb3+-anti-GST antibody respectively in complete co-
regulator buffer A was prepared. 5 μL of this solution were added to each 
well rows A to D, columns 1 to 12 of the 384 well plate.  
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Representative 384-well plate layout: 
 1 2 3 4 5 6 7 8 9 10 11 12 
A 
Agonist in serial dilution in triplicate B 
C 
D Negative Control Positive Control 
Diffusion TR-FRET 
Control 
 
The plate was left to equilibrate for 2-4 h and read using a Perkin-Elmer 
Envision 2103 Multilabel Reader with a 340 nm excitation filter (14 nm 
bandwidth for the Tb3+) and 495nm (14 nm bandwidth, for the Tb3+) and 520 
nm (10 nm bandwidth, for the fluorescein) emission filters and a 400 nm 
dichroic mirror, with a delay window of 100 μs and an integration window of 
200 μs. 5 repeat measurements were obtained and the results of each 
measurement were averaged during data processing. Each assay was 
performed at least twice with a z’ factor > 0.85. 
The results were normalised by dividing the TR-FRET ratio of each well 
(emission at 520 nm / emission at 495 nm) by the average baseline TR-
FRET ratio. 
General Procedure Ι: Assaying reaction mixtures from the microreaction 
arrays using the Invitrogen TR-FRET Androgen Receptor co-activator assay 
kit – agonist mode.  
Stock solutions were prepared as indicated in General Procedure Η (above). 
Each microreaction stock solution of Σ[Pn] = 100 mM in DMSO was diluted to 
give a stock assay solutions of Σ[Pn] = 1 mM, 0.1 mM and 0.01 mM in 
DMSO, appropriately, for the intramolecular reaction arrays one, two and 
three, respectively. This solution was used as the 100× agonist solution. 
Similarly, for the intermolecular reaction arrays, each stock solution was 
diluted to give a stock assay solutions of Σ[Pn] = 1 mM, 5 mM and 0.1 mM in 
DMSO, appropriately for the intermolecular reaction arrays one, two and 
three, respectively. 
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1µL of each 100× agonist solution was added to 49 μL of complete co-
regulator buffer A. 10 μL of the resulting solution were added to duplicate 
wells in a 384 well plate 
Positive Control: A 5 μM solution of testosterone was prepared by adding 2 
μL of 500 µM of testosterone in DMSO to 98 µL of complete co-regulator 
buffer A and 5 μL of this solution were added to each well in row D columns 
5 to 8 of the 384 well plate. 
Negative Control: A solution of 2% DMSO in complete co-regulator buffer A 
was prepared and 5 μL of this solution were added to each well in row A, 
columns 1 to 4 and 9 to 12 of the 384 well plate. 
Diffusion TR-FRET baseline control: 10 μL of complete co-regulator buffer A 
were added were added to each well in row A, columns 9 to 12 of the 384 
well plate. 
A 5 nM solution of the AR-LBD in complete co-regulator buffer A was 
prepared. 5 μL of this solution were added to each well of the plate with the 
exception of row A, columns 9 to 12 (Diffusion TR-FRET baseline control). 
A solution with a final concentration of 500 nM of the fluorescein-tagged 
peptide and 5 nM of the Tb3+-anti-GST antibody respectively in complete co-
regulator buffer A was prepared. 5 μL of this solution were added to each 
well of the 384 well plate. 
Intramolecular reaction arrays: 
For the first reaction array the final assay concentration was Σ[Pn] = 10 μM.  
For the second reaction array the final assay concentrations were Σ[Pn] = 
10 μM and 1 μM.  
For the third reaction array the final assay concentrations were Σ[Pn] = 1 μM 
and 100 nM.  
Intermolecular reaction arrays: 
For the first reaction array the final assay concentration was Σ[Pn] = 10 μM.  
For the second reaction array the final assay concentrations were Σ[Pn] = 
10 μM and 5 μM.  
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For the third reaction array the final assay concentrations were Σ[Pn] = 5 μM 
and 1 μM.  
The plate was left to equilibrate for 2-4 h and read using a Perkin-Elmer 
Envision 2103 Multilabel Reader (see General Method F for optical 
configuration). 5 repeat measurements were obtained and the results of 
each measurement were averaged during data processing. Each assay was 
performed at least twice with a z’ factor > 0.85. 
The results were normalised by dividing the TR-FRET ratio of each well 
(emission at 520 nm / emission at 495 nm) by the average baseline TR-
FRET ratio. These results were transformed into an activity percentage, by 
setting the normalised TR-FRET ratio of the positive control as 100% and 
the normalised TR-FRET ratio of the negative control as 0%. 
 
7.2.4. Experimental procedure for the metal scavenging 
studies 
 
1 mM solutions of Rh2(OAc)4 in CH2Cl2 and THF and Rh2(pfb)4 in toluene 
and EtOAc were prepared.  100 μL of Rh2(OAc)4 in CH2Cl2 were added to 
the wells of column A, rows 1-7 of a custom made 96-well PTFE plate. 100 
μL of Rh2(OAc)4 in THF were added to the wells of column B, rows 1-6 of the 
96-well plate. 100 μL of Rh2(pfb)4 in toluene were added to the wells of 
column C, rows 1-6 of the 96-well plate. 100 μL of Rh2(pfb)4 in EtOAc were 
added to the wells of column D, rows 1-6 of the 96-well plate. Increasing 
amounts of QuadraPure TU resin were added to the wells in column A, rows 
2-7, column B, rows 2-6, column C rows 2-6 and column D, rows 2-6. In the 
wells in columns A, B, C and D of row 1 no resin was added and served as 
negative control. The wells were sealed using disposable sealing caps and 
left to scavenge. After 24 h the wells were unsealed and aliquots of the 
resulting solutions were run through the microanalyser and compared 
against a calibration curve produced from three standard solutions (for 
rhodium: 5 ppm, 10 ppm and 15 ppm).  
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Table 7.1: Percantage of metal removed by the addition of different amounts 
of QuadraPure TU resin in different solutions of Rh(II) catalysts. 
 
Entry QP TU 
resin 
(mg) 
Metal 
conc in 
solution 
(ppm) 
% of 
metal 
removed 
Solvent Catalyst 
1 0 475 1 THF Rh2(OAc)4 
2 5.91 342 29 THF Rh2(OAc)4 
3 14.53 78 84 THF Rh2(OAc)4 
4 18.29 14 97 THF Rh2(OAc)4 
5 25.47 8 98 THF Rh2(OAc)4 
6 38.72 8 98 THF Rh2(OAc)4 
7 0 341 0 CH2Cl2 Rh2(OAc)4 
8 4.97 253 26 CH2Cl2 Rh2(OAc)4 
9 10.55 99 71 CH2Cl2 Rh2(OAc)4 
10 15.62 37 89 CH2Cl2 Rh2(OAc)4 
11 19.83 8 98 CH2Cl2 Rh2(OAc)4 
12 28.56 6 98 CH2Cl2 Rh2(OAc)4 
13 47.68 5 99 CH2Cl2 Rh2(OAc)4 
14 0 1210 2 Toluene Rh2(pfb)4 
15 4.2 998 19 Toluene Rh2(pfb)4 
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16 5.9 798 35 Toluene Rh2(pfb)4 
17 11.8 349 72 Toluene Rh2(pfb)4 
18 17.8 31 97 Toluene Rh2(pfb)4 
19 30.5 14 99 Toluene Rh2(pfb)4 
20 0 1176 0 EtOAc Rh2(pfb)4 
21 7.7 672 43 EtOAc Rh2(pfb)4 
22 14.18 246 79 EtOAc Rh2(pfb)4 
23 20.13 32 97 EtOAc Rh2(pfb)4 
24 24.17 26 98 EtOAc Rh2(pfb)4 
25 29.11 24 98 EtOAc Rh2(pfb)4 
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7.2.5. Experimental procedure for quantitative HPLC 
analysis of product mixtures containing the β-lactam 25 
 
Three solutions of the β-lactam 25 in MeOH–DMSO (50:50), 0.8 mg/mL, 0.4 
mg/mL and 0.15 mg/mL, were prepared and used as standard solutions to 
produce a calibration curve. These solutions were run on an Agilent 1290 
Infinity LC system, equipped with a PHENOMENEX LUNA 3µ Phenyl-Hexyl 
column (75×46 mm), eluting with a 5-95% gradient over 32 minutes of a 
MeCN—water—0.1% TFA solution, with a flow rate of 0.5 mL/min. The 
product was identified to have a retention time of 21.2 minutes (λabs = 
254 nm) and a peak area of 253.7 mAU×min (96%) for the 0.8 mg/mL 
sample. Aliquots from the intramolecular reaction array 3 were diluted in 
MeOH–DMSO (50:50) accordingly, analysed using the above conditions and 
the yield of the product determined. 
 
% of activity at 
Σ[Pn] =  100 nΜ Yield 25 % Solvent Catalyst 
24.4 71.8 DCM Rh2(OAc)4 
9.6 4.7 DCM Rh2(tfa)4 
19.1 45.4 DCM Rh2(esp)2 
10.3 12.1 DCM Rh2(pfb)4 
10.7 26.0 DCM Rh2(tpa)4 
24.0 72.5 DCM Rh2(oct)4 
21.8 58.7 PhMe Rh2(OAc)4 
7.6 2.2 PhMe Rh2(tfa)4 
19.3 47.1 PhMe Rh2(esp)2 
9.9 8.8 PhMe Rh2(pfb)4 
15.7 35.3 PhMe Rh2(tpa)4 
17.7 45.8 PhMe Rh2(oct)4 
22.9 59.1 EtOAc Rh2(OAc)4 
9.1 4.3 EtOAc Rh2(tfa)4 
23.8 70.3 EtOAc Rh2(esp)2 
6.8 1.4 EtOAc Rh2(pfb)4 
21.6 58.1 EtOAc Rh2(tpa)4 
6.2 0.0 EtOAc Rh2(oct)4 
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Efficient discovery of bioactive scaffolds by
activity-directed synthesis
George Karageorgis1,2, Stuart Warriner1,2* and Adam Nelson1,2*
The structures and biological activities of natural products have often provided inspiration in drug discovery. The
functional benefits of natural products to the host organism steers the evolution of their biosynthetic pathways. Here, we
describe a discovery approach—which we term activity-directed synthesis—in which reactions with alternative outcomes
are steered towards functional products. Arrays of catalysed reactions of α-diazo amides, whose outcome was critically
dependent on the specific conditions used, were performed. The products were assayed at increasingly low concentration,
with the results informing the design of a subsequent reaction array. Finally, promising reactions were scaled up and, after
purification, submicromolar ligands based on two scaffolds with no previous annotated activity against the androgen
receptor were discovered. The approach enables the discovery, in tandem, of both bioactive small molecules and
associated synthetic routes, analogous to the evolution of biosynthetic pathways to yield natural products.
T
he astonishing functional and structural diversity of natural
products continues to provide tremendous inspiration in
drug discovery and chemical biology1–3. Natural products
arise through the evolution of biosynthetic pathways, driven by
functional benefit to the host organism4,5. In stark contrast,
synthetic routes to bioactive small molecules are almost always
developed in isolation from the assessment of their function.
In many discovery programmes, bioactive small molecules are
initially identified by high-throughput screening, and, to facilitate
this approach, cheminformatic approaches have been developed to
assess the scaffold diversity of screening libraries6. The annotated
bioactivity of known scaffolds can also facilitate the exploration of
chemical space, and can provide inspiration in the design of bio-
active molecules based on related scaffolds7,8. The optimization of
small-molecule function is generally undertaken through iterative
rounds of design, synthesis and assaying9. To expedite ligand optim-
ization, a narrow toolkit of reliable synthetic methods with predict-
able outcomes has emerged to support medicinal chemistry10,11.
Established medicinal chemistry approaches12 may have inadver-
tently steered molecular design towards a subset of molecular scaf-
folds, and tended to exacerbate chemists’ exceptionally uneven
historic exploration of chemical space13. The emergence of diver-
sity-oriented synthesis14–16 has expanded the diversity of small-mol-
ecule screening collections, but is still reliant on an expanded toolkit
of synthetic methods with inherently predictable outcomes.
Although function has steered the directed evolution of biosyn-
thetic pathways, for example to produce carotenoids with specific
colours17, the emergence of chemical syntheses has rarely been
directed by the function of the resulting products. Chemical strat-
egies that link structure and function include the in situ synthesis
of enzyme inhibitors from building blocks within active sites18–20.
In addition, dynamic combinatorial chemistry exploits reversible
reactions to template the formation of cognate ligands for specific
molecular targets21. To apply such approaches in bioactive small-
molecule discovery, the challenge of developing reactions that
operate efficiently under buffered aqueous conditions must be
met. To date, only a few reactions have been developed that
operate efficiently under conditions compatible with folded
proteins, fundamentally limiting the chemical diversity of the
small molecules that may be discovered.
Here, we describe a novel discovery approach in which bioactive
small-molecule function directs the emergence of an associated syn-
thetic route. We specifically chose to exploit catalysed reactions with
alternative possible outcomes that might be steered by the specific
catalyst and reaction conditions used. It was anticipated that such
reactions would enable the efficient exploration of the relevance of
a wide range of molecular scaffolds to a required biological function.
In each round, an array of reactions was designed and, after
scavenging, the products were assayed at increasingly low concen-
tration for agonism of the androgen receptor. The results informed
the design of a subsequent reaction array until, finally, promising
reactions were scaled up to reveal, after purification, bioactive
small-molecule ligands (Fig. 1a).
Crucially, the approach enabled the discovery of ligands with
submicromolar activity, based on two scaffolds with no previously
annotated activity against the androgen receptor. To our knowledge,
the study constitutes the first example in which the emergence of
synthetic routes conducted under non-aqueous conditions was
directed by the biological activity of the resulting small-
molecule products.
Results
Rationale for selection of chemistry. We chose to exploit catalysed
reactions of diazo compounds because alternative outcomes are
possible with many substrates, and yet may often be controlled
through judicious choice of catalyst and reaction conditions. For
example, α-diazo carbonyl compounds are well known to
participate in many intermolecular22 reactions (for example,
C−H, N−H and O−H insertions, cyclopropanations, ylide
formation/cycloaddition) as well as intramolecular variants that
form alternative ring sizes23–25. Such inherently unpredictable
reactions are generally unsuitable in current ligand discovery
approaches, which typically involve the synthesis and purification
of arrays of small molecules. However, such reactions are ideal in
activity-directed synthesis because their outcome may often be
controlled by appropriate catalysts and ligands26,27, and
1Astbury Centre for Structural Molecular Biology, University of Leeds, Leeds LS2 9JT, UK, 2School of Chemistry, University of Leeds, Leeds LS2 9JT, UK.
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synthetically accessible bioactive molecules based on alternative
scaffolds might be discovered.
Three rounds of activity-directed synthesis. We investigated
whether activity-directed synthesis could enable the discovery of
novel chemotypes from a fragment found in a wide range of
androgen receptor modulators28–32. Initially, we prepared33 twelve
α-diazo amides 1–12, which each bear the 4-cyano-3-
trifluoromethylphenyl group and a variable R′ group. Some
possible intra- and intermolecular reactions that these substrates
might undergo are outlined in Fig. 1b. The range of R′
substituents was chosen to increase the scaffold diversity of
possible cyclization products (for example, formed by
intramolecular C−H insertion, cyclopropanation or ylide
formation/cycloaddition). We performed an array of reactions in a
96-well plate in which the diazo substrate (100 mM in
dichloromethane) and catalyst (1 mol%; for structures see
Supplementary Fig. 1) were varied. After 48 h, the crude reactions
were scavenged to remove metal contaminants (for optimization
see Supplementary Fig. 2), evaporated and assayed for agonism of
the androgen receptor (total concentration of products: 10 µM in
1% dimethylsulfoxide (DMSO) in pH 7.5 aqueous buffer) (Fig. 2a
and Supplementary Table 1). Activity was determined using a
commercially available assay with a time-resolved Förster
resonance energy transfer (FRET) readout34. Crucially, we had
already established that the diazo substrates were all inactive
under the conditions of the assay (Supplementary Fig. 3). Four
substrates (1, 3, 6 or 7) yielded products that were highly active.
These substrates were fed into the design of the subsequent
reaction array, together with, as a control, two substrates (11 and
12) that had not yielded active product mixtures.
In round two we performed an array of reactions in which the
substrate (1, 3, 6, 7, 11 and 12), catalyst (1 mol%) and solvent
(dichloromethane, THF, toluene or ethyl acetate) were varied. The
reactions were evaporated, scavenged and assayed at tenfold lower
concentration (total concentration of products: 1 µM in 1%
DMSO in pH 7.5 aqueous buffer). Crucially, substrates 11 and 12,
which were included as controls, did not yield active product mix-
tures in round two. Furthermore, the activity of the product mix-
tures derived from the other substrates was critically dependent
on the specific catalyst and reaction conditions used. For example,
the most active product mixtures were derived from reactions of
substrates 1 and 3, but only when a specific class of catalyst
(rhodium carboxylates) was used in specific solvents (dichloro-
methane, toluene or ethyl acetate) (Fig. 2b, Supplementary
Table 2). These data suggest that the fate of these substrates may
depend critically on the catalyst used, with only a specific class of
catalyst steering the reaction towards active products.
In round three we exploited substrates 1 and 3, as well as four
additional structurally related substrates 13–16. We performed a
reaction array in which these six substrates were varied,
together with the solvent (dichloromethane, toluene or ethyl
acetate) and catalyst (six rhodium carboxylates including the
two most promising catalysts from the previous round).
The reaction products were assayed at tenfold lower con-
centration (total concentration of products: 100 nM in 1% DMSO
in pH 7.5 aqueous buffer) (Fig. 2c, Supplementary Table 3).
Again, for three substrates (1, 3 and 15), reactions were only
steered towards active products by a narrow range of catalysts and
reaction conditions.
Identification and characterization of bioactive products. Finally,
on the basis of active product mixtures identified in round 3, we
scaled up eight reactions whose products had had the most
promising biological activity (Table 1). In each case, a major
product was purified, and its structure was elucidated. The three
distinct major products were assayed at a range of concentrations
for agonism of the androgen receptor (Table 1, Fig. 3) (for the
Pr
CH2Ph
(CH2)2Ph
(CH2)2CH=CH2
(CH2)2iPr
CH2CONMe(CH2)2CH=CH2
(CH2)2OMe
4-pyridylmethyl
(CH2)2CN
propargyl
1
3
5
7
9
11
13
14
15
16
2
4
6
8
10
12
 -
 -
 -
 -
Rʹ
R
Ac H
N
O
R'
CF3
NC
R
N2
A
C
B M
Substrate
Scale-up,
purification,
evaluation
1. Perform reactions
2. Screen reaction
mixtures
3. Analyse data and
design next array
Ac
tiv
ity
a b
Figure 1 | Application of activity-directed synthesis to the discovery of androgen receptor agonists. a, Overview of activity-directed synthesis. In each
round, arrays of reactions are performed in which the substrate, catalyst and solvent are varied. The resulting product mixtures are scavenged and then
assayed at increasingly low concentrations to identify combinations that yield bioactive products. Analysis of the screening results can inform the design of
the reaction array in the subsequent round. Finally, promising reactions are scaled up, and the products are purified, identified and evaluated. b, Design of
α-diazo amide substrates that may react to yield androgen receptor agonists. Each substrate bears a 4-cyano-3-trifluoromethylphenyl group, a fragment that
is found in a range of androgen receptor modulators. Possible fates of catalysed reactions of the substrates include intramolecular reaction with the
appended N-aryl ring (A), intramolecular reaction with the R’ side chain (B), and intermolecular reaction with a different molecule M (C).
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structure and activity of the reference ligands testosterone and
flutamide, see Supplementary Fig. 4). To confirm its activity, the
most potent ligand, 17, was also prepared using an independent
synthetic route (Supplementary Fig. 5a). This sample was found
to have identical activity to that prepared by Rh2(esp)2-catalysed
cyclization of substrate 3 (Supplementary Fig. 5b). The β-lactams
17 and 19 were full agonists of the androgen receptor, whereas
γ-lactam 18 functioned as a partial agonist.
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Figure 2 | Activity of product mixtures derived from reaction arrays.
a, In round 1, substrates 1, 3, 6 and 7 yielded active product mixtures. These
substrates were fed into round 2, together with, as a control, two substrates,
11 and 12, that had not yielded active product mixtures. b, In round 2,
substrates 1 and 3 yielded active product mixtures when treated with
rhodium carboxylate catalysts in dichloromethane, toluene or ethyl acetate.
c, In round 3, the combinations of substrates, catalysts and solvents used
were informed by the results from round 2. Specifically, we exploited the two
most promising substrates (1 and 3) and four structurally related substrates
(13–16); three promising solvents; and the two most promising catalysts and
four related rhodium carboxylates. Eight promising reactions were selected
for scale up on the basis of the activity of their products. Biological activity is
expressed relative to 5 µM testosterone. See Supplementary Tables 1–3 for
the catalysts (represented by different colours, including Rh2(OAc)4, black;
Rh2(tfa)4, dark blue; Rh2(cap)4, light green) and solvents (represented by
different shapes). Experiments were performed in duplicate. The error bars
represent the standard deviation between replicates, and are omitted from
b and c for clarity (typical error 1.5–4.5%, Supplementary Tables 1–3).
tfa = trifluoroacetate; cap = caprolactamate.
Table 1 | Yield and activity of the products of reactions that
were scaled up.
Entry Reaction
conditions*
Product Yield
(%)
EC50 (nM)
1 3, 1 mol%
Rh2(esp)2, EtOAc
N
O
O
CF3
NC
17
75 340 ± 30
(agonist)
2 3, 1 mol%
Rh2(oct)4 , CH2Cl2
71
3 3, 1 mol%
Rh2(OAc)4 ,
CH2Cl2
68
4 1, 1 mol%
Rh2(esp)2, CH2Cl2
N
CF3
NC
18
O
O
90 470 ± 40
(partial
agonist†)
5 1, 1 mol%
Rh2(oct)4 , CH2Cl2
88
6 1, 1 mol%
Rh2(OAc)4 ,
CH2Cl2
55
7 15, 1 mol%
Rh2(esp)2, EtOAc
N
O
O
CN
CF3
NC
19
78 440 ± 60
(agonist)
8 15, 1 mol%
Rh2(tpa)4 , PhMe
70
*esp = α,α,α′,α′-tetramethyl-1,3-benzenedipropionate; tpa = triphenylacetate; oct = octanoate;
†maximum activity was 50% that of testosterone.
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Figure 3 | Dose-dependent agonism of the androgen receptor by
compounds 17, 18 and 19. The major products of reactions described in
Table 1 were tested as agonists at a range of concentrations to show a dose-
dependent effect. 17 (squares), 18 (circles) and 19 (triangles).
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Discussion
Activity-directed synthesis provides a novel and highly efficient
approach to the discovery of bioactive small molecules, together
with associated synthetic routes. The discovery of reactions that
yield active products is undertaken in parallel through iterative
rounds of reactions and screening. Only reactions that yield
highly active products are scaled up, and the products then purified,
identified and characterized. Resources are thus highly focused on
bioactive reaction products. Conventional ligand optimization
approaches tend to invest similar resources in all compounds pre-
pared. Although parallel synthesis techniques are often exploited,
purification of the resulting arrays of compounds is usually under-
taken in series (often using mass-directed liquid chromatography)
before assays are undertaken in parallel and structure–activity
relationships are formulated.
To enable the discovery of alternative bioactive chemotypes,
activity-directed synthesis requires methods where the outcome
may be varied through the choice of specific catalyst and reaction
conditions. We deliberately chose to exploit metal-catalysed
reactions of diazo compounds on the basis of the range of intra-
and intermolecular reaction types that are possible. To demonstrate
the fitness of diazo chemistry for activity-directed synthesis we
showed that the fate of α-diazo amide 3 varies widely, with three dis-
tinct compounds being observed in total, the distribution of which
depends critically on the specific catalyst and reaction conditions
used (Supplementary Fig. 6, Supplementary Table 4).
Promising reactions were identified solely on the basis of the
activity of the resulting product mixtures. To demonstrate that the
activity of the product mixtures provides insights into the activity
of individual components, we purified and assayed the products
of a limited number of reactions (Fig. 4, Supplementary Fig. 7).
The Rh2(OAc)4-catalysed reaction of 8 (from round 1) gave low
yields of oxindole 20 (yield, 13%; EC50 = 10.1 ± 0.1 µM), oxindole
21 (yield, 12%; inactive up to 1 mM) and δ-lactam 22 (yield, 26%;
EC50 = 0.71 ± 0.14 µM; partial agonist); the activity of this product
mixture was determined (Supplementary Table 1), but did not
quite reach the threshold used to select substrates for round 2.
The Rh2(tfa)4-catalysed reaction of 3 in CH2Cl2 (from round 2,
screened at a total product concentration of 1 µM) and the
Rh2(OAc)4-catalysed reaction of 13 in CH2Cl2 (from round 3,
screened at a total product concentration of 100 nM) gave oxindoles
25 (yield, 92%; EC50 = 2.4 ± 0.5 µM) and 26 (yield, 85%;
EC50 = 12.0 ± 0.3 µM), respectively. In each case the activity of the
product mixture was low (Supplementary Tables 2 and 3), reflecting
the expected activity of these compounds at the concentrations
screened. Thus, in addition to the active β- and γ-lactams (17–19)
prepared from 1, 3 and 15, significant chemical space accessible
to the substrates was thus explored, yet ultimately discarded, in
the search for synthetically accessible, bioactive compounds.
We analysed the impact of screening at tenfold lower concen-
tration in each round of activity-directed synthesis. Accordingly,
we retrospectively assayed the product mixtures from rounds 2
and 3 at the total product concentrations used in the previous
round (that is, 10 µM and 1 µM, respectively) (compare Fig. 2b,c
with Supplementary Fig. 8b1 ,c1). At the lower concentration, the
dynamic range of the assay was greater, improving confidence
that the most promising reactions were taken forward, either to
feed into round 3 (from round 2) or for scale up (from round 3).
The screening of mixtures has already been adopted in discovery
programmes35, and approaches to help identify the active
components have been developed36. However, in activity-directed
synthesis, the activity observed would probably be influenced not
only by the activities of the individual components, but also by
their yield. It was therefore expected that the approach would
allow the identification of reactions in which a substrate was
steered towards the most active product. To test this, and to under-
stand the basis of the discovery of the most active ligand 17, we
correlated, retrospectively, the activity of the product mixtures
derived from 3 with its yield (Supplementary Fig. 9,
Supplementary Tables 5 and 6). In round 2, a low level of activity
was observed for most product mixtures at a total product concen-
tration of 1 µM, usually because the reaction had been steered
towards the poorly active oxindole 25 (EC50 = 2.4 ± 0.5 µM)
(Supplementary Fig. 8). However, under specific reaction con-
ditions, a high level of activity was observed that correlated with a
high yield of β-lactam 17 (EC50 = 340 ± 30 nM). Optimization of
the yield of active components (such as 17) greatly facilitated their
purification and structural elucidation.
In addition to optimizing the yield of active products, activity-
directed synthesis also enabled the discovery of structurally related
bioactive small molecules. The reactions performed in round 3
were inspired by the most promising substrates, catalysts and sol-
vents used in round 2. Two of the reactions selected for scale up
involved substrate 15, which had first been introduced in round 3,
and both reactions gave the active β-lactam 19 in good yield (78%
and 70%, Table 1). The discovery of this bioactive molecule thus
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Figure 4 | A selection of the alternative products accessible from α-diazo amides 8, 3 and 13, which were explored in rounds one, two and three. The
chemical space occupied by the products—oxindoles 20, 21, 25 and 26 and δ-lactam 22—was explored yet ultimately discarded in the search for bioactive,
synthetically accessible compounds. The activity of the product mixtures derived from these reactions is discussed in the main text.
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stemmed from a reaction in round 2 that had yielded the structurally
related β-lactam (19).
Activity-directed synthesis was exploited in the discovery of bio-
active small molecules by the development of a fragment. A directed
approach enabled the discovery of three bioactive small molecules
with submicromolar activity: β-lactam 17 (EC50 = 340 nM),
γ-lactam 18 (EC50 = 470 nM) and β-lactam 19 (EC50 = 440 nM).
In each case, it was simple to identify the most active component
from the product mixture, a process that was greatly facilitated by
the emergence of a high-yielding synthesis (highest yield of 17,
75% from 3; highest yield of 18, 90% from 1; highest yield of 19,
78% from 15). Notably, the optimal catalyst for the synthesis of
the most active ligands (17–19)—Rh2(esp)2—was designed ration-
ally to catalyse C–H aminations37, and would have been unlikely
to have been exploited in a deliberate synthesis of β- or γ-lactams.
Activity-directed synthesis is broadly analogous to the evolution
of a biosynthetic pathway, because bioactive small molecules emerge
in tandem with routes for their synthesis. Because the approach was
underpinned by reactions with alternative outcomes, the discovery
of bioactive compounds based on two distinct scaffolds was possible.
Remarkably, neither of these chemotypes had previously annotated
activity against the androgen receptor. In addition to metal-cata-
lysed reactions of diazo compounds, it is likely that many other
reactions that have alternative possible outcomes—such as metal-
and organo-catalysed inter- and intramolecular reactions—may
also have value in activity-directed synthesis. By liberating chemists
to exploit the most powerful transformations at their disposal, we
anticipate that this highly general approach could be applied in
the discovery of novel and diverse chemotypes with a very broad
range of biological functions.
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